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SUMMARY 
Group B Streptococcus (GBS), a common designation for Streptococcus agalactiae, 
is the leading cause of morbidity and mortality in newborns and a rising agent of 
serious invasive diseases in immunocompromised non-pregnant adults. The 
intrapartum antibiotic prophylaxis to GBS colonized women has help in reducing the 
incidence of early onset GBS disease to the actual values. However, the limitation 
of these programs, the risk associated with antibiotic overuse, and the increasing 
rates of infection in adults, highlight the need for an effective GBS vaccine.  
We have demonstrated that the glycolytic enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) is a GBS virulence factor and is an effective vaccine in a 
neonatal mice model of GBS lethal infection. Having in mind the emergence of GBS 
infection in non-pregnant adults, and the intent to use this vaccine in clinical practice, 
the first aim of this thesis was to evaluate the safety of the GAPDH vaccine and its 
efficacy against GBS infection in an adult susceptible and in a diabetic mouse 
model. For the purpose of testing the safety of the vaccine formulations, a 
comprehensive series of toxicological and clinical parameters were evaluated in 
repeated-dose immunized animals and related controls. To test its efficacy, sham- 
or rGAPDH-immunized adult susceptible mice were infected with GBS serotype Ia 
and V strains, the two serotypes most associated with the invasive disease in adults. 
Sham and vaccinated mice were also rendered diabetic by streptozotocin 
administration and infected with the serotype V GBS strain. The obtained results 
showed that GBS GAPDH vaccine is safe and confers protection against the 
infections caused by GBS in susceptible and diabetic adult mice.  
GAPDH-based vaccines have been proposed against several bacterial and parasitic 
diseases due to its ability to bind to host extracellular matrices and/or modulate the 
host immune responses. The second aim of this thesis was to test whether this 
vaccination strategy could also be used against another neonatal pathogen, the 
Escherichia coli. In the last decades, this Gram-negative bacterium rise in 
importance as a cause of neonatal sepsis and meningitis, affecting mainly preterms 
and very low birth weight infants. Due to the increase on antibiotic-resistant E. coli 
strains and to the improvement of the survival of preterm infants, it is believed that 
the rates of E. coli neonatal infections will continue to grow in the next years. 
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Therefore, the development of efficient therapies against E. coli neonatal infections 
is urgent. The evaluation of the cross-reactivity showed that antibodies raised 
against the recombinant GBS GAPDH were not able to recognize E. coli’s GAPDH, 
and vice versa, ruling out the possibility of cross-protection. For the vaccination 
study, female mice were immunized with E. coli GAPDH and the progeny was orally 
infected with the pathogen. Unexpectedly, maternal vaccination with the E. coli 
GAPDH vaccine not only did not confer protection to pups against oral infection, but 
increased the mortality of infected animals. These results show that GAPDH cannot 
be used as a target antigen for vaccination against E. coli infections, and there must 
be caution in the development of GAPDH-based vaccines. 
The reason why newborns, especially preterm, are so susceptible to E. coli-causing 
sepsis and meningitis strains (mostly represented by E. coli K1) is not clear. 
Therefore, the third aim of this thesis was to characterize the innate immune 
response to E. coli K1 using a neonatal mouse model of infection that address the 
pathogenesis of vertical transmission that occurs in humans. We adapted a model 
of E. coli K1 oral infection, used in neonatal rats, to the mouse model. Thus, less 
than 24 or 48 h old Balb/c pups were orally infected with 2x106 colony-forming units 
(CFUs) of E. coli K1 and sacrificed at specific timepoints. Similar to what happens 
in humans, an age-dependency for the systemic E. coli infection was observed, 
where only mice with less than 24 h are susceptible to this pathogen. To determine 
which immune mediators were produced first in response to E. coli K1, we started 
by a kinetics study of the bacterial colonization in blood, lung, liver, spleen and brain, 
during the first 48 h of infection. As soon as 30 min post-infection, E. coli K1 was 
detected in the pup’s blood, lung and liver. However, the inflammatory response to 
this bacteraemia, evaluated by the production of pro-inflammatory cytokines and 
chemokines, and phagocyte recruitment to infected organs, was only observed 6 h 
post-infection. This delay in the development of an immune response was not due 
to IL-10, since antibody blocking the signalling of this cytokine did not influence the 
outcome of infection. On the other hand, anti-IL-1R treatment increased the 
susceptibility to E. coli, providing evidence that the pro-inflammatory cytokine IL-1β, 
has a protective role during E. coli K1 neonatal infection. These findings indicate 
that E. coli K1 is able to rapidly colonize the neonatal mice but the infected host 
does not promptly develop an immune response. Understanding the reason for the 
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delay of the immune response activation could allow the discovery of therapeutic 
targets against E. coli neonatal infections.  
In conclusion, we have, in this thesis, determined the safety and efficacy of the 
GAPDH-vaccine against GBS adult infections and E. coli neonatal infections and 
characterized a murine model of E. coli K1 oral infection, uncovering the kinetics of 
immune response to this bacterium.  
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RESUMO 
A bactéria estreptococos do grupo B (EGB) ou Streptococcus agalactiae é a 
principal causa de mortalidade e morbidade em recém-nascidos e um agente 
patogénico emergente de doença invasiva em adultos imunocompometidos. A 
profilaxia antibiótica intrapartum a mulheres colonizadas com esta bactéria permitiu 
reduzir a incidência das doenças neonatais de início precoce causadas por EGB 
para os níveis actuais. Contudo, as limitações desta profilaxia, o risco associado ao 
uso abusivo de antibióticos, bem como o aumento das infecções em adultos, 
realçam a necessidade do desenvolvimento de uma vacina eficaz contra as 
infecções por EGB.  
O nosso grupo mostrou que a enzima glicolítica gliceraldeído-3-fosfato 
desidrogenase (GAPDH) é um factor de virulência do EGB e, quando usada como 
vacina, confere protecção contra infecções letais por esta bactéria em ratinhos 
recém-nascidos. Tendo em consideração o aumento das infecções por EGB em 
adultos não gestantes, assim como a intenção do uso desta vacina nos humanos, 
o primeiro objectivo desta tese foi avaliar a segurança da vacina de GAPDH e a sua 
eficácia contra as infecções por EGB em ratinhos adultos susceptíveis ou 
diabéticos. De forma a testar a segurança das formulações da vacina, foi avaliado 
um conjunto extenso de parâmetros toxicológicos e clínicos em animais que 
receberam várias doses da vacina e nos respectivos controlos. Para testar a sua 
eficácia, ratinhos adultos susceptíveis foram imunizados com a GAPDH 
recombinante (rGAPDH) ou apenas com o adjuvante da vacina e foram infectados 
com EGB de estirpes pertencentes ao serotipo Ia ou V, as mais associadas a 
infecções invasivas em adultos. Induziu-se a diabetes em ratinhos imunizados com 
a vacina ou apenas com o adjuvante através da administração de estreptozotocina 
e em seguida infectaram-se com EGB do serotipo V. Os resultados obtidos provam 
que a vacina de GAPDH de EGB é segura e confere protecção contra infecções 
causadas por esta bactéria em ratinhos adultos susceptíveis e diabéticos.  
Vacinas baseadas na GAPDH têm sido propostas contra várias doenças 
bacterianas e parasitárias graças à capacidade desta enzima se ligar a 
componentes da matriz extracelular e/ou de modular a resposta imune do 
hospedeiro. O segundo objectivo desta tese foi por isso, testar se esta estratégia 
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de vacinação poderia ser utilizadas contra outro patogéneo neonatal, a Escherichia 
coli. Nas últimas décadas, a importância desta bactéria Gram-negativa como 
causadora de sépsis e meningite neonatal, principalmente em prematuros e 
crianças com muito baixo peso à nascença, tem crescido de forma preocupante. 
Devido ao aumento de estirpes de E. coli resistentes a antibióticos estima-se que o 
número de infecções neonatais por E. coli continuarão a crescer nos próximos 
anos. É, portanto, urgente desenvolver terapias eficazes contra as infecções 
neonatais por esta bactéria. A avaliação da reactividade cruzada mostrou que os 
anticorpos contra a GAPDH recombinante do EGB não são capazes de reconhecer 
a GAPDH da E. coli, e vice-versa, excluindo assim a possibilidade de protecção 
cruzada. Para os estudos de vacinação, ratinhas fêmeas foram imunizadas com a 
GAPDH de E. coli e a descendência infectada oralmente com o patogéneo. 
Inesperadamente, a vacinação materna com GAPDH de E. coli em vez de conferir 
protecção aos recém-nascidos contra a infecção aumentou a mortalidade dos 
animais infectados. Estes resultados provam que a GAPDH não pode ser usada 
como alvo de vacinação contra infecções por E. coli e alertam para o cuidado a ter 
no desenvolvimento de vacinas baseadas nesta proteína.  
A razão pela qual os recém-nascidos, especialmente prematuros, são tão 
susceptíveis à sepsis e meningite provocadas por estipes de E. coli (representadas 
essencialmente pela E. coli K1) não é ainda claro. Por este motivo, o terceiro 
objectivo desta tese foi caracterizar a resposta imune inata à E. coli K1, usando um 
modelo de murganhos recém-nascidos que respeita a  patogénese da transmissão 
vertical que ocorre bos humanos. Adaptámos um modelo de infecção oral com E. 
coli K1 usada em ratos recém-nascidos, para ratinhos recém-nascidos. Deste 
modo, ratinhos Balb/c com menos de 24 ou 48 h horas de vida foram infectados 
oralmente com 2x106 células de E. coli K1 e sacrificados a diferentes tempos 
experimentais. À semelhança do que acontece em humanos, observámos uma 
dependência da idade para a infecção sistémica com E. coli, só os ratinhos 
infectados antes das 24 h de vida eram susceptíveis a esta bactéria. De forma a 
determinar que mediadores imunes estão a ser produzidos primeiro na resposta 
imune à E. coli K1, começamos por um estudo cinético da colonização no sangue, 
pulmão, fígado, baço e cérebro, nas primeiras 48 horas da infecção. Logo aos 30 
minutos após infecção, E. coli K1 foi detectada no sangue, pulmão e fígados dos 
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ratinhos recém-nascidos. Contudo, a resposta inflamatória a esta bacteriemia, 
avaliada pela produção de citocinas pro-inflamatórias e quimiocinas, e 
recrutamento de fagócitos para os órgãos infectados, foi apenas observada 6 horas 
após a infecção. Este atraso no desenvolvimento da resposta imune não foi 
consequência da produção de IL-10, uma vez que o bloqueio da sinalização desta 
citocina não influenciou o resultado da infecção. Por outro lado, o tratamento com 
anti-IL1R aumentou a susceptibilidade à E. coli, indicando um papel protector da 
citocina pró-inflamatória IL-1β durante a infecção neonatal por E. coli K1. Estas 
evidências indicam que a E. coli K1 é capaz de rapidamente colonizar os ratinhos 
recém nascidos, contudo estes não conseguem desenvolver prontamente uma 
resposta imune. A compreensão dos mecanismos moleculares e celulares deste 
atraso poderá permitir a descoberta de novos alvos terapêuticos contra infecções 
neonatais por E. coli.  
Em conclusão, nesta tese, determinámos a segurança e eficácia da vacina GAPDH 
contra infecções por EGB em adultos e infecções em recém-nascidos por E. coli, e 
caracterizámos um modelo de infecção oral com E. coli K1 em murganhos, 
avaliando a cinética da resposta imune neonatal a esta bactéria a tempos muito 
iniciais da infecção.  
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THESIS OUTLINE 
The present thesis is organized in three main chapters: Introduction, Results and 
Final Discussion. 
The experimental work reported in this thesis focus on three related projects.  
In Chapter I, a general introduction, reviewing the main topics addressed in this 
thesis, is presented. It intends to give the state of the art concerning the relevance 
of the two human pathogens: Group B Streptococcus and Escherichia coli infections 
in neonates and adults, the significance of GAPDH as virulence factor and 
vaccination target, and the pathophysiology of neonatal infections caused by 
Escherichia coli.  
In Chapter II, the Results section, compiles a set of studies and are presented in the 
form of three manuscripts. Thus, experimental data are accompanied by an 
abstract, introduction, methods, results and discussion, and references. 
The general discussion of the work is presented in Chapter III, and intends to 
illustrate the major contributions of this research for the immunobiological 
knowledge of GBS and E. coli, and also presents/discuss new research directions. 
Introduction and Discussion chapters were written trying to avoid repeating ideas 
also presented in the Results section. Nevertheless, some information presented in 
this thesis is reiterated in different sections in order to highlight the importance of 
the presented data. 
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SCOPE OF THE THESIS 
 
This work is divided in three major goals each one connected with the previous: 
I. To investigate the safety, stability and effectiveness of the neonatal 
rGAPDHGBS vaccine on an adult susceptible mouse model of GBS 
infection.  
II. To determine whether a GAPDH-based vaccine could be used against 
Escherichia coli neonatal infection 
III. To develop a mouse model of E. coli K1 infection that address the 
pathogenesis of human vertical transmission and to characterize the 
neonatal innate immune response against this pathogen.  
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I - STREPTOCOCCUS AGALACTIAE OR GROUP B 
STREPTOCOCCUS 
Streptococcus agalactiae also referred to as Group B Streptococcus (GBS) is known 
as the leading cause of life-threatening bacterial infections in newborns [1,2]. However, 
in the last decades its importance as a pathogen in immunocompromised adults 
increased to levels that cannot be dismissed [3,4].  
 
I.1 From a veterinary to a human pathogen 
GBS, a Gram-positive β-hemolitic diplococcus bacterium, was first reported in 1887 by 
Norcard and Mollereau as a veterinary pathogen causing bovine mastitis [5]. One of 
the most relevant consequence of bovine mastitis is the loss of ability to produce milk, 
a characteristic that rendered the Streptococcus agalactiae (agalactie is latin for no 
milk) designation to this in pathogen [6]. In 1933, Rebecca Lancefield, based on the 
serological cross-reactivity to the cell wall carbohydrate antigens, divided the hemolytic 
streptococci into groups. In this classification S. agalactiae was the only specie 
belonging to the serogroup B leading to the use of the term “Group B Streptococcus” 
[7]. 
Only in the late 30’s, was GBS recognized as human pathogen, after Hare and 
Colebrook noticed that the hemolytic streptococci isolated from vaginal samples 
resembled those found in mastitis in cattle and when Fry described 3 cases of fatal 
puerperal sepsis caused by GBS [8,9]. In 1960’s GBS emerged as the leading cause 
of neonatal infections in the United States (US) and in Europe, due to a replacement 
of the human GBS population by tetracycline resistant clones [10]. Despite the 
advances in diagnosis, treatment and prophylaxis, GBS remains the leading agent of 
neonatal diseases causing morbidity and mortality that affect 0.3 to 3 newborns in 
every 1000 live births with a mortality rates between 4 and 10% [11-16]. In Portugal, 
the overall incidence of invasive GBS disease is 0.54 per 1000 live births, with a 
mortality rate of 6.6% [17]. However, the mortality increases if data is reported to 
premature infants, with 15.2% fatality rates vs. 6.4% for term infants [16]. 
INTRODUCTION 
 
4 
 
I.2 – GBS, a neonatal pathogen  
GBS is a common colonizer of the gastrointestinal and genitourinary tracts of healthy 
adults [18,19]. The presence of GBS in the genital microflora of pregnant women is the 
major determinant of colonization and infection in neonates [20-22] (Figure1). Maternal 
colonization increases 24 times the risk of neonatal disease in the first week after birth 
[21]. It is estimated that one third of pregnant women is chronic, transient or 
intermittently colonized with GBS in the vagina and/or rectum, making them at 50-70% 
risk of transmitting this pathogen to their newborn infant in the perinatal period [23-25]. 
On the other hand, only 5% of infants born from culture-negative woman become 
colonized during the first 48 h of life. About 2% infants vertically colonized with GBS 
will develop invasive disease and this risk is proportional to the density of maternal 
colonization [26,27]. Black race, maternal age of <20 years, low parity, and diabetes 
are some of the risk factors for positive maternal GBS colonization [28,29]. 
 
 
 
 
 
 
 
Figure 1. Stages of pathogenesis of neonatal GBS infection. GBS colonizes the 
gastrointestinal and genitourinary tracts of pregnant women. The fetus can acquire the 
bacterium in utero, leading to amnionitis. When the newborn acquires the bacteria during birth, 
it causes pneumonia, sepsis or meningitis. The first two are usually early onset manifestations 
of disease (that occurs in the first week of life), while meningitis is characteristic of late onset 
disease (occurs after the first week up to three months of age). Modified from [27]. Illustrations 
from Amanda Montanez. 
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Intrauterine infection of the fetus occurs either by the ascension of GBS to the amniotic 
cavity or by fetal aspiration of contaminated fluids. This can lead to placental 
membrane rupture, triggering premature delivery and stillbirths. Alternatively, the 
newborn can acquire the bacteria during passage through the birth canal, by ingestion 
or aspiration of infected vaginal fluids, leading to pneumonia and sepsis [2,27,30] 
(Figure1).  
Two distinct syndromes of neonatal invasive GBS disease have been described, 
according to the timing of manifestation of the symptoms. Early-onset disease (EOD) 
occurs in the first 7 days after birth, with symptoms being more clinically apparent on 
the first 24-48 hours in the case of term infants, or in the first 6 hours in the case of 
preterm newborns [13,31]. Gestational age, maternal intrapartum fever, 
chorioamnionitis, and prolonged rupture of membranes are some of the known risk 
factors that increase the risk of GBS’ EOD [31]. The most typical clinical manifestations 
of EOD are sepsis (80-85%), pneumonia (10-15%) and meningitis (5 to 10%) [13] 
(Figure1).  
Late-onset disease (LOD) is defined by a GBS infection that starts after the first week 
up to 90 days of age. LOD cases are characterized by septicaemia (65%) and a high 
frequency of meningitis (25%). GBS meningitis remains associated with high mortality 
and leaves 25-50% of surviving infants with long-term health problems, including 
developmental disabilities, paralysis, seizure disorder, hearing and vision loss [32].  
GBS is an encapsulated bacterium that can be subclassified, according to the 
immunogenic capsular polysaccharides (CPS), into ten serotypes (Ia, Ib, II–IX). Global 
colonization rates reveal significant regional variations in prevalence and serotype 
distribution. Currently, serotype Ia, II, III and V are the most frequent GBS isolates from 
vaginal-rectal cultures of women in Western Europe, North America, South Africa and 
China [33-36]. Portugal follows a similar profile, with serotypes III (35%), V (33%), Ia 
(16%) and II (10%) the most commonly found [37]. Serotypes VI and VIII were most 
frequently detected in Japan and serotype IV was common in United Arab Emirates 
[38,39].  
Regarding the neonatal invasive-disease isolates responsible for EOD, serotype III and 
Ia were found to be overrepresented [13,40,41]. In the US the most frequent serotypes 
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associated with EOD were Ia (30%), III (28%), V (18%), and II (13%) [13] while in 
Portugal, are the serotypes Ia (31%) and III (29%) [42]. 
In case of LOD the majority, 50-90%, depending on the region, are caused by serotype 
III infections [13,34,40,42-44]. Almost all cases of meningitis are a consequence of an 
infection with a highly virulent clone of serotype III that belongs to bovine-derived 
sequence type (ST) 17 [44]. The impact of ST-17 among invasive neonatal infections 
is worldwide recognized due to its rapid dissemination and successful adaptation to 
human neonates [45]. The ability of this clone to cause neonatal meningitis relies on a 
ST-17-specific surface-anchored protein, the hypervirulent GBS adhesin (HvgA) that 
enhances GBS adherence and translocation across intestinal epithelium and the 
blood-brain barrier (BBB) [46]. 
 
I.3 The burden of GBS infections in pregnant and non-
pregnant adults  
GBS colonization in pregnant women in frequently asymptomatic. Nevertheless, in 
about 0.12 per 1000 live births, it leads to maternal invasive disease, a rate that has 
been declining since the implementation of IAP [47-50]. Pregnancy increases five 
times the risk for GBS disease in women and the majority of pregnancy-associated 
disease occur in the postpartum period [48]. Half of pregnancy-associated invasive 
GBS disease resulted in upper genital tract, placental and aminiotic infections and 
resulted in fetal death. The remained cases included manifestations as bacteremia 
without focus (31%), endometritis without fetal death (8%), chorioamnionitis without 
fetal death (4%), pneumonia (2%), and puerperal sepsis (2%) [13]. Most obstetric 
patients with GBS infection, even in the presence of bacteremia, show a rapid 
response after initiation of antimicrobial therapy. Potential fatal outcomes, although 
rare, can occur, and include meningitis [51,52], endocarditis [53,54], sepsis [55], 
epidural abscess [56] and necrotizing fasciitis [57].  
In the past 3 decades, invasive GBS infections in non-pregnant adults started to 
represent a significant and growing health burden worldwide [4]. The age distribution 
of invasive GBS cases in United Kingdom (UK) and in US shows a clear shift from 
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neonatal towards non-pregnant adult [4,58]. Data from the UK shows that, between 
1991 and 2010, the rate of GBS infection in adults increased from 0.92 to 2.39 per 
100,000 individuals [58]. Likewise, the incidence of infections among the adult 
community in the US more than doubled between 1990 and 2007, from 3.6 to 7.3 cases 
per 100.000 individuals [4]. The incidence increased in all adult age groups but was 
most preeminent among older patients (ages from 65 to 79 years old) reaching the 
value of 22 cases per 100,000 individuals (an increase of 114.7% when compared with 
adults with <65 years old) [4]. Disease rates also seem to discriminate color and sex 
of the individuals, with black and males being affected more than their white and female 
counterparts [59,60]. These infections are associated with substantial morbidity and 
mortality, particularly in individuals with chronic underlying conditions. Diabetes 
mellitus is the most frequent comorbid condition associated with GBS infection, 
typically presented in 20-50% of non-pregnant adults with GBS disease [4,61-63]. 
Other comorbidities include liver disease (such as cirrhosis), obesity, cardiovascular 
diseases, cancer, renal disease and neurologic disease [3,4,64,65]. The majority of 
GBS infected patients presented at least one of these conditions [4,66]. In the case of 
elderly adults, residence in nursing homes, bedridden state and gastrointestinal 
disease also appear as factors associated with GBS infections [67-69]. Some studies 
point out that aging of the population and the rising numbers of patients with chronic 
disease such as obesity and diabetes, are part of the reason for the observed increase 
of GBS infections in adults. Another important aspect of these infections is its 
recurrence (4.3-28%) rate, usually caused by the same strain from the first infection, 
indicating a bacterial reinvasion from a colonizing site [19,66,70].  
The fatality ratio is strikingly higher amongst non-pregnant adults (8%–24%) than the 
one reported for neonates with GBS invasive disease (4-6%) [4,13] and this proportion 
increases in the older age groups, showing the importance for the development of a 
vaccine for these risk group of individuals. 
Clinical manifestations of GBS infections in adults can be presented in a large 
spectrum of pathologies. The most common are bacteremia without focus and skin and 
soft-tissue infections, mainly in the form of cellulitis [4]. Conditions such as 
lymphedema, vascular insufficiency, chronic dermatitis, radiation-induced injury and 
mastectomy are frequently predisposing factors for GBS-caused cellulitis [60,65,71]. 
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Decubitus, foot ulcers are other relevant clinical presentations of skin and soft-tissue 
GBS infections, with the latter occurring predominately in patients with diabetes. Bone 
and joint infections, especially osteomyelitis, are present in 10% of GBS adult 
infections [4] and most often linked to vascular insufficiency and overlying ulcers and 
spread from adjacent skin and soft tissue infection [72]. GBS pneumonia and urinary 
tract infections generally occur in in elderly adults [73], the first in older adults with 
neurological impairments and the latter is normally associated with prostate disease, 
prior cases of urinary tract infections, urinary catheters and anatomic abnormalities of 
the urinary tract [60,74-76]. GBS-caused meningitis and endocarditis, although less 
frequent, due to their poor outcome represent a concern among physicians. Among 
GBS infected non-pregnant adults only 2-5% presented meningitis, representing up to 
4% of all cases of bacterial meningitis in adults [4,50,61,77]. Most cases occur in 
postpartum women, elderly adults, or adults with significant underlying diseases. 
Symptoms are generally abrupt in onset, and bacteremia is present in approximately 
80% of cases [77,78]. In elderly patients, GBS meningitis is often fatal with an overall 
case-fatality rate of 27-34%, and 56% among adults with more than 65 years of age 
[77]. A proportion of survivors (7%) are left permanently deaf [77].  
In recent studies, GBS endocarditis accounted for 3-10% of the invasive disease in 
adults [4,61,79]. In the last decades the focus of GBS endocarditis reports changed 
from parturient women to non-pregnant adults, with a higher incidence in the elderly 
[61,80]. Diabetes mellitus, chronic obstructive pulmonary disease, neoplasms, 
urological disorders and chronic liver disease were frequently associated with this 
manifestation of GBS invasive disease [79]. These infections often require cardiac 
surgery due to a rapid destruction of mitral or aortic valves. Complications include 
metastatic infection, heart failure, major emboli, myocardial abscess, and complete 
heart block [79-83]. Despite the decrease in GBS endocarditis in the past few years, 
its rates remain high. In young patients, fatality rates can reach 21% while among the 
elderly these rates can go as high as 45% [68,79,80]. 
GBS serotypes distribution in non-pregnant adults is distinct from the one associated 
with vaginal colonization of pregnant women and invasive infection of neonates. In the 
US, serotype V was the most prevalent GBS serotype associated with adult disease 
(29%), followed by serotype Ia (24%), II (12,5%) and III (11,4%) [4]. In France and UK, 
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the serotype III was most commonly found (25-26%), followed by V and Ia [61]. 
Nevertheless, when stratified by age, serotype V was predominant in individuals with 
more than 40 years old in both the US and France [4,61]. A markedly increase in the 
frequency of this serotype among adults (from 9% in 1995 to 24% in 2010) was 
observed in the UK [58]. In Portugal, serotype Ia was responsible for the majority of 
invasive infections in all age groups (34.7%). In the subpopulation with less than 65 
years, serotype Ia was isolated three times more frequently than other serotypes 
(44.2%), such as III (14.7%), V (14.7%), and II (11.6%). In the elderly, although 
serotype Ia was still the most prevalent (27.7%), serotypes such as V (23.0%) and III 
(15.4%) were almost as frequent [59]. 
In eastern countries like Japan and Taiwan, serotype Ib is the main identified cause of 
invasive GBS infections in non-pregnant adults, immediately followed by serotype V 
[84,85]. In these countries, serotype IV (that has a negligible incidence in the US and 
Europe) was responsible for 8 -18% of GBS infections in adults [84,85]. 
The incidence of serotype V is steadily increasing since the early 90’s. A recent report 
determined that 92% of bloodstream infections caused by serotype V in Houston and 
Toronto were caused by genetically related ST-1 strains and that these strains were a 
single loci variant of the first serotype V strains identified in humans. This evidence 
indicates that the emergence of serotype V GBS-causing invasive disease in non-
pregnant adults was not driven by major genetic alteration on this serotype but is, most 
probably, a result of the phenotypic diversity resulted from small genetic changes [86].  
 
I.4 GBS virulence factors  
The uninterrupted and growing impact of GBS as a human pathogen, first in newborns 
and currently in non-pregnant adults, is a clear reflex of its ability to colonize and invade 
host tissues, to resist and evade host immune defenses and to adapt/resist to antibiotic 
treatments. To be successful in all those stages, GBS possesses a diverse array of 
surface-associated and secreted virulence factors that mediate specific host-cell 
interactions and interfere with immune clearance mechanisms (Figure 2). 
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Figure 2. GBS virulence factors associated with the different stages of neonatal 
infection. Surface-expressed proteins FbsA/B/C, ScpB, Srr, pili, BsaB, LTA, α-C proteins and 
Lmb mediate GBS binding to host cells and extracellular matrix components, such as 
fibrinogen, fibronectin and laminin, contributing to cell adhesion. Some of those proteins are 
also involved in degradation of the extracellular matrix components in which they adhere, 
promoting cell invasion. Secreted β-haemolysin/cytolysin promotes GBS invasion, by breaking 
down host barriers to reveal novel receptors on the basement membrane and by inducing cell 
death. GBS GAPDH activates host plasminogen and degrade the extracellular matrix. CIP, β-
protein, ScpB and BibA are associated with inhibition of complement activation after GBS 
infection. Secreted GBS hyaluronidase degrades pro-inflammatory hyaluronan fragments to 
disaccharides that block TLR2/4 signaling. GBS GAPDH induces an early IL-10 production 
that inhibits neutrophil recruitment to infected organs. See text for references. 
 
I.4.1 Adherence and cell invasion 
Colonization of the gastrointestinal tract of pregnant and non-pregnant adults as well 
as vaginal colonization of pregnant women is an early step for the development of a 
disseminated infection. GBS has the capacity of binding avidly to human epithelial cells 
of colon and genital tract or vaginal tissue culture, with maximal biofilm formation under 
the low pH conditions, characteristic of vaginal mucosa [87-89]. GBS cell-wall-
associated lipoteichoic acid (LTA) mediates low-affinity interactions with epithelial 
cells, whereas hydrophobic GBS surface proteins mediate higher-affinity interactions 
[90]. Many of these interactions involve attachment of the bacterium to extracellular 
matrix molecules such as fibronectin, fibrinogen and laminin. Some bacterial adhesion 
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factors were named according to their specific ligand, such as fibrinogen-binding 
protein A (FbsA), fibrinogen-binding protein B (FbsB), fibrinogen-binding protein C 
(FbsC) and laminin-binding proteins (Lmb) [91,92]. Bacterial surface adhesin of GBS 
(BsaB) and streptococcal C5a-peptidase (ScpB) binds to fibronectin [93,94], serine-
rich repeat protein (Srr)-1 binds to human keratin 4 and fibrinogen [95,96] and Srr2 
binds to both fibrinogen and plasminogen [97]. The Srr1 interaction with fibrinogen was 
associated with GBS virulence in an animal model of meningitis and contributed to the 
pathogenesis of infective endocarditis [95,98]. GBS surface protein containing the 
leucine-rich-repeat (LRR) motifs, binds to human lung and cervical epithelial cells in a 
dose-dependent manner [99].  
GBS alpha C proteins and Srr proteins are adhesion factors characterized by the highly 
conserved LPxTG (Leu–Pro–X–Thr–Gly) motif at the C- terminus. LPxTG is cleaved 
between Thr and Gly by the transpeptidase Sortase A, which covalently binds GBS to 
the cell wall promoting colonization and invasion [87,100,101]. 
Additional structures involved in adhesion are Pili, a filamentous cell surface 
appendages. GBS pili are constituted by three subunits: a major shaft subunit, the 
backbone protein (PilB), which is critical for pilus assembly; a pilus-associated 
adhesion (PilA) and a component anchoring the protein assembly to the cell wall (PilC). 
PilA contributes to the adherence of GBS to vaginal and brain endotelium [100,102-
104]. 
The regulation of some of these and other GBS adherent factors is controlled by the 
two-component gene regulation system CovRS which, in turn, is modulated by acidic 
epithelial pH, high glucose levels and passage through intestine [105,106]. Deletion of 
CovRS, results in increased bacterial adherence but decreased invasion of vaginal 
epithelial cells [107].  
Following cellular adherence and colonization, GBS needs to promote bacterial entry 
and survival within host cells in order to promote a systemic infection. Some of the 
factors associated with cell adherence are also associated to cell invasion, which is 
the case for FbsB, Lmb, ScpB and alpha C proteins [101,108-110]. It was described, 
for instance, that Lmb is important for GBS translocation across the intestinal 
epithelium and the blood–brain barrier (BBB) [108]. GBS ST17 possesses a surface-
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anchored hypervirulent adhesin (HvgA) as a specific virulence factor. Both HvgA and 
pili are involved in the colonization and invasion of the intestine and confer meningeal 
tropism in neonatal mice [46,111].  
The invasion of epithelial cells provides an intracellular niche for GBS survival but can 
also promote tissue damage and inflammation, contributing to the disease’s pathology.  
GBS β-haemolysin/cytolysin (β-H/C), a pore-forming toxin, is responsible for the 
cellular damage of both choroamniotic and lung tissue, compromising their barrier 
function [112-114]. Several studies demonstrated the crucial role of GBS β-H/C in 
disruption of the maternal-fetal barrier and subsequent vertical transmission of GBS, 
causing preterm births and abortions [113,114]. Moreover, β-H/C expression was 
proved to be essential for GBS penetration of pulmonary barriers and development of 
systemic infections [112,115]. 
Another important GBS virulence factor is the glycolytic enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). This protein is present on the cell surface of the 
bacteria and can bind to lysine residues of the host’s plasminogen [116,117]. The 
association of plasminogen to GBS surface activates the bound pro-enzyme to 
plasmin, thereby gaining the ability to degrade the host’s matrix proteins such as 
fibronectin. This surface modification facilitates the GBS traversal of the extracellular 
matrix barriers and tissue penetration leading to an increase blood-brain-barrier 
bacterial invasion [118]. 
I.4.2 Host immune evasion  
As soon as GBS reaches the bloodstream and establishes an infection, the host 
mounts an immune response to eliminate the pathogen. The high ability of the GBS to 
survive in the host is a reflex of the aptitude of its virulence factors for resistance and 
evasion of the bactericidal host responses.  
A first step of any immune response is the recognition of danger- or pathogen-
associated molecular patterns (DAMPs and PAMPs) by the immune cells. In response 
to infectious or sterile tissue injury, hyaluronan (HA), a glycosaminoglycan polymer of 
the extracellular matrix of nearly all tissues, is rapidly degraded by reactive oxygen 
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species or host hyaluronidases. The end products of these reactions are tetramic HA 
or larger fragments that have immunostimulatory activity, in part for their recognition 
by Toll-like receptor (TLR) 2 and/or TLR4 leading to the activation of pro-inflammatory 
responses. GBS secretes a hyaluronidase that degrades the host or pro-inflammatory 
HA into disaccharides. These disaccharides block TLR2/4 signaling by both pro-
inflammatory HA and TLR2/4 agonist inhibiting the protective inflammatory response. 
By this mechanism GBS hyaluronidase promotes bacterial dissemination [119].  
CPS is another virulence factor of the GBS that avoid the host immune recognition. 
The distinct types of CPS are created by arrangements of four monosaccharides into 
unique repeating units. However, every single CPS contains a terminal sialic acid 
bound to galactose in a α2 → 3 linkage. This conserved component is identical to a 
sugar epitope widely displayed on the surface of human cells. This not only avoids 
immune recognition, but also allows direct binding to immunoglobulin-like lectins 
(Siglecs) on leukocytes, inhibiting complement C3 activation and dampening the 
oxidative burst and bactericidal activities of phagocytic cells [120-123].  
GBS is not only able to avoid immune recognition, but can also modulate the immune 
response triggered after its recognition. It is widely recognized that newborns have an 
undeveloped immune system that immediately after birth has to deal with the colossal 
challenge of efficient elimination of potentially dangerous microorganisms and the 
tolerance of commensals on skin and mucosal surfaces. To control the inflammatory 
responses, the neonatal immune system is polarized to an anti-inflammatory status 
[124-126]. GBS take advantage of this regulatory environment to evade the immune 
response. Bacterium recognition through TLR2 and secretion of GBS GAPDH to 
extracellular space induces an early and exacerbated production of the anti-
inflammatory cytokine IL-10, in newborns [127-129]. This IL-10 impaired neutrophil 
recruitment into infected organs thus preventing bacterial clearance. Blocking either 
TLR2, IL-10 signaling or GAPDH, restores the recruitment of neutrophils to infected 
organs and confers neonatal resistance to lethal infections with GBS hypervirulent 
strains [127,128]. 
In addition to CPS, several others GBS virulence factors contribute to the inhibition of 
activation and deposition of some key molecules of the complement cascade (from 
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both classical and lectin pathways). ScpB mediates the proteolytic C5a inactivation 
[130], BibA binds to human C4-binding protein, a regulator of classical complement 
pathway [131], β-protein binds to factor H, enabling the unbound active region to block 
C3b deposition on the bacterial cell surface [132], and complement interfering protein 
(CIP) binds to C4b, preventing the formation of the C4bC2a convertase [133]. 
Complement activation is also inhibited by factors that induce the coating of the 
bacterial surface with human proteins, as in the case of GBS beta-antigen of the c 
protein complex, that leads to a unspecific IgA-binding on bacterial surface by GBS 
[134] and by cell-surface protease (Csp) A, that produces adherent fibrin-like cleavage 
products [135]. 
Some of GBS virulence factors allow its evasion from phagolysosomal processing. 
GBS is a catalase negative bacterium, yet it is still able to neutralize reactive oxygen 
species via BibA, β-H/C, superoxide dismutase (SodA), and another unknown factors 
[136-138]. 
GBS exploits the cationic nature of most antimicrobial peptides (AMP), and the need 
of a negatively charged microbial cell surface for its electrostatic attraction, by 
incorporating positively charged D-alanine residues into its cell-wall LTA, reducing the 
negative surface charge and, consequently, its affinity for the cationic peptides [139]. 
This resistance to AMP is further amplified by surface-anchored penicillin-binding 
protein (PBP) 1a, and pilus backbone protein PilB [140,141]. 
An alternative bacterial defense mechanism to avoid phagocytic clearance is the 
induction of apoptosis, or programmed cell death. Several GBS proteins have this 
ability, depending on the environment. For instance, β-H/C induces cell death in 
epithelial, meningeal cells and astrocytes in vitro [142], phosphoramidon-sensitive 
metalloprotease induces apoptosis of human endothelial cells in vitro [143] and 
GAPDH induces apoptosis in murine macrophages [144]. 
Neutrophils and macrophages, beside their capacity to phagocyte and directly kill 
pathogens, are able to form extracellular traps (NET in neutrophils and MET in 
macrophages). NET and MET consist in a high local DNA matrix with elastase, 
enzymes, proteases, histones and antimicrobial peptides that are able to bind and kill 
pathogens extracellularly, independently of phagocytic uptake [145,146]. The structure 
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of NETs and METs, held together by a DNA backbone, is critical to their antimicrobial 
function. GBS secretes a nuclease A (NucA) that is able to degrade the DNA matrix 
compromising NET stability. In vivo infection studies confirmed that NucA decreases 
bacterial clearance from lung tissue and increases mortality in infected mice [147].  
Bacterial modulation of the immune system doesn’t simply rely on shutting down 
protective immune responses but can also occurs by increase the production of pro-
inflammatory mediators towards tissue causing damage. For instance, GBS PilA 
promotes the activation of host chemokine expression and neutrophil recruitment to 
brain endothelium, increasing the blood-brain-barrier permeability and inducing 
bacterial central nervous system penetration [102].  
 
I.5 GBS recognition and immune response 
During GBS infection, a wide array of immune responses is induced, including the 
production of cytokines, cell recruitment to infected organs and production of 
antimicrobial factors. The recognition of bacterial pathogen-associated molecular 
patterns (PAMPs) by pattern recognition receptors (PRRs) comprises the first stage of 
the innate immune response. Amongst the several functionally distinct classes of PRR, 
TLRs have been extensively studied in the context of GBS infection.  
The mammalian TLR comprises a family of cell surface (TLR1, TLR2, TLR6, TLR4 and 
TLR5) or endossomal transmembrane (TLR3, TLR7, TLR8, TLR9, TLR10, TLR11, 
TLR12 and TLR13, the last three are not present in humans) germline-encoded 
membrane glycoproteins that lead to the production of pro- and anti-inflammatory 
cytokines when stimulated. A central role of TLRs in GBS infection was confirmed by 
the requirement of the TLR adaptor MyD88 for optimal host defense and pro-
inflammatory cytokine production [148-151]. GBS lipoproteins (but not LTA) stimulate 
the production of pro-inflammatory cytokines by a mechanism involving TLR2/TLR6. 
These receptors, however, appear to be essential only for the recognition of released 
factors from GBS, whereas whole GBS organisms potently induce cytokines in a TLR2-
, TLR6-independent fashion in vitro [152]. A recent study implicates the TLR (and 
excluded nucleotide-binding oligomerization domain (NOD)-dependent) signaling in 
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the activation of dendritic cells (DCs) by GBS. The same article showed that abrogation 
of TLR2 in GBS-infected DCs only partially affected the production of IL-6 and CXCL1, 
indicating that other TLR should have an importance on cytokine production on DC in 
response to GBS [153].  
The role of TLR2 in GBS infection deeply depends on the model and the bacterial dose 
used. Interaction of GBS with TLR2 was beneficial to the host in a low dose GBS 
neonatal infection model [148] but had, however, a detrimental role in neonatal models 
of GBS lethal infections [127,148]. In the case of adult mice models, TLR2 deficiency 
was associated with enhanced severity of infection in a sub-lethal (or low-mortality) 
GBS infection [148,154,155]. However, in a model with an inoculum that leads to the 
death of 90% WT mice, the lack of TLR2 signaling conferred resistance to GBS 
infection [148].  
TLR2 engagement and/or MyD88 activation during GBS infection is associated with 
the production of both pro-inflammatory and anti-inflammatory cytokines. The 
protective role of each one of the cytokines that are produced during GBS infection is 
highly dependent on the magnitude and timing of their production. GBS is a potent 
inducer of TNF-α [156] which is assumed to be one of the main molecular mediators 
in the pathophysiology of sepsis, in mice and humans [157]. A dramatic increase in 
TNF-α and other pro-inflammatory cytokines has been observed in adult GBS-
susceptible mice when compared with resistant strains [148,155]. However, the 
treatment with anti-TNF serum prior to the GBS infection didn’t alter the GBS-induced 
lethality of adult mice [158] and, in a mice model of GBS-induced arthritis, the chemical 
block of TNF-α production showed a negligible involvement of this cytokine in the 
pathogenesis of the disease [159]. Also, in neonatal infections, the role of this cytokine 
is controversial. A study using a neonatal model of GBS subcutaneous infection 
showed that, depending on the inoculum, the blockage of TNF-α could result in 
increased resistance (high dose) or susceptibility (low dose) [148]. By contrast, 
treatment of neonatal mice and rats with TNF-α specific antibodies, prior to the lethal 
infection with GBS, did not affect mortality, simply delaying it 24 h in one of the studies 
[127,160]. The expression of TNF-α during GBS infection implicates the activation of 
nuclear factor (NF)-κB and activator protein (AP)-1 and is greatly amplified by the 
activation of the alternative complement pathway [156,161]. 
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IL-1β is another pro-inflammatory cytokine highly associated with the septic-shock and 
that is markedly elevated during GBS disease. Production of IL-1β is comprised by two 
phases, the induction of pro-IL-1β synthesis and the caspase-1 cleavage of the inactive 
precursor to the active “mature” cytokine. GBS infection is able to induce both phases 
[151,162]. Higher maternal IL-1β plasma concentrations were associated with early 
term births and with an increased risk for GBS infection [163]. IL-1R signaling pathway 
has distinct effects to the pathogenesis of GBS infection, depending on GBS inoculum. 
Infections with sub-lethal GBS doses proved the importance of IL-1β production and 
signaling in protecting the host against GBS infection by inducing the production of the 
chemokines KC and MIP-1α and the recruitment of polymorphonuclear leukocytes to 
sites of GBS infection [149,151,164]. In a model of GBS arthritis, however, IL-1 was 
strongly associated with the pathogenesis of the disease [159,165] and, in a neonatal 
mouse model with a lethal GBS infection, abrogation of IL-1R signaling was able to 
partially reduce mortality [127].  
IL-10 is an important anti-inflammatory cytokine that limits the production of pro-
inflammatory cytokines, chemokines and adhesion molecules. High concentration of 
plasma and cord blood IL-10 in preterm neonates during sepsis was associated with 
mortality. Several studies stated that an early and exacerbated production of this 
cytokine during neonatal GBS infection facilitated pathogen immune evasion by 
inhibiting protective immune responses [127,128,166]. In a model of arthritis induced 
by GBS, IL-10 helped to control the inflammation that is associated with the worst 
prognosis of the disease [167]. In another study, however, the neutralization of IL-10 
with specific antibodies had no effect on lethality of neonatal GBS infection and the 
administration of recombinant IL-10 at 4 or 24 h before bacterial challenge resulted in 
improved survival [168]. The reasons for these discrepancies in the role of this anti-
inflammatory cytokine are still uncertain. 
Others TLRs have also been associated with GBS recognition. For instance, GBS 
activation of TLR7 in lysosomes by single-stranded RNA (ssRNA) potently induced 
type I interferon production in conventional DCs [169]. This and other studies suggest 
the involvement of the chaperone protein UNC93B1 (that is required for the function of 
intracellular but not cell surface-associated TLRs) in GBS ssRNA recognition 
[169,170]. This type I interferon (IFN) production in murine macrophages and dendritic 
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cells is critical to the host’s defense against GBS [171,172]. This cytokine primes 
immune cells to increase pro-inflammatory responses and, upon GBS infection in the 
absence of type I IFN signaling, a robust impairment of the production of TNF-α and 
IFN-γ was observed [171].  
IFN-γ is an important cytokine that enhances the recruitment of phagocytes and 
increases the effector functions of these cells. IFN-γ production during GBS infection 
seems to have a protective role since administration of recombinant IFN-γ to GBS 
infected pups increased survival and decreased GBS colonization [173]. Therapeutic 
use of IFN-γ in a mouse model of GBS-induced arthritis led to the development of 
milder manifestations of the disease but prophylactic use induced the opposite results 
[174]. In vitro studies, with human umbilical vein endothelial cells and cord blood 
monocyte-derived macrophages, concluded that the activation of the cells by IFN-γ 
decreased the viability of intracellular GBS [175,176]. IL-12 is a heterodimeric cytokine 
and a potent IFN-γ inducer that directs the generation of T-helper type 1 responses. 
The protective effects of this cytokine are similar to the ones already described for IFN-
γ. For instance, administration of recombinant IL-12 had a protective effect in GBS 
infected pups, not only therapeutically, but also prophylactically [177]. A deficiency of 
this cytokine, like a deficiency in IFN-γ, contributed to an increased susceptibility of 
newborns to GBS infection [178,179] and had beneficial effects on GBS-induced 
arthritis [167]. Additionally, it was demonstrated the important role of IL-18 in control of 
GBS infection and inducing host survival, by inducing IFN-γ production [179,180]. The 
protective role of Th1-dependent responses in GBS adult infections was further 
confirmed by evaluation of the Th2-associated cytokine IL-4. The deficiency of this 
cytokine decreased GBS-induced lethality due to an up-regulation of pro-inflammatory 
cytokines, leading to a higher bacterial clearance in IL-4 KO animals than in controls 
[181]. However, the increased production of pro-inflammatory cytokines in IL-4 KO 
mice intensified the severity of arthritis caused by GBS [181]. Treatment with 
recombinant IL-6 also amplified the severity of this disease in mice infected with GBS 
[159]. 
In addition to TLRs, intracellular receptors and CD11b/CD18 β2-intregrin (complement 
receptor 3, CR3), have been described as GBS signaling receptors [182]. GBS β-
hemolysin induce the secretion of IL-1β on mouse dendritic cells through activation of 
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the intracellular NOD-like receptors (NLRs) family pyrin domain- containing 3 (NLRP3; 
also known as cryopyrin or NALP3) inflammasome [151]. This NLRP3 inflammasome 
role was proven to be crucial for in vivo anti-GBS defense [151]. Alternatively, the 
association of GBS with CR3 mediates not only the phagocytosis of the bacteria, but 
contributes to the cytokine production, such as TNF-α and IL-6, in vitro [156,183-185]. 
Despite these findings, a study with peritoneal macrophages from CD11b KO mice 
showed a decrease in opsonic uptake of the GBS but a normal pro-inflammatory 
response [150].  
Aside from systemic immune responses, GBS also induces a mucosal immune 
response. A correlation was reported between rectal or cervical GBS colonization and 
levels of serotype-specific IgA and IgG in cervical secretions [19,186]. The induction 
of specific antibodies on mucosal sites may prevent genital colonization and decrease 
the vertical transmission of the bacteria. 
Overall, it is clear that the nature of the immune response produced upon GBS-
infection will define the fate of the host and the level of pathology induced. 
 
I.6 Treatment 
In 1996 the Centers for Disease Control and Prevention (CDC), in collaboration with 
relevant professional Societies, published guidelines that several countries adopted as 
a policy for the use of intrapartum antibiotic prophylaxis (IAP) to prevent perinatal GBS 
diseases [187,188]. In 2002 and 2010 the guidelines were revised and republished but 
the foundations remained unchanged [31,189]. Following these recommendations, 
pregnant women should receive IAP if: the vaginal-rectal screening for GBS 
colonization at 35-37 weeks give positive, the women had delivered a previous infant 
with GBS disease, the GBS status is unknown at deliver, during the labor women 
developed a fever >38°C, or if the women has a rupture of membranes for 18 hours or 
longer [31]. 
The recommended antibiotics for IAP are penicillin and ampicillin and, in case of allergy 
to β-lactams, the antibiotic of choice should be cefazolin, erythromycin or clindamycin 
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[31]. These are also the first-line agents against the treatment of GBS infections in 
adults. 
In the US, as a result of an active prevention, there was more than 80% decline in the 
incidence of GBS EOD, from 1.7 per 1000 live births in the early 1990s to less than 0.3 
per 1000 live births in 2013 [31,190-192]. Nevertheless, IAP did not have an impact on 
the incidence of GBS-caused LOD, stillbirths or premature births [193,194].  
Moreover, the use of antibiotic, as prophylaxis and treatment, raises several important 
questions due to its limitations and side effects. One of the most relevant and well 
known consequences of antibiotic use is the emergence of antibiotic-resistance strains 
[195]. 
Clinically isolated GBS have been considered to be uniformly susceptible to β-lactams, 
however very rare isolates with reduced susceptibility to penicillin have been identified 
in Japan and the US [85,196,197]. Of higher concern, however, are the increasing 
resistances to macrolides and clindamycin among GBS invasive isolates [198]. 
Streptococcal resistance to macrolides is commonly mediated by two major 
mechanisms: (i) alteration of the antibiotic binding site, that can confer inducible or 
constitutive resistance to macrolides, lincosamides and streptogramin B (MLSB 
phenotype) and (ii) increase of macrolide-specific efflux mechanism (M phenotype), 
encoded by the mefA gene [199,200]. 
In Portugal, erythromycin resistance among colonizing strains of GBS, were similar to 
those described in France and Canada (18%) [37,199,201] with a higher percentage 
relatively from the one reported in Czech Republic (3,8%) [202] but lower than the one 
reported in the US (38–41.9%) [203,204]. 
Regarding antibiotic resistance among invasive GBS strains, serotype V has been 
pointed out as having a central role. The resistance is mainly observed against 
erythromycin and clindamycin. A report from Korea, for instance, showed that, among 
37 studied erythromycin-resistant strains, 29.7% of them belonged to serotype V, with 
a rate of erythromycin-resistance for this serotype of 68.8% [205]. In the US 44-63% 
of erythromycin-resistant GBS belong to serotype V, with a rate of erythromycin and/or 
clindamycin resistance for this serotype of 40-48% [204,206]. Moreover, a study from 
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southwest Germany focused on neonatal and maternal GBS isolates, showed that 
37% of the erythromycin-resistant GBS isolates belonged to serotype V, representing 
the majority of the erythromycin-resistant strains [207].  
Antibiotic use during pregnancy has been shown to have not only an effect on the 
emergence of GBS-resistance strains, but also to be associated with the shift to 
Escherichia coli neonatal infections [208-210]. Other studies however, rebut that 
association [211,212]. 
The shaping of GBS epidemiology has been influenced by antibiotic use since its 
emergence as a human pathogen. It was recently proposed that the widespread use 
of tetracycline helped drive the adaptation of GBS to neonatal hosts [10]. 
In the last year, our knowledge on the importance of gut microbiota in several aspects 
of the human development as increased significantly. It is now known that the 
colonizing microorganisms play a key role in driving postnatal maturation of the gut 
and development of the immune system [213,214]. Antibiotic exposure near the time 
of birth reduces the diversity and composition of intestinal microbiota of both the mother 
and child and vaginal microbiota of the mother, delaying the appearance of beneficial 
bacteria in the child [215,216]. These alterations may interfere with the development 
and maturation of the child’s immune system and are linked to an increased 
susceptibility to the development of LOD, allergic diseases, asthma, rheumatoid 
arthritis, atopic dermatitis and autoimmune diseases [217,218]. A study using neonatal 
mice model identified a role of the microbiota in regulating postnatal granulocytosis 
and increasing resistance to sepsis. In this study, antibiotic-exposed neonatal mice 
were more susceptible to E. coli and Klebsiella pneumoniae infection than control mice 
[219]. Furthermore, a recent study where maternal gut microbiota is altered by 
administration of non-absorbable antibiotics during pregnancy showed an influence of 
maternal gut microbiota on behavior of the offspring [220]. 
Overall, the long-term consequences of actual antibiotic prophylaxis and treatment, as 
well as its limitations, impose a need for an effective alternative against GBS infections. 
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 I.7 Vaccination 
Vaccination represents the most attractive strategy for GBS disease prevention. 
Several efforts are being made to find an efficient vaccine that would stimulate the 
production of antibodies that would not only confer protection against GBS infections 
in adults, but should also be transferable by placenta and milk, conferring protection 
against the neonatal forms of the disease.  
A real investment has been made in GBS CPS-based vaccines. The interest in the use 
of these antigens began with the detection of a correlation between low levels of 
maternal antibodies against CPS with neonatal susceptibility to GBS infection. The 
development of neonatal GBS disease was associated with low or undetected 
maternal levels of CPS-specific antibodies and, on the other hand, among mothers of 
neonates that didn’t developed GBS diseases, the majority had antibodies with CPS-
binding capacity [221-224]. Moreover, a poor neutrophil-mediated functional activity 
against GBS serotype V in healthy elderly adults was associated with low 
concentrations of type V CPS–specific antibodies [225]. 
The conjugation of CPS antigens to a carrier protein enhanced the immunogenicity 
and induced a long-lasting immune response against the polysaccharide. Monovalent 
conjugate vaccines against serotypes Ia, Ib, II, III and V have been prepared coupled 
to tetanus toxoid (TT) and were already tested in phase I and II of clinical trials. Each 
vaccine was able to induce functionally active serotype-specific IgG and, CPS III–TT 
vaccine in pregnant women, induced titers of protective IgG antibody against type III 
CPS that persisted through at least 2 months of life [226-229]. Currently, a trivalent 
vaccine against CPS of serotypes Ia, Ib and III, is already in phase II of clinical trials 
[230]. The results of the bivalent CPS-vaccine trial in healthy adults showed that the 
vaccine was well tolerated and lead to the production of higher IgG titers in those 
subjects with pre-existing anti-capsular antibody to GBS [231]. Similar results were 
obtained in vaccinated healthy elderly adults. A single intramuscular dose of serotype 
V GBS CPS–TT vaccine induced specific-antibodies that were able to promote 
opsonophagocytic killing of serotype V GBS in vitro [232]. Although capsular conjugate 
vaccines are in an advanced stage of development, the constant variation of serotype 
distribution, the existence of non-typable GBS isolates, as well as serotype 
INTRODUCTION 
23 
 
replacement/switching, hint to potential problems in the global coverage of CPS-based 
vaccines [35,233,234]. 
A GBS effective vaccine should be based on immunogenic antigens that should not 
only be surface-exposed but should also be conserved among all invasive strains. 
Some GBS surface proteins appeared as promising antigen to GBS vaccination as the 
α and β components of the C protein complex [235,236], alpha-like protein 3 [237], Rib 
protein [238], FbsA fragments [239], and C5a peptidase ScpB [240,241]. Although 
highly immunogenic and effective against GBS infections, all these protein lack the 
universality aspect of a suitable GBS vaccine.  
Surface-immunogenic protein (Sip) [242] and a combination of 3 antigens of pili 
proteins were pointed as highly conserved antigens able to induce cross-protective 
immunity against all invasive GBS serotypes [243]. Nevertheless, due their structural 
role, it is likely that under selective pressure vaccination with these antigens will lead 
to selection of GBS clones expressing new antigen variants, as already happened with 
the Neisseria gonorrhoeae pili vaccine [244].  
Our group developed a vaccine based on the GBS immunomodulatory protein 
GAPDH. This glycolytic enzyme was found at surface and in the supernatants of every 
analyzed invasive strain belonging to the different GBS serotypes [116,128]. Maternal 
vaccination with recombinant GAPDH as well as passive immunization of neonates 
with anti-GAPDH IgG antibodies confer protection to the offspring in a mouse model 
of lethal GBS infections. The mechanism responsible for the observed protection is the 
blockage of GAPDH modulatory effect on the neonatal immune system, since the anti-
GAPDH F(ab’) 2 fragments were as effective in improving survival and bacterial 
clearance as whole antibodies [128].  
Although GAPDH is ubiquitously expressed in all type of cells, including mammalian 
cells, antibodies produced against either native or denatured GBS GAPDH are not able 
to recognize human or mouse GAPDH [128]. 
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The efficacy of GAPDH vaccination, associated with the fact that this protein is highly 
conserved and essential for bacterial survival (thus being less susceptible to selective 
pressure), make it an ideal target antigen for the development of a universal vaccine.  
Vaccination would substantially reduce the burden of infant GBS disease in low-
income settings, where prenatal screening and intrapartum antibiotics are generally 
not feasible [245], and in theory, could help the control of GBS diseases in elderly 
and/or immunocompromised adults. 
The first aim of this thesis was to evaluate if the neonatal GAPDH vaccine developed 
by our group could be used against GBS infection in adults. 
 
II MICROBIAL GAPDH AS A VIRULENCE FACTOR 
GAPDH is an essential cytoplasmic enzyme involved in the glycolytic pathway and 
catalyzes the conversion of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate. 
Despite the lack of secretion signal or transmembrane domain this enzyme has been 
found at the surface or in the supernatant of several bacteria, fungi, protozoans and 
even humans. In GBS and Streptococcus pneumoniae, GAPDH extracellular presence 
is, at least in part, associated with bacterial cell lysis [144,246]. In enteropathogenic E. 
coli, cytoplasmatic GAPDH is secreted through a type III secretion system [247]. In this 
unexpected location, GAPDH exhibits various functions facilitating colonization and 
invasion of host tissues, as well as immune evasion. 
In group A Streptococcus (GAS), when surface export of GAPDH was prevented (by 
insertion of a hydrophobic tail at the C-terminal end) virulence was seriously reduced 
[248]. 
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II.1 GAPDH, a protein associated with adhesion and invasion 
Some bacterial GAPDH has the capacity to bind to extracellular matrix components 
increasing pathogen adhesion, and in some cases invasion, of host tissues. That is the 
case of GAS GAPDH which attaches to fibronectin, actin and the ATPase domain of 
myosin, suggesting a role in streptococcal colonization, particularly on injured tissues. 
The extracellular-GAPDH ability to bind cytoskeletal and extracellular matrix proteins 
has also been described in GBS, enteropathogenic and enterohemorrhagic E. coli and 
Candida albicans [116,249-251]. 
Furthermore, GAPDH of GAS, GBS, Staphylococcus spp, S. pneumoniae and 
Mycoplasma pneumoniae binds to plasminogen, which is then converted to the 
proteolytically active plasmin form. The bacterial coverage with plasmin plays an 
important role in the pathological process of infection, allowing it to escape from blood 
clots and tissue invasion [117,252-254].  
 
II.2 GAPDH in immune evasion 
As previously stated, GBS exploits GAPDH’s ability to induce an early IL-10 production 
in neonates, delaying the protective neutrophil influx to infected organs and, therefore, 
evading the host innate immune response [128]. 
GAPDH of other microorganism are also able to modulate and escape the immune 
system. For instance, GAS’ GAPDH can capture the complement C5a protein (an 
essential step for its cleavage by streptococcal C5a peptidase), which inhibits the 
recruitment of neutrophils and H2O2 production [255]. S. pneumoniae and parasitic 
nematode Haemonchus contortus GAPDH interacts with C1q and C3 complement 
protein, respectively, inhibiting their activity [246,256]. 
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II.3 GAPDH-based vaccines 
Beside the previously mentioned GBS GAPDH vaccine developed by our group, others 
GAPDH-based vaccines were already proposed, not only for human but also for 
veterinary diseases. A DNA vaccine encoded for GAPDH, for instance, was tested 
against Haemophilus parasuis, the causative agent of swine bacterial polyserositis, 
polyarthritis, and meningitis [257]. GAPDH protein of Streptococcus zooepidemicus, 
an important agent of for septicemia, meningitis and mastitis in horses, pigs, sheep, 
cows, and several other mammalian species, was also proved to be immunogenic 
[258]. 
Surprisingly, GAPDH vaccination has been a widely studied strategy against infection 
in the fishing industry. This vaccination against Edwardsiella tarda, Edwardsiella 
ictaluri, Vibrio anguillarum, Streptococcus iniae, Aeromonas hydrophila, Vibrio harveyi 
and Lactococcus garvieae, induced a protective immune response in fish [259-264]. 
Glycolytic enzymes associated with the cell surface of S. pneumoniae, of which 
GAPDH, were proved to be antigenic in humans and elicited protective immune 
responses in mice [265].  
A new approach to vaccine design consisted in using antigen presented cells loaded 
with peptide antigens as vectors. A study with DCs loaded with the Listeria 
monocytogenes GAPDH1−22 peptide conferred higher protection and security against 
listeriosis than the most explored L. monocytogenes peptide [266]. 
Overall, GAPDH seems to be a highly conserved protein between several pathogens, 
both in terms of sequence and importance as virulence factor. Nonetheless, the 
protective effect of GAPDH-based vaccination was not yet characterized in several 
microorganism where the association of this protein with virulence have been already 
described. E. coli is one of these cases. Thus, the second aim of this thesis was to 
understand if a GAPDH could be used as a vaccination target against E. coli infections, 
in a neonatal model of infection.  
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III ESCHERICHIA COLI 
E. coli is a non-sporulating Gram-negative rod-shapped bacteria with approximately 
0.5 µm in width and 2 µm in length. This bacteria is a typical colonizer of the intestine 
of warm-blooded animals and, in the human digestive tract, is the most common 
aerobic organism [267]. It is normally located in the large intestine, residing in the 
mucus layer that covers the epithelial cells, especially in the caecum and the colon. 
Usually, the host colonization by E. coli is beneficial for both species. On the one hand, 
the bacteria benefits from the host with a steady supply of nutrients, a stable 
environment and protection against some stresses, as well as a means of 
transportation and dissemination, while on the other hand, the induction of a resistant 
colonization by the normal E. coli microbiota prevents the colonization of the host 
digestive tract by pathogens [268]. Besides the innocuous commensal E. coli, this 
specie also comprises strains and variants with pathogenic potential. Some of these 
strains have the ability to cause extraintestinal infections, being therefore designated 
ExPEC (from Extraintestinal Pathogenic E. coli). The pathotypes implicated in 
extraintestinal infections are usually divided in three different sub groups: 
uropathogenic E. coli (UPEC), neonatal meningitis-associated E. coli (NMEC) and 
sepsis-causing E. coli (SEPEC) [269]. 
 
III.1 E. coli as a neonatal pathogen 
NMEC and SEPEC pathotypes are the most common cause of gram-negative neonatal 
sepsis and meningitis, with a case fatality rate of 15-40% [211,270,271]. Moreover, 
they also cause severe neurological defects in up to 50% of the survivors [211,272]. 
Over the past years, the incidence of E. coli neonatal infections seems to be increasing, 
representing about 24-29% of all EOS cases, 44% of all early-onset meningitis [211]. 
This bacterium became progressively recognized as the leading sepsis pathogen 
among preterm, being responsible for 81% of all EOS occurring in these infants. When 
very low birth weight (VLBW) infants are considered separately, E. coli surpasses GBS 
as the most frequent cause of EOS, accounting for 33.4% of all episodes [273]. The 
INTRODUCTION 
 
28 
 
rise of pathogenic E. coli in neonatal infections can be in part explained by the increase 
in preterm births and in the survival of VLBW [28,212]. 
In the 1997-2006 period in the US, E. coli EOS in VLBW infants occurred in 10.22 
cases per 1000 VLBW admissions whereas LOS was observed in 21.66 cases per 
1000 VLBW admissions and 8.23 cases per 1000 admissions of term infants [212]. 
As already described for GBS neonatal infections, E. coli vaginal colonization of 
pregnant women seems to be an important step for vertical transmission. Early and 
heavy E. coli vaginal colonization during pregnancy is associated with higher risk of 
VLBW and prematurity [274]. The presence of this bacterium in vaginal microbiota was 
observed in 13–15% of pregnant women [275,276].  
E. coli strains fall into 5 major taxonomic lineages, A, B1, B2 and D, and are commonly 
classified by their three major surface antigens: the O antigen (that is part of the 
lipopolysaccharide, LPS), the H antigen (flagellum) and the K antigen (capsular 
polysaccharide) [277]. Neonatal sepsis and meningitis are associated with a limited 
number of phylogenetic groups, in sharp contrast with the wide genetic diversity of 
human commensal E. coli isolates. Most of E. coli strains that cause these diseases 
belong to the highly clonal B2 group [272,278] and 81-83% of NMEC and 60% of 
SEPEC strains express the K1 capsule antigen [278-281]. These strains come from 
the intestinal flora and are positively select for their ability to adapt to the vaginal 
environment and to the amniotic fluid during pregnancy [278]. 
The ability of E. coli K1 strains to pass over to the bloodstream after gastrointestinal 
colonization has been vastly documented in neonatal rat models [219,282-286]. Oral 
or intragastric administration of E. coli K1 resulted in stable and persistent 
gastrointestinal colonization of both adults and pups but systemic infection was only 
detected on the latter group. The ability to induce a systemic infection was closely 
dependent with the age of the neonates. Two-day old pups were considerably more 
susceptible to bacterial invasion than nine-day-old ones [285,286]. At early stages of 
infection, a small number of E. coli K1 were found in the mesenteric lymphatic system 
indicating that this route could be important for the invasion of the blood circulation 
[283,285].  
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Two-day old pups colonized in the gastrointestinal tract by E. coli K1 are unable to 
produce defensin peptides in the lumen of the small intestine. This dysregulation, 
associated with a poor maturation of the mucus barrier in newborn pups was 
insufficient to prevent translocation of E. coli K1 from gut lumen to blood circulation. 
An integral mucus barrier is already formed at day nine after birth, preventing systemic 
invasion [286]. In a study with bioluminescent E. coli K1 infection, both keratinized and 
non-keratinized surfaces of esophagi were colonized to a considerably greater extent 
in susceptible two-day old pups than in corresponding tissues from infection-resistant 
olds pups [285]. The bacteria appeared to damage and penetrate the non-keratinized 
esophageal epithelium of infection susceptible animals. This result raises the 
possibility that the esophagus represents an additional place of translocation of E. coli 
K1 to the blood [285]. 
Currently, there are no guidelines for prophylaxis of E. coli neonatal diseases. During 
EOS, the antibiotics are selected empirically, based on the likelihood of etiologic 
pathogens, and typically consist of ampicillin and gentamicin. Usually, bacterial 
identification, in blood, cerebrospinal fluid (CSF) and/or urine, is made only after the 
initial treatment. In several cases, if E. coli infection is confirmed, cephalosporins are 
added to the initial treatment [28,287].  
E. coli resistance to antibiotics has been increasingly reported, particularly by the 
production of extended-spectrum beta-lactamase (ESBL). These enzymes confer 
resistance to nearly all β-lactam antimicrobial drugs, including the third-generation 
cephalosporins. Resistance to aminoglycosides was also observed in ESBL producers 
[211,288]. In Poland, 91,7% of all E. coli neonatal isolates were resistant to ampicilin, 
54,2% to amoxicillin, 41,7% to trimethoprim-sulfamethoxazole and 33.3% to 
aztreonam [272]. 
 
III.2 E. coli virulence factors  
From the initial site of colonization, E. coli transcytoses the gastrointestinal tract into 
the bloodstream, and from there, colonizes several organs or traverses the BBB into 
the central nervous system (CNS). Since a successful CNS invasion requires a high 
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bacteremia, NMEC must survive in the bloodstream. Bacterial invasion, survival and 
replication within the host cells are traits mediated by bacterial virulence factors.  
Isolates associated with ExPEC and specifically to NMEC and SEPEC, express 
specialized virulence genes when compared to the isolates of other groups. That is the 
case of the K1 capsule, fimbriae, alpha-hemolysin, rough lipopolysaccharide, brain 
endothelium invasion proteins (Ibe), outer membrane protein A (OmpA), cytotoxic 
necrotizing factor (CNF) 1, Traj, TraT, Nlpl, arylsulfatase-like A (aslA) and increased 
serum survival protein (Iss) (Figure 3).  
Since CSF and human serum are iron-deficient environments, iron acquisition genes 
and proteins have also been implicated as important factors for E. coli virulence. NMEC 
and SEPEC possess iron uptake systems that are not found in non-virulent fecal E. 
coli strains from both human and animal sources [272,289]. 
 
Figure 3. E. coli K1 virulence factors associated with the different stages of neonatal 
infection. Some of the E. coli K1 virulence factors associated with immune evasion stages 
(inhibition of complement activation, phagocyte intracellular killing and dendritic cell (DC) 
maturation) and blood-brain barrier (BBB) adhesion and invasion. K1 capsule impairs 
complement opsonization. E. coli K1 Iss and TraT inhibit the formation of complement 
membrane attack complex. OmpA, with the help of Nlpl binds to C4 bp, a classical complement 
pathway regulator, to block the complement cascade reaction. The association of E. coli K1 
OmpA with its receptors in phagocytes induces bacterial internalization but inhibits the 
microbicidal mechanism (ROS formation, apoptosis and pro-inflammatory cytokine production 
dependent of NF-ΚB), while increases iNOS production and consequent up-regulation of 
OmpA receptor, allowing the intracellular survival of the bacterium. E. coli K1 infection induces 
the expression of CD47 and its ligand TSP-1, inhibiting DC maturation. The association of E. 
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coli K1 fimbriae and OmpA to their receptors, as well interaction of CNF1, aslA, Ibe and traJ 
proteins with brain endothelium cells, allow bacterial adherence and induce cytoskeletal 
rearrangements essential for E. coli K1 BBB invasion. See text for references. 
III.2.1 Adherence and cell invasion 
Blood-brain barrier (BBB) adherence and invasion is probably the most studied feature 
of NMEC. It is widely accepted that E. coli successful crossing of BBB requires a 
threshold level of bacteremia [290], invasion of brain microvascular endothelial cells 
(BMEC), and specific host cell signal-transduction pathways [291]. E. coli invasion of 
BMEC monolayers was visualized by electron microscopy and intracellular E. coli 
organisms were found within intracellular vacuoles [292]. 
Several E. coli proteins have been associated with bacteria-BMEC interactions with 
important roles in central nervous system invasion. E. coli attachment to the BBB is 
essentially mediated by OmpA and Type 1 fimbriae (Figure 3). 
Type 1 fimbriae are filamentous surface organelles produced by E. coli that are 
regulated by a phase variation, in which each individual bacterium can alternate 
between fimbriated and nonfimbriated states. In E. coli K1, type 1 fimbriae have been 
shown to be important for oropharyngeal colonization in a neonatal rat model, although 
not relevant for intestinal colonization or bloodstream invasion [293]. The fimbriae are 
composed of a major FimA protein and a small tip structure containing FimF, FimG, 
and FimH [294]. Type 1 fimbriae contribute to the interaction between the meningitis-
causing E. coli K1 and human BMEC (HBMEC) [295] in part by association of the 
lectin-like adhesin FimH with glycosylphosphatidylinositol-anchored receptor CD 
(cluster of differentiation) 48 on HBMEC’s surface [296]. This association triggers host 
cell signaling cascades that are involved in E. coli K1 invasion of HBMEC [296] . 
OmpA is one of the major outer membrane proteins in E. coli and its expression 
significantly enhances the E. coli invasion of BMEC [297,298]. OmpA binds to the 
GlcNAc1-4GlcNAc epitopes of Ecgp96, a homologue of endoplasmic reticulum specific 
gp96, which is present specifically on BMEC but not on systemic endothelial cells [299]. 
Blocking of E. coli K1 association with Ecgp96 with a derivative of telmisartan, an 
angiotensin II receptor type 1 (AT1R) blocker, prevented the onset of neonatal E. coli 
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meningitis [300]. Although the contributions of type 1 fimbriae and OmpA to E. coli K1 
binding to and invasion of HBMEC are independent of each other or at least partially 
additive, the deletion of OmpA genes in E. coli K1 is associated with a decrease in the 
expression of type 1 fimbriae [301].  
Deletion of E. coli K1 proteins, such as Ibe proteins [302], traJ [303], aslA [304], and 
CNF1 [305] decreased the ability of the bacteria to invade BMEC. This invasion is a 
prerequisite for penetration into the central nervous system and requires actin 
cytoskeletal rearrangements (Figure 3). E. coli internalization into BMEC was inhibited 
by more than 90% when microfilament-disrupting agents were added to infected 
cultures [292]. The Rho family GTPases, including RhoA, Rac1, and Cdc42, have been 
identified as molecular switches that regulate actin cytoskeleton organization. FimH 
and CNF1 are likely to contribute to HBMEC invasion via RhoA activation, whereas Ibe 
proteins and OmpA contribute to HBMEC invasion via Rac1 activation and cytosolic 
phospholipase A2. The addition of human transforming growth factor-beta (TGF-β) in 
E. coli K1 infected HBMEC increased invasion in a RhoA-dependent way [306]. 
 
III.2.2 Host immune evasion  
Newborns are especially susceptible to infection by ExPEC, before or soon after birth, 
due to particular characteristics of their immune system which is adapted for early 
postnatal life [307]. Both innate and adaptive immunity are distinct at birth relative to 
adulthood, as the development of the immune system entails a number of age 
dependent maturation, during the first years of life.  
Upon birth, newborns are exposed for the first time to a wide range of foreign antigens 
and, since they don’t possess immunologic memory, they are thought to be heavily 
dependent on their innate immune system for protection against infection [308]. 
Complement system 
One of the first serological defenses of the innate immune system is the complement 
system. The concentration of all circulating complement proteins and complement 
INTRODUCTION 
33 
 
mediated opsonic capabilities are decreased in the neonatal plasma, when compared 
to the levels in adults [308-310]. Complement levels increase after birth and take 
months to reach adult concentrations [309]. These reduced levels are associated with 
deficient opsonization and impaired bacterial killing. In particular, the serum 
concentration of complement factor C9, essential for the formation of the membrane 
attack complex (MAC), is profoundly decreased in the newborns. Supplement of C9 
protein to neonatal human serum enhanced the capacity to kill E. coli K1, although less 
efficiently than pooled adult sera [311].The K1 antigen is a polysialic acid 
immunochemically indistinct from the capsular antigen of serogroup B Neisseria 
meningitidis. It confers invasiveness to the bacteria by impairing complement 
opsonization and consequent phagocytosis [312]. E. coli K1 OmpA binds to C4-binding 
protein (C4 bp), a classical complement pathway regulator, to block the complement 
cascade reaction, and thereby avoid bacteriolysis and recognition by immune cells 
[313]. E. coli lipoprotein NlpI seems to contribute for this effect on the complement 
pathway [314]. Moreover, E. coli TraT and Iss protein have been associated with an 
interference with MAC formation [315,316] (Figure 3).  
Innate immune cells 
The increased susceptibility of the neonate to bacterial infections has also been 
associated with a quantitative and qualitative age-dependent deficit in the neonatal 
innate cell population [317,318]. Neutrophils, macrophages and dendritic cells develop 
and mature during fetal life, but at different times, and the function of all components 
of innate cell immunity is weak in newborns compared to later in life [307,319]. At the 
end of the third trimester there are already mature neutrophils, which increase in 
number, shortly before birth, due to stimulation with granulocyte-colony-stimulating 
factor [307]. Their number then returns to a stable level within days however, in 
response to infection, newborns showed a limited capacity to increase neutrophil 
numbers, probably due to a diminished bone marrow storage pool [320]. Additionally, 
neonatal neutrophils show a reduced bactericidal function and NET formation [321-
323], poor responses to inflammatory stimuli, reduced adhesion to endothelial cells 
and diminished chemotaxis when compared to neutrophils from adult counterparts 
[324,325]. 
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The survival of E. coli in neutrophils appears to be the first step in the pathogenicity of 
these bacteria and has already been described in peripheral blood-derived human 
neutrophils [326]. E. coli K1 infection of neutrophils increases the cell surface 
expression of gp96, enabling the association with E. coli OmpA. The interaction of 
OmpA with its receptor on neutrophils allows the internalization of the bacteria and 
inhibits the production of reactive oxygen species (ROS), even in the presence of 
external stimuli such as LPS. This suppression of the oxidative burst allows bacterial 
survival inside neutrophils (Figure 3). Proof of concept was established by neutrophil 
depletion that prevented the onset of meningitis in three-days old newborn mice 
intranasally infected [327].  
Moreover, ExPEC express a secretory immunoglobulin A-binding protein (EsiB) that, 
by interaction with secretory immunoglobulin A (SIgA), interfered with SIgA-induced 
neutrophil chemotaxis and respiratory burst [328]. Conversely, neutropenia was 
associated with impaired host defense and increased susceptibility to E. coli K1 
infection in a model of microbiota disruption in five-day old intraperitoneally infected 
mice [219] and a decrease on neutrophil recruitment was associated with higher 
colonization levels of TRIF KO neonatal [329].  
Monocytes, macrophages and dendritic cells of preterm and newborn infants have both 
quantitative and qualitative differences when compared with adults. Monocytes have 
reduced MHC II expression, which potentially contributes to impairment of antigen 
presentation [330,331]. Despite human newborns having a basal TLR expression in 
blood monocytes similar to adults (with exception of preterm that have diminished 
TLR4 expression), the functional consequences of the activation of the signaling 
pathways is quite different [308]. 
As neutrophils, macrophages have been characterized as permissive niches for E. coli 
K1 survival. Bacterial entrance, survival, and intracellular replication were observed in 
both murine and human macrophage cell lines, as well as in monocytes and 
macrophages of newborn rats [332]. Again, OmpA is the central protein for this effect. 
The interaction of this protein with the alpha chain of Fcγ receptor I (FcγRI, CD64) is 
required for E. coli K1 entry into macrophages, for which IgG opsonization is not 
necessary [333,334] (Figure 3). The bacteria increases FcγRI expression on 
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macrophages by inducing pterin production, which, not only helps the entry of E. coli 
K1 in macrophages but also suppresses reactive oxygen species [335]. E. coli 
internalization and survival within professional phagocytes during early dissemination 
seems to also be dependent on TraJ expression [336]. Bacterial entry and 
multiplication within monocytes and macrophages permits the high grade bacteremia 
crucial to the pathogenesis of meningitis in neonates [336]. Nevertheless, in TRIF KO 
neonatal mice, the susceptibility to E. coli infection was associated with a decreased 
in the recruitment of peritoneal neutrophils and macrophages [329] and in a model of 
intracerebral injection of E. coli K1, the depletion of neutrophils and monocytes 
increased the susceptibility to the infection [337]. Overall, the detrimental/ protective 
effect of phagocytes in E. coli infection in vivo seems to be dependent on the animal 
model and type of inoculation that is used.  
To survive within phagocytes, E. coli K1 uses several strategies. One of the 
approaches is the induction of anti-apoptotic protein BclXL expression and consequent 
blockade of mitochondrial cytochrome c release and inhibition of macrophages 
apoptosis [338]. Another, and unexpected, strategy for survival inside macrophages 
appears to be the induction of inducible nitric oxide (iNOS). Peritoneal macrophages 
and polymorphonuclear leukocytes isolated from iNOS KO mice demonstrated 
enhanced uptake and killing of E. coli K1 compared with macrophages and 
polymorphonuclear leukocytes from wild-type mice [339]. This counterintuitive effect of 
iNOS in E. coli infection is in part linked to the increase of OmpA receptor expression 
by NO production [340].  
E. coli K1 infection of monocytes suppresses the production of cytokines and 
chemokines (TNF-α, MIP-1α, IL-1β and IL-8). This suppression is dependent of OmpA 
surface expression. OmpA prevents the phosphorylation and degradation of inhibitor 
ΚB, thereby blocking the translocation of nuclear factor (NF)-ΚB to the nucleus and 
consequent cytokine and chemokine production [341]. 
E. coli K1 invasion, intracellular survival and replication were also observed in myeloid 
DCs. Once more, OmpA deletion impairs this E. coli capability. Exposure of DCs to live 
E. coli K1, significantly up-regulates the expression of CD47, an integrin-associated 
protein, and its natural ligand thrombospondin 1 (TSP-1). CD47 is one of the molecules 
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that have been implicated in the tolerogenicity of immune cells and, in this case, 
prevented DCs from progressing in their maturation process [342] (Figure 3). The 
inhibitory effect on DC maturation was confirmed by failure to upregulate costimulatory 
molecules, CD40, HLA-DR, and CD86 and by an increased production of IL-10 as well 
as TGF-β and decreased production of IL-6, TNF-α, IL-1β, and IL-12p70 [343]. 
Blocking of OmpA with specific antibodies abrogated the suppressive effects of E. coli 
on DC maturation and the inhibition of CD47 expression conferred protection to 
infected pups in a model of E. coli K1-induced meningitis [342,343]. 
Moreover, immunosuppressive CD71+ erythroid precursor cells have been shown to 
compromise neonatal host defenses against E. coli infection. These cells are enriched 
in neonatal mice and human cord blood and have distinctive immunosuppressive 
properties, essentially due to the expression of the enzyme arginase-2. The depletion 
of CD71+ cells in neonatal mice, or the decline in number of these cells as postnatal 
development progresses, restored resistance to E. coli infection [344]. 
Toll-like Receptors and cytokines 
The proper development of an immune response by innate immune cells is not only 
dependent on the inherent properties of the cells, but also on the identification of the 
pathogen and on the subsequent cell signals.  
As previously mentioned, TLR basal expression and cellular distribution in monocytes 
from term newborns occurs at adult-like levels. Moreover, similar activation of neonatal 
and adult mononuclear samples is achieved in response to several tested TLR ligands 
[345]. Nevertheless, decreased expression and activation of intracellular signaling 
intermediates was detected in cord-blood cells [346-348]. 
Another important neonatal PRR is the β2-integrin CR3. Beside its role in binding 
complement, it also binds LPS and other microbial surface components [349]. The 
expression of this receptor is decreased on neonatal PMN and monocyte cells, with 
reduced levels in preterm neonates [350,351]. 
Although not observed on all studies, in response to many stimuli, including most TLR 
agonists, human neonatal cord blood cells exhibit a market polarization, with reduced 
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capacity to produce TH1-polarizing cytokines such as TNF-α, INF-γ and IL-12p70 and 
increased production of TH2/TH17 and anti-inflammatory cytokines such as IL-6, IL-
10, IL-17, IL-1β and IL-23 [308,345]. Interestingly the capacity to produce IL-10 is even 
greater in preterm infants, whereas production of IL-6 and IL-23 are dominant in term 
infants [345,352].  
TNF-α and IL-1β production during infection is associated with premature labor and 
favors abortion. This is, possibly, a relevant reason for the bias of maternal and fetal 
immune responses towards Th2-polarizing cytokines [353]. Plasma adenosine, an 
endogenous plasma metabolite that rises with hypoxia and stress, is elevated in 
newborn blood plasma and is, at least in part, responsible for the shift towards a high 
IL-6/TNF-α production ration by newborn cells [354].  
TLR signaling proceeds through one of three different pathways: MyD88 alone, TRIF 
alone or the unique case of TLR4 in which both MyD88 and TRIF pathways are 
activated. TRIF KO mice neonates were more susceptible to intraperitoneal E. coli 
infection than WT or MyD88 KO pups [329]. Consistently, newborn TLR2 KO mice 
were proved to be more resistant to E. coli K1 meningitis, while TLR4 KO ones 
succumb to infection sooner than WT. In this study, resistance of TLR2 KO mice was 
associated with a decrease expression of Ecgp96 at the surface of BMEC [299]. The 
presence of the K1 capsule appears to be an important factor for the modulation of 
innate immune recognition of E. coli. The lack of CD14 (co-receptor with TLR4 and 
MD-2 of LPS) expression had no effect in survival of adult mice to E. coli K1, whereas 
CD14 KO mice presented higher resistance to K1-negative E. coli infection than WT 
mice [355].  
Surprisingly, Toll-like receptor pre-stimulation appears to confer protective effects to 
immune cells, both in vitro and in vivo, against E. coli K1 infection. Stimulation of 
murine microglial cells with both TLR1/TLR2, TLR3, TLR4 and TLR9 agonists 
increases the phagocytic activity of the cells, promoting the killing of the bacteria as 
well as the production of TNF-α and neutrophil chemoattractant CXCL1 [356,357]. 
Moreover, intraperitoneal prophylaxis with CpG oligodeoxynucleotides (TLR9 agonist) 
protected neutropenic adult susceptible mice against intracerebral E. coli K1 infection 
[358]. 
INTRODUCTION 
 
38 
 
The presence of cytokines, such as TNF-α, IL-1β, and IL-6 in CSF and blood is a 
hallmark of the pathogenesis of neonatal meningitis and sepsis. E. coli LPS is a well-
known inducer of pro-inflammatory cytokines and several studies show a pro-
inflammatory cytokine production after LPS or E. coli challenge. In neonates, however, 
E. coli K1 infection of monocytes blocked the production of cytokines and chemokines, 
even after stimulation with exogenous LPS [341], indicating that suppression of pro-
inflammatory response in the replication stage is advantageous to E. coli for the 
establishment of meningitis. Nevertheless, the production of the anti-inflammatory 
cytokine IL-10, that is triggered during neonatal intranasal infection with E. coli K1 
infection [359], is required for host survival, pathogen control and prevention of hyper-
inflammatory immune responses [359]. IL-10 administration prior infection or during 
high grade bacteremia improved the outcome of E. coli K1 sepsis and meningitis 
[359,360]. This IL-10 administration induced the up-regulating CR3 expression on 
neutrophils and macrophages of infected mice, whereas infected and untreated mice 
displayed increased expression of FcγRI and TLR2 [359], receptors associated with 
bacterial survival inside host cells [299,335]. A protective effect of IL-10 administration 
on newborns was also observed on a model of maternal E. coli intrauterine inoculation 
and neonatal white matter injury [361]. Moreover, anti-TNF antibody pre-treatment was 
not capable of preventing the occurrence of E. coli K1 meningitis in newborn mice 
[359]. However, in a model of E. coli neonatal sepsis, TNF-α blocking resulted in a 
significant improvement in survival rate compared with not treated mice. [360] 
Overall, the neonatal immune response to E. coli still needs to be further elucidated. 
So, the third aim of this thesis was to decipher some of the key aspects of E. coli K1 
interaction with the neonatal immune system, by using a mice model with a natural 
route of infection.  
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ABSTRACT 
Group B Streptococcus (GBS), a commensal organism, can turn into a life-
threatening pathogen in neonates and elderly, or in adults with severe underlying 
diseases such as diabetes. We developed a vaccine targeting the GBS 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a glycolytic enzyme 
detected at the bacterial surface, which was proven to be effective in a neonatal 
mouse model of infection. Since this bacterium has emerged as an important 
pathogen in non-pregnant adults, here we investigated whether this vaccine also 
confers protection in an adult susceptible and in a diabetic mouse model of infection. 
For immunoprotection studies, sham or immunized adult mice were infected with 
GBS serotype Ia and V strains, the two most prevalent serotypes isolated in adults. 
Sham and vaccinated mice were also rendered diabetic and infected with a serotype 
V GBS strain. For toxicological (pre-clinical) studies, adult mice were vaccinated 
three times, with three concentrations of recombinant GAPDH adjuvanted with 
Allydrogel, and the toxicity parameters were evaluated twenty-four hours after the 
last immunization. For the stability tests, the vaccine formulations were maintained 
at 4°C for 6 and 12 months prior immunization. The results showed that all tested 
doses of the vaccine, including the stability study formulations, were immunogenic 
and that the vaccine was innocuous. The organs (brain, blood, heart, and liver) of 
vaccinated susceptible or diabetic adult mice were significantly less colonized 
compared to those of control mice. Altogether, these results demonstrate that the 
GAPDH-based vaccine is safe and stable and protects susceptible and diabetic 
adult mice against GBS infections. It is therefore a promising candidate as a global 
vaccine to prevent GBS-induced neonatal and adult diseases.  
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INTRODUCTION 
Streptococcus agalactiae, or Group B Streptococcus (GBS), is the leading cause of 
life-threatening bacterial infections in newborns [1]. In the past three decades, this 
bacterium have emerged as a major cause of invasive infections in non-pregnant 
adults, mainly in individuals with more than 65 years old or with underlying medical 
conditions [2-5]. Diabetes mellitus appears as the most common predisposition for 
GBS bacteremia in this group [2,5]. The case fatality rates are higher in adults than 
in neonates [2,6]. Eighty percent of human GBS isolates are resistant to tetracycline 
and it has been recently proposed that the widespread use of this antibiotic from 
1948 was responsible for the selection of few tetracycline-resistant clones 
particularly adapted to the human host, thereby causing the emergence of GBS 
diseases in neonates in the 60s [7]. GBS express a capsular polysaccharide (CPS) 
and ten serotypes have been described to date (Ia, Ib, and II–IX). While GBS 
serotype III strains are strongly associated with neonatal meningitis, serotype V 
isolates emerged in the United States as the most frequent serotype causing 
invasive disease in nonpregnant adults, followed by serotypes Ia and III [5]. These 
three capsular serotypes are also associated with the vast majority of invasive 
infections in several European countries [8-10]. The only available treatment against 
GBS infections is based on the use of antibiotics. The implementation of the 
intrapartum antibiotic prophylaxis (IAP) in colonized pregnant women contributed to 
the decrease of the early-onset manifestations of GBS diseases (infection occurring 
in the first week of life). However, the IAP treatment has contributed to the 
emergence of antibiotic-resistant clones [6] with no effect on the late-onset neonatal 
disease (infections occurring between the first week and the first month of life). The 
rate of adult GBS disease has not declined until now and the use of antibiotics will 
likely cause increased resistance as observed with neonatal GBS isolates. 
Therefore, the development of a vaccine, as an alternative approach to the current 
use of antibiotics, will benefit neonates, pregnant and nonpregnant adults [11].  
GBS vaccines have been initially developed by coupling capsular polysaccharide 
(CPS) antigens to immunogenic protein carriers but the existence of distinct epitope-
specific capsular serotypes has hampered the development of a global GBS vaccine 
[12]. To avoid the selection of mutants that escape immune recognition, the ideal 
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human GBS vaccine should be directed against structurally conserved antigens that 
are essential for GBS virulence and/or growth, but none of the hitherto described 
candidate antigens fulfills these requisites. 
We showed in a mouse model of neonatal GBS infection that GBS glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) is a valuable vaccine candidate. Maternal 
vaccination with the recombinant form of this protein was highly effective in 
protecting the offspring against a lethal infection with GBS [13]. Importantly, the 
antibodies raised against the bacterial GAPDH did not react with the human GAPDH 
[13]. However, before being used in clinical practice, a vaccine must pass several 
rigorous pre-clinical tests to evaluate its safety, effectiveness, or possible side 
effects [14]. Therefore, in this study, we conducted a comprehensive series of 
experiments to evaluate the stability, systemic toxicity, and local reactogenicity of 
the rGAPDH vaccine. These experiments were designed to identify any potential 
systemic and organ-specific toxicity, and to evaluate the stability of the vaccine 
formulation. Moreover, given the increased cases of adult infections with this 
pathogen, we assessed the effectiveness of rGAPDH vaccine against the infection 
caused by GBS in adult susceptible mice using two GBS strains, A909 and 
2603V/R, belonging to serotypes Ia and V, respectively. Since diabetes is present 
in 20-40% of non-pregnant adults infected with GBS [2,4,5], we also tested the 
efficacy of rGAPDH vaccine in mice rendered diabetic. The obtained results showed 
that rGAPDH vaccine is highly immunogenic and stable for at least 12 months at 
4°C, and no systemic or organ specific toxicity were observed. The protective 
assays proved that the vaccine constituted by GAPDH is effective against the 
infections caused by GBS in susceptible and diabetic adult mice. These results 
identify GBS GAPDH as a valuable global human vaccine to prevent neonatal and 
adult GBS diseases.   
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MATERIALS AND METHODS 
Animals 
Balb/cAnNCrl mice were purchased from Charles River (Italy). All the animals were 
kept in the animal facilities of the Institute Abel Salazar during the time of the 
experiments. Mice were 6-8 weeks of age at the beginning of experiences. They 
were housed in Techniplast ventilated polycarbonate cages under positive pressure 
with hardwood bedding and provided with Mucedola Diet and fresh tap water, ad 
libitum, throughout the study. All animals were housed in environmentally controlled 
cages with 40 air changes per hour.  
Ethics statement 
This study was carried out in strict accordance with the recommendations of the 
European Convention for the Protection of Vertebrate Animals used for 
Experimental and Other Scientific Purposes (ETS 123) and Directive 2010/63/EU 
and Portuguese rules (DL 113/2013). The animal experimental protocol was 
approved by the competent national authority Direção Geral de Alimentação e 
Veterinária (DGAV) (Protocol Permit Number: 0420/000/000/2008). All animal 
experiments were planned in order to minimize mice suffering. 
Bacteria 
GBS A909 (NEM2526) and 2603V/R (NEM2433) belong to capsular serotype Ia and 
V, respectively. They were grown in Todd-Hewitt broth or agar (Difco Laboratories) 
at 37°C.  
Purification of recombinant GAPDH 
E. coli BL21 (DE3) strain (Novagen) and the pET28a plasmid (Novagen) were used 
for production of the recombinant GAPDH (rGAPDH) protein from GBS NEM316 as 
described previously [15]. 
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Formulations 
rGAPDH vaccine for protection and safety studies were formulated prior to 
immunization with 10 µg (V10 group), 20 µg (V20 group), or 40 µg (V40 group) of 
protein, a dose corresponding to 0.5, 1 and 2 mg/kg of rGAPDH, respectively, in a 
1:40 PBS-Alhydrogel suspension. The sham-immunized control animals received 
200 µL of PBS (Vehicle control without Alhydrogel) or a 1:40 PBS-Alhydrogel 
suspension (Vehicle control with Alhydrogel). The vaccine used in stability studies 
was formulated immediately after rGAPDH purification with 20 µg of rGAPDH in a 
final volume of 200 µL of a 1:40 PBS-Alhydrogel suspension (Aluminium hydroxide 
Gel; Brenntag) and was maintained at 4°C for 0, 6, and 12 months (S0, S6 and S12 
groups, respectively). 
Vaccine safety studies  
A total of 30 female Balb/c mice, in groups of 6, were injected s.c. three times, with 
a three-week intervening period, with 200 µL of V10, V20, or V40. The sham-
immunized controls received 200 µL of PBS or 1:40 PBS-Alhydrogel suspension.  
Cage side observations were performed daily and included evaluation of mortality, 
morbidity, general health, and signs of toxicity. Clinical observations were performed 
twice a week. Body weight was determined twice a week. Reactogenicity of 
immunization site was scored for edema, ulcer, and erythema using a scale from 
zero for no symptoms to four for severe symptoms. Reactogenicity scoring was 
performed on all the mice in each study group after each dosing. One day after 
administration of the last dose (Day 43), all animals were fasted overnight and 
euthanized for interim necropsy. Prior to necropsy, terminal blood was collected 
from all mice under Rompum/Imalgene 1000 anesthesia. Plasma was used for 
clinical chemistry analyses which included alanine aminotransferase (ALAT), 
aspartate aminotransferase (ASAT), albumin, amylase, lactate dehydrogenase 
(LDH), complement component 3 (C3), creatine kinase (CK), creatine kinase MB 
(CK-MB), total protein, creatinine, total bilirubin, glucose and Clara cell secretory 
protein 16 (CC16). Moreover, quantitative tests of 24-hour urine were also carried 
out with metabolic cages, for the evaluation of the levels of creatinine, N-acetyl-beta-
D-glucosaminidase (NAG), and urea. All reagents were obtained from PZ Cormay 
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S.A with exception of NAG reagents that were obtained from Diazyme Europe 
GmbH. 
Plasma biochemical parameters were measured in duplicate on an AutoAnalyser 
(PRESTIGE 24i, PZ Cormay S.A). Urinary urea, creatinine and total proteins were 
measured in duplicate according to previously described methods [16,17]. 
Plasmatic Clara cell 16 was quantified with an Enzyme Linked Immunosorbent 
Assay kit (USBiological) used according to the manufacturer's instructions. 
Animals were subjected to a full gross necropsy. External features suggesting any 
abnormality, especially evidence of lymph node enlargement was register. After 
opening the chest and abdominal cavities, an in situ examination was done. Heart, 
lungs, liver, spleen, kidneys, gastrointestinal tract, pancreas, thymus and injection 
site were studied. The individual organs (liver, spleen, kidney, lung and heart) were 
removed and re-examined for gross morphology changes. After examination, they 
were weighed, adequately sliced and fixed in 4% (v/v) neutral buffered 
paraformaldehyde by diffusion, for 24h, and subsequently dehydrated with graded 
ethanol and included in paraffin blocks. Xylene was used in the transition between 
dehydration and impregnation. Sections of 5 µm were cut from paraffin blocks on a 
microtome (Leica Microsystems, Model RM2125) and mounted on silane coated 
slides. After dewaxing with xylene and rehydrated with graded alcohol, slides were 
stained with hematoxylin/eosin and examined under a light microscope (Zeiss Axio 
ImagerA1) by a certified veterinary pathologist. For every visual field, the 
histopathological evidences of tissue damage were analyzed as previously 
described [18] and a total histopathological score was calculated for each organ, 
allowing the comparison among all groups. 
Vaccine stability studies 
A total of 20 female Balb/c mice, in groups of 4, were injected subcutaneously (s.c.), 
three times, with a three-week intervening period, with 200 µL of S0, S6 and S12 
preparations containing 20 µg of rGAPDH in a 1:40 PBS-Alhydrogel suspension. 
The sham-immunized control animals received 200 µL of PBS or a 1:40 PBS-
Alhydrogel suspension. Cage side and clinical observations as well as evaluation of 
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the reactogenicity of immunization site were performed as described above for 
safety vaccination studies. 
Immunoprotection studies  
Balb/c mice were injected subcutaneously (s.c.), three times, with a 3-week 
intervening period with 20 μg dose of rGAPDH in a 1:40 PBS-Alhydrogel 
suspension. The sham-immunized control animals received 200 µL of 1:40 PBS-
Alhydrogel suspension. Mice were infected i.p. with 0.3 ml of PBS containing 3x106 
CFU of GBS A909, or 3x107 CFU of GBS 2603V/R, and sacrificed at indicated 
timepoints. Survival curves were determined over a 20-day experimental period. 
Prior to necropsy, terminal blood was collected from all mice under 
Rompum/Imalgene 1000 anesthesia. Blood was collected and analyzed for GBS 
counts and the serum was used for cytokine analysis. The analyzed organs were 
aseptically removed, homogenized in PBS and serial dilutions of homogenized 
organs were plated on Todd-Hewitt agar to enumerate bacterial CFU.  
Diabetes mouse model 
Balb/c mice were injected subcutaneously (s.c.), three times, with a 3-week 
intervening period with 20 μg dose of rGAPDH in a 1:40 PBS-Alhydrogel 
suspension. The sham-immunized control animals received 200 µL of 1:40 PBS-
Alhydrogel suspension. One week after the second immunization, diabetes was 
induced by i.p. administration of a single dose of streptozotocin (Sigma) at 200 
mg/kg freshly dissolved in 0.05M citrate buffer, pH 4.5 [19]. Plasma glucose levels 
were measured by OneTouch Verio blood glucose meter system (LifeScan, 
Johnson and Johnson Company). Serum glucose levels of control animals ranged 
from 75-195 mg/dl. Mice showing non-fasting serum glucose levels above 600 mg/dl 
at the time of the third immunization STZ-injection were considered diabetic and 
used for the study. Mice were infected i.p. with 0.3 ml of PBS containing 3x107 CFU 
of GBS 2603V/R one week after the last immunization and sacrificed 18h post-
infection. Prior to necropsy, terminal blood was collected from all mice under 
Rompum/Imalgene 1000 anesthesia. Peritoneal lavage was performed with 5 mL of 
ice-cold PBS. The analyzed organs were aseptically removed, homogenized in PBS 
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and serial dilutions of homogenized organs were plated on Todd-Hewitt agar to 
enumerate bacterial CFU.  
Quantification cytokines and CRP  
TNF-α, IL-6, IL-1β and C-reactive protein (CRP) were quantified with an Enzyme 
Linked Immunosorbent Assay kit (eBioscience) used according to the 
manufacturer's instruction. 
Antibody titration 
Total IgG and rGAPDH-specific IgG antibodies titers were assessed in the plasma 
of immunized mice by Enzyme Linked Immunosorbent Assay. Briefly, serial dilutions 
of the serum of immunized mice were added to the wells of a microtiter plate (NUNC) 
coated with rGAPDH (5 µg/mL) for two hours at room temperature.  
A conjugated goat anti-mouse IgG-HRP (H+ L, 1:1000, SouthernBiotech) antibody 
was then added and the plate was incubated for two additional hours at room 
temperature. The o-phenylenediamine substrate solution (Pierce) was added and, 
after addition of the stop solution, the color reaction was measured immediately by 
the absorption at 450 nm using a spectrophotometer (Thermo Multiskan Ex).  
Statistical analysis 
All statistical analyses were performed in GraphPad Prism version 5.0 for Windows 
(GraphPad Software, San Diego, California). For safety studies, one-way ANOVA 
with post-hoc Dunnett's Multiple Comparison Test with 95% of confidence was used 
to analyze the differences between all groups and Alhydrogel group. For stability 
studies, a one-way ANOVA with post-hoc Tukey’s t-test with 95% of confidence was 
used to compare the different tested groups. For colonization and cytokine analysis, 
unpaired Student’s t-test was used to determine the differences between GAPDH-
immunized and sham-immunized groups. For survival curve analysis, Mantel-Cox 
test was performed. Considering the abnormal distribution of the histopathological 
score data, differences among groups were tested using the nonparametric Kruskal-
Wallis test followed by Dunn's test. A P value < 0.05 was considered statistically 
significant.  
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RESULTS 
Safety studies evaluation 
Mortality and clinical observations  
All mice survived to the assigned end point and appeared outwardly healthy after 
exposure to the vaccine, with no visible physical disability or behavior alterations.  
Reactogenicity 
Small nodules (< 3 mm) were only observable after necropsy at the site of each 
injection in mice of the groups V10, V20, V40 and Alhydrogel alone. The nodules 
were too small to be noticed by touch during reactogenicity observations. This was 
considered as a normal reaction resulting from the vehicle components. Signs of 
edema or erythema were not observable in any animal during the time of 
experiment. 
Body weight and body weight increase 
No significant effects on body weight and body weight increase were observed 
during the study among all test groups. Overall, most animals gained weight 
throughout the study. 
Anatomical pathology and histopathology  
There were no significant changes in organ weights (Table 1) and no gross 
morphological changes. Microscopic analysis was performed on several sections 
from different locations in every organ with a magnification of 40x in order to 
guarantee a global and precise organ overview. This examination took into account 
the severity of tissue organization, the degree of cellular degeneration, the amount 
of interstitial inflammatory cells, and the existence and extension of tissue necrotic 
areas. In all groups, none of these histopathological traits was detected in the vital 
organs studied and the total histopathology score calculated for each organ did not 
show significant differences among groups (data not shown). 
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Immunogenicity 
The efficacy of a vaccine is closely associated with the strength of the induced 
immune response [14]. To confirm the immunogenicity of vaccine, titers of IgG 
specific for rGAPDH were determined in the serum of the animals twenty-four hours 
after the last immunization.  
All tested vaccine doses (V10, V20, and V40) induced the production of IgG 
antibodies against rGAPDH (Fig 1). The titer values show a tendency to increase 
with the dose of rGAPDH-Alhydrogel injected, but the observed differences are not 
statistically significant. As expected, rGAPDH-specific IgG antibodies were not 
detected in the serum of the controls (Vehicle and Alhydrogel).  
Plasma and urine chemistry 
The serological and urine biochemical parameters were evaluated in all animals and 
found to be in normal range after repeated exposure to the vaccine compounds 
(Table 2). The parameters evaluated were: hepatotoxicity by quantifying the levels 
of alanine transaminase (ALT), aspartate transaminase (AST), lactate 
dehydrogenase (LDH) and albumin [20]; cardiotoxicity by assessing the levels of 
creatine kinases (CK) and specifically its isoform creatine kinase-MB (CK-MB) [21]; 
and nephrotoxicity by measuring the levels of urea, creatinine and N-acetyl-beta-D-
glucosaminidase [22]. Moreover, to evaluate pancreatic and lung toxicity, the 
amylase and clara-cell 16 were analyzed, respectively [23,24]. The systemic toxicity 
was also considered by quantifying the serum levels of glucose and total proteins.  
Inflammatory parameters 
Acute-phase proteins were used as markers for acute inflammation induced after 
rGAPDH immunization. These acute-phase proteins are produced by cells or 
tissues in response to inflammatory stimulus. The degree of inflammation can be 
evaluated by measuring the serum level of these proteins [25].  
The levels of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6 in the serum of 
the animals were below detection level in all groups and the levels of C-reactive 
protein were not significantly different between groups (Table 2). 
RESULTS 
 
88 
 
Stability studies evaluation 
The shelf-life is an important feature for any vaccine or drug to be used in humans, 
especially when intended for use in low-income countries where it is often difficult 
to provide appropriate storage conditions [26]. The vaccine formulations were 
maintained at 4°C for 6 (S6) and 12 (S12) months before immunization. An 
immunization protocol similar to that of the safety studies was used and the potency 
of the formulations was evaluated by comparing the resulting specific antibody titers 
with those obtained with a fresh prepared formulation (S0). 
Antibody titers 
The titers of IgG antibodies against rGAPDH induced by vaccines stored at 4°C for 
6 and 12 months were similar to those induced by a freshly prepared vaccine (Fig 
2). Moreover, as expected, rGAPDH-specific IgG antibodies were not detected in 
the serum of the controls (Vehicle and Alhydrogel) (Fig 2). The levels of total IgG 
were similar between all groups (vaccinated and controls, data not shown). The 
storage of the vaccine did not alter the potency or the specificity of the response. 
 
Safety assessment of S0, S6, and S12 formulations 
Treatment with S6 and S12 formulations had no life-threatening effect. All mice 
survived to the assigned end point and appeared healthy outwardly after exposure 
to the vaccine, with no visible physical disability or behavior alterations, and with no 
difference in body weight associated with the immunization. The treatment with the 
vaccines and adjuvant alone produced small nodules only observable after 
necropsy at the site of injection. The levels of the pro-inflammatory cytokines IL-1β, 
TNF-α, and IL-6 in the serum of the animals were below detection threshold in all 
groups. The levels of C-reactive protein were not significantly different between 
groups (Data not shown). 
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rGAPDH vaccination protects susceptible and diabetic adult mice 
from GBS infections 
To assess the effectiveness of rGAPDH vaccine against GBS infections in adult 
mice, immunized adult Balb/c mice were infected with A909 (serotype Ia) or 
2603V/R (serotype V). As shown in Fig 3 and 4, rGAPDH immunization confers 
protection to adult mice against GBS infections caused by both serotypes. The 
survival of rGAPDH-vaccinated mice, either infected with serotype Ia or V, were 
significantly increased compared with the respective sham-immunized group (Fig 3 
and Fig 4). Indeed, none of the immunized mice succumbed to the infection (100% 
survival) whereas ~40% and ~60% of sham-immunized mice infected with serotype 
Ia and V, respectively, died within the first 48h (Fig 3A and 4A). To investigate 
whether the longer survival of rGAPDH-vaccinated mice was associated with an 
early control of GBS growth, we next determined organ colonization at 6h and 18h 
post-infection. When infected with GBS serotypes Ia or V, lower numbers of viable 
bacteria were found in blood, heart, liver, and brain of the rGAPDH-immunized mice, 
as compared with the sham-immunized controls (Fig 3B and 4B). Lower bacterial 
levels were also found in the lung of rGAPDH-immunized animals infected with 
serotype Ia (Fig 3B). Since non-pregnant adult humans with diabetes are highly 
susceptible to GBS infections, we also evaluated the efficacy o rGAPDH vaccine in 
mice rendered diabetic by streptozotocin induction and infected with GBS 2603V/R, 
i.e. a strain belonging to the emerging serotype causing invasive disease in non-
pregnant adults. As shown in Table 3, rGAPDH vaccination rendered the diabetic 
mice more resistant to GBS infection, compared with sham-vaccinated diabetic 
mice. Indeed, 18h post-infection, lower levels of GBS CFUs were observed in blood, 
heart, liver, peritoneum, kidney, spleen and brain of the rGAPDH-immunized 
compared with the sham-immunized controls (Table 3).  
To characterize the pro-cytokines associated with protection in rGAPDH-immunized 
mice, IL-6, TNF-α, and IL-1β were analyzed 3h post-infection in blood, liver and 
spleen of both groups. As shown in Fig 3C and 4C, an increased production of the 
pro-inflammatory cytokines, mainly IL-6 and IL-1β, were observed in vaccinated 
mice. Indeed, compared to the sham-immunized controls, the rGAPDH-immunized 
mice infected with either GBS serotype Ia or V, presented higher levels of IL-6 in 
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sera, spleen, and liver, and of IL-1β in liver. Higher levels of TNF-α were observed 
in the spleen of immunized mice infected with GBS serotype V (Fig 4C).  
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DISCUSSION 
In the past few decades GBS infections have been responsible for a significantly 
high morbidity and mortality rates amongst nonpregnant adults, particularly in 
elderly or individuals with chronic underlying conditions, such as diabetes [2-5]. 
Currently, the invasive disease in adults is increasing and represents about two-
thirds of all cases of GBS infections, with a case fatality ratio of about 10-20% [4]. 
The antibiotic use as prophylactic measure in pregnancy and as treatment in adult 
against GBS infections raised several obvious concerns regarding the emergence 
and dissemination of antibiotic-resistant clones [6,7,27]. Moreover, while the use of 
IAP for prevention of GBS disease since 1996 was highly effective at preventing 
early-onset diseases, it did not changed the rate of late onset diseases, as well as 
the rates of stillbirths and prematurity caused by GBS infections [28]. Thus, 
vaccination is considered as a promising and complementary alternative since it 
could be easily and broadly applicable and could protect not only adults, but also 
newborns without the inherent limitations and problems associated with antibiotic 
use [29].  
Since low levels of maternal antibodies to capsular polysaccharide antigens 
correlate with neonatal susceptibility, efforts were concentrated in the production of 
a vaccine based on the GBS capsular polysaccharide [30,31]. However, this 
strategy is not consistent with the fact that the distribution of the ten GBS serotypes 
can vary in space and time [32,33]. Moreover, capsular polysaccharide switching 
has been recently reported in GBS [34]. The possibility of a shift in serotype 
prevalence supports the need for a universal GBS vaccine based on a different 
antigen [35]. Accordingly, Grandi and colleagues developed a vaccine utilising a 
component of each of the three pilus identified so far in GBS [36]. However, a 
change in the pili variant was described to occur in the case of Neisseria 
gonorrhoeae, rendering a promising vaccine ineffective [37]. Based on this 
observation, one might predict that, following vaccination with pilus antigen, the 
immune selective pressure will select GBS pilus variants to escape immunity.  
We have identified GAPDH as a valuable universal GBS vaccine candidate [13,15]. 
In a mouse model of GBS infection, maternal vaccination with rGAPDH or passive 
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immunization with anti-rGAPDH IgG antibodies conferred neonatal protection [13]. 
Since GAPDH is ubiquitously expressed in all type of cells, including mammalian 
cells, we demonstrated that the antibodies produced against the GBS GAPDH do 
not react with its human counterpart [13]. Eukaryotic and prokaryotic GADPH 
sequences display only two 10-aminoacid long identical segments and we 
consistently showed that antibodies produced against either native or denatured 
GBS GAPDH do not recognize human GAPDH [13].  
In the present work, the protective effect of this vaccine was extended to adult 
susceptible mice. We showed that adult mice vaccinated with rGAPDH are 
protected against GBS infections caused by the two serotypes, Ia and V, mostly 
associated with the human invasive disease [5]. The survival of rGAPDH-vaccinated 
adult mice is significantly increased compared with sham-vaccinated animals. Mice 
vaccinated with rGAPDH presented decreased number of bacterial counts in blood, 
brain, and heart, compared with sham-immunized animals. This observation is 
particularly important since endocarditis and meningitis are the two clinical 
presentations of GBS invasive infections with the worst prognosis in terms of 
morbidity and mortality [38,39]. The rising incidence rate of GBS infections in non-
pregnant adults has been associated with the aging of the population and with the 
increasing prevalence of individuals with underlying comorbidities, like diabetes 
mellitus [4,5]. Thus, to mimic the impact of diabetes in the susceptibility to GBS 
infections, we determined the efficacy of the rGAPDH vaccine in a mouse model of 
streptozotocin-induced diabetes. Our results show that vaccination with rGAPDH 
protects adult diabetic mice against GBS serotype V infection. 
GAPDH is an essential cytoplasmic enzyme involved in the glycolytic pathway 
which, despite the lack of standard signal sequences, has been found at the surface 
of unrelated GBS isolates [13]. This abundant enzyme is most likely released upon 
cell lysis to then bind to the surface of living bacteria [40]. GAPDH possesses a 
critical metabolic function, being essential for bacterial growth in blood, and plays 
an important role in GBS virulence. Alike GAPDH, other metabolic and cytosolic 
proteins have been also detected at the surface of numerous microorganisms where 
they exert a distinct function, being therefore called “moonlighting” proteins [41]. In 
pathogens, extracellular “moonlighting” proteins are often involved in colonization 
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and invasion of host tissues and we previously reported that cell surface bound 
GAPDH confers to GBS the ability to bind plasminogen and fibrinogen [42,43] and 
displays immunomodulatory properties that contributes evasion from the host 
immune system [13,15]. The potential of these “moonlighting” proteins as a vaccine 
target have also be experimentally assayed [44-47] in other streptococci. For 
example, the α-enolase of Streptococcus sobrinus and Streptococcus suis [46,47], 
the fructose-bisphosphate aldolase of Streptococcus pneumoniae’ [45] and the 
arginine deiminase and the trigger factor of Streptococcus pyogenes [44] were 
characterized as protective antigens.  
To move a candidate vaccine from the laboratory to the clinic, preclinical tests 
including safety studies in animals are mandatory [14,48]. The evaluation of 
toxicological parameters of repeated administration of rGAPDH-Alhydrogel 
formulations showed no effect on mortality, clinical appearance, behavior, or body 
weight change. In the first months of life, newborns protection against infectious 
diseases is highly dependent on passive immunity mediated by mother’s specific 
IgG antibodies that are transferred trough the placenta [49]. Therefore, a maternal 
vaccine aimed at protecting the newborn should elicit high levels of IgG antibody 
[48]. Consistently, our results showed that all tested doses of GAPDH were 
immunogenic and induced high and similar levels of specific rGAPDH IgG 
antibodies. Gross and histopathological examinations revealed no obvious 
abnormalities in organs and tissues of vaccinated mice. Moreover, the biochemical 
characterization of serum samples confirmed the innocuity of the vaccine deduced 
from the histological data. The serum levels of acute phase proteins or organ 
specific markers were not altered by the immunization, which indicates that rGAPDH 
vaccination does not induce acute inflammation or organ toxicity. Therefore, our 
study demonstrates the safety and immunogenicity of the rGAPDH vaccine. The 
WHO guidelines for nonclinical and clinical evaluation of vaccines stress a need for 
stability data to support clinical trial approval [50] and we showed here that the 
rGAPDH vaccine conserves its potency and safety, without significant alteration, at 
4°C for at least 12 months.  
This study predicts a potential application of rGAPDH vaccine in humans to prevent 
GBS-induced adult and neonatal diseases.   
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Figure Legends 
 
Fig 1. rGAPDH vaccine is immunogenic at all tested doses. rGAPDH-specific 
IgG titers of 6 female Balb/c mice per group, immunized three times with a three 
week interval, 24h after the third immunization with 10 (V10), 20 (V20) or 40 (V40) 
µg of rGAPDH with 1:40 Alhydrogel, alhygrogel alone, or PBS. The ELISA plates 
were coated with rGAPDH and revealed with goat anti-mouse IgG - HRP. Titers are 
represented as minimal serum dilution necessary for the lost absorbance signal.  
Fig 2. rGAPDH vaccine preserves its potency after prolonged storage at 4ºC. 
rGAPDH-specific IgG titers of 4 female Balb/c mice per group, immunized three 
times with a three week interval, 24 h after the third immunization with PBS, 
Alhydrogel and 20 µg of rGAPDH in a 1:40 PBS/Alhydrogel suspension prepared 
fresh (S0) or conserved at 4°C for 6 (S6) and 12 (S12) months. The ELISA plates 
were coated with rGAPDH and revealed with goat anti-mouse IgG - HRP. Titers are 
represented as minimal serum dilution necessary for the lost absorbance signal. 
One-way ANOVA with post-hoc Tukey’s t-test. ns – not significant. 
Fig 3. rGAPDH vaccination improves survival and induces protection against 
serotype Ia GBS infection in an adult mouse model. A) Kaplan–Meier survival 
curves. The lethality was monitored for 20 days. The numbers in parentheses 
represent the number of animals that survived out of the total number of infected 
animals. B) Blood, liver, lung, heart and brain colonization 6 and 18 hours post-
infection (6 hours - Sham and GAPDH-immunized n=7; 18 hours - Sham n=7, 
rGAPDH-immunized n=6) and C) sera, liver and spleen cytokine production 3 hours 
post-infection (n=6 for both groups). Balb/c mice were immunized three times, with 
a three week interval, with 20 µg of rGAPDH in 1:40 Alhydrogel or treated with 
Alhydrogel alone and infected i.p. with 3x106 CFU of A909 (serotype Ia). Unpaired 
Student’s t-test. *p < 0.05; **p < 0.01; *** p < 0.001  
Fig 4. rGAPDH vaccination improves survival and induces protection against 
serotype V GBS infection in an adult mouse model. A) Kaplan–Meier survival 
curves. The lethality was monitored for 20 days. The numbers in parentheses 
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represent the number of animals that survived out of the total number of infected 
animals. B) Blood. liver. lung. heart and brain colonization 6 and 18 hours post-
infection and (6 hours - Sham n=8. GAPDH-immunized n=7; 18 hours - Sham n=9. 
rGAPDH-immunized n=8) C) sera. liver and spleen cytokine production 3 hours 
post-infection (n=6 for both groups). Balb/c mice were immunized three times, with 
a three week interval, with 20 µg of rGAPDH in 1:40 Alhydrogel or treated with 
Alhydrogel alone and infected i.p. with 3x107 CFU of 2603V/R (serotype V). 
Unpaired Student’s t-test. *p < 0.05; **p < 0.01; *** p < 0.001 
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Table 1. Organ weight in mice with different vaccine doses 
Organ 
Vehicle control 
(w/out Alhydrogel) 
Vehicle control 
(w/ Alhydrogel) 
rGAPDH (with Alhydrogel) 
V10 V20 V40 
Heart 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 
Lungs 0.52 ± 0.04 0.50 ± 0.04 0.59 ± 0.11 0.58 ± 0.09 0.51 ± 0.05 
Kidneys 2.02 ± 0.33 2.14 ± 0.29 2.11 ± 0.34 2.40 ± 0.39 2.19 ± 0.20 
Liver 8.91 ± 1.41 9.11 ± 1.34 8.99 ± 1.31 7.84 ± 1.42 9.74 ± 0.92 
Spleen 0.08 ± 0.01 0.07 ± 0.01 0.08 ± 0.01 0.08 ± 0.01 0.08 ± 0.01 
Values are expressed as mean ± S.D; Number of animals per goup = 6; V10 – 10 µg s.c.; V20 – 20 µg s.c.: V40 
– 40 µg s.c. One-way ANOVA with post-hoc Dunnett's Multiple Comparison Test, p > 0.05. 
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Table 2. Biochemistry of plasma and urine collected 24h after the last vaccine 
injection  
 
 
Vehicle control 
(w/out Alhydrogel) 
Vehicle control 
(w/ Aldhydrogel) 
rGAPDH (with Alhydrogel) 
V10 V20 V40 
Plasma Parameters 
Albumin (g/L) 32.61 ± 2.21 29.19 ± 4.65 29.86 ± 1.19 31.89 ± 1.81 30.91 ± 2.22 
Total proteins (g/L) 51.84 ± 3.41 48.04 ± 1.09 47.22 ± 1.96 48.98 ± 3.08 47.34 ± 2.24 
Glucose (mg/dL) 85.7 ± 30.7 106.6 ± 29.9 90.5 ± 25.8 86.2 ± 10.8 87.0 ± 25.8 
CK-MB (U/L) 227.9 ± 30.3 230.9 ± 38.8 236.0 ± 97.6 224.1 ± 67.9 196.2 ± 53.8 
CK (U/L) 1111 ± 265 1192 ± 397 1754 ± 721 1460 ± 476 1175 ± 546 
ALAT (U/L) 31.7 ± 2.9 35.1 ± 11.5 34.0 ± 2.9 29.4 ± 4.7 31.0 ± 3.5 
ASAT (U/L) 99.0 ± 19.2 92.5 ± 20.7 111.1 ± 37.2 112.1 ± 33.4  90.2 ± 26.7 
LDH (mg/dL) 743.6 ± 360.7 633.6 ± 234.7 625.6 ± 107.7 677.4 ± 65.6 623.9 ± 203.5 
Amylase (U/L) 966.2 ± 262.2 870.5 ± 197.6 1000 ± 251.9 867.2 ± 167.9 806.8 ± 101.9 
C3 (mg/mL) 11 ± 3 11 ± 3 14 ± 4 9 ± 3 14 ± 5 
Urea (mg/dL)  46.3 ± 11.3 47.9 ± 10.3 53.2 ± 22.6 45.5 ± 5.8 45.3 ± 9.7 
Creatinine (mg/dL) 0.35 ± 0.08 0.35 ± 0.05 0.28 ± 0.12 0.35 ± 0.05 0.30 ± 0.10 
CC16 (ng/mL) 125.1 ± 43.1 154.9 ± 29.3 161.3 ± 37.9 121.2 ± 55.5 116.4 ± 25.6 
Urine Parameters 
Urea (mg/24h) 4.47 ± 3.40 5.18 ± 2.68 5.48 ± 3.68 4.46 ± 2.35 4.91 ± 2.41 
Creatinine (mg/dL) 57 ± 24 65 ± 14 70 ± 18 67 ± 22 66 ± 25 
NAG (U/L) 12.04 ± 2.63 11.71 ± 3.95 15.80 ± 1.95 14.57 ± 3.6 11.56 ± 3.5 
Inflammatory Parameters 
IL-1β (pg/mL) BDL BDL BDL BDL BDL 
IL-6 (pg/mL) BDL BDL BDL BDL BDL 
TNF-α (pg/mL) BDL BDL BDL BDL BDL 
CRP (ng/mL) 2.30 ± 0,76 2.50 ± 0,81 2.30 ± 0,30 2.40 ± 0.31 2.23 ± 0,62 
Values are expressed as mean ± S.D; Number of animals per group=6; BDL – Below detection Level; 
CK - Creatine kinase; CK-MB - Creatine kinase MB; ALAT - Alanine aminotransferase; ASAT - 
Aspartate aminotransferase; LDH - Lactate dehydrogenase; C3 – Complement component 3; CC16 
- Clara cell secretory protein 16; NAG - N-acetyl-beta-D-glucosaminidase; IL – Interleukine; TNF-α – 
Tumor necrosis factor α; CRP – C-reactive protein. One-way ANOVA with post-hoc Dunnett's 
Multiple Comparison Test, p > 0.05. 
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Table 3. Organ colonization of rGAPDH and Sham-immunized diabetic mice infected 
with GBS serotype V strain 2603V/R 
 
Organs 
Diabetic mice 
P-valuea 
Sham-immunized (log CFU/organ ) rGAPDH-immunized (log CFU/organ) 
Blood  4.35 ± 0.732 0.902 ± 0.462 0.0010*** 
Liver  5.22 ± 0.550 3.06 ± 0.216 0.0017** 
Spleen  4.76 ± 0.505 3.16 ± 0.460 0.0329* 
Lung  4.60 ± 0.665 2.46 ± 0.501 0.0198* 
Brain  2.61 ± 0.625 0.189 ± 0.189 0.0014** 
Heart  4.43 ± 0.908 1.52 ± 0.511 0.0114* 
Kidney  4.18 ± 0.754 1.92 ± 0.300 0.0107* 
Peritoneum 5.69 ± 0.887 2.93 ± 0.621 0.0204* 
Mice were killed 18h post-infection and the organs collected for bacterial counts. Values are 
expressed as mean ± S.E.M.; Number of animals Sham-immunized = 8. rGAPDH-immunized = 9; 
aStudent’s t Test. *p<0.05; **p<0.01. ***p<0.001 
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Figure 1 
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Figure 2 
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Figure 3 
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ABSTRACT 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a glycolytic enzyme that 
has been associated with virulence of several microorganisms. Vaccines containing 
GAPDH have been tested and proved effective against infections with several 
pathogens. One of those vaccines, against the neonatal infectious agent Group B 
Streptococcus (GBS), was developed by our group. Since GAPDH was reported as 
an extracellular virulence factor for Escherichia coli, another important neonatal 
pathogen, here we investigated whether the recombinant GAPDH of GBS 
(rGAPDHGBS) or the recombinant GAPDH of E. coli (rGAPDHE.coli) could be used as 
a vaccine against the neonatal infections caused by this pathogen. The cross-
reactivity of the antibodies produced against rGAPDHGBS and of rGAPDHE.coli was 
tested but, despite the 53% homology between the two GAPDHs, the antibodies 
produced against one of the GAPDH were unable to recognize the other. Having in 
mind the properties already described for rGAPDHGBS, the ability of rGAPDHE.coli to 
stimulate splenic B cell populations from neonatal and adult mice and induce IL-10 
production in these cell cultures was evaluated at different timepoints. However, the 
rGAPDHE.coli did not induce splenic B lymphocytes activation in neonatal or adult 
mice cell cultures and did not promote IL-10 production. For vaccination studies, 
female Balb/c mice were immunized with rGAPDHE.coli and the offspring was orally 
infected with E. coli K1. Unexpectedly, maternal rGAPDHE.coli immunization instead 
of conferring resistance to its offspring against E. coli infection increased its 
susceptibility to this pathogen. In conclusion, GAPDH of E. coli cannot be used as 
a target antigen for vaccination against E. coli infections and this study highlights 
the need for precaution in the generalization of the use of GAPDH-based vaccines. 
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INTRODUCTION 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, EC 1.2.1.12) is a key 
glycolytic enzyme that is responsible for the reversible conversion of 
glyceraldehyde-3-phosphate to 1-3 di-phosphoglycerate. However, in the last years, 
several other functions have been identified and associated with this highly 
conserved protein, both in eukaryotic and prokaryotic cells. In mammals, for 
instance, GAPDH has been associated with gene regulation and maintenance of 
DNA integrity, and appears to be involved in several cellular processes as apoptosis 
and autophagy (reviewed in [1]). In prokaryotic cells GAPDH has been vastly 
associated with the virulence of the microbe. Indeed, beside its intracellular 
localization, important for its glycolytic function, GAPDH has been found associated 
with the surface or excreted by several pathogens (reviewed in [2]). Its ability to bind 
to matrix proteins like plasminogen and fibrinogen is an important aspect for 
adherence and cell invasion of Gram-positive and [3-7], as well as Gram-negative 
bacteria [8]. Bacterial GAPDH has also been associated with iron uptake (by 
association with haemoglobin, haem and transferrin) [9,10] and immune evasion (by 
induction of the anti-inflammatory cytokine IL-10) [11]. Because of these properties, 
several groups have already invested efforts in developing GAPDH-based vaccines 
that proved to be efficient against human and veterinary infectious diseases 
(reviewed in [12]). One of those GAPDH-based vaccines was developed by our 
group against the bacterium Group B Streptococcus (GBS) responsible for serious 
illness and mortality in newborns and immune-compromised individuals [13]. We 
proved that GBS’ recombinant GAPDH vaccine is effective in a neonatal and adult 
mouse model of infection [11,14]. Having in mind that GAPDH is a highly conserved 
protein we hypothesized that GAPDH could be a suitable target for a vaccine to 
control neonatal infections caused by other pathogens. E. coli is the second most 
common cause of neonatal infections and, in preterm and especially very-low birth 
weight infants E. coli is considered the main bacterial cause of neonatal death [15]. 
Moreover, GAPDH was already described as an extracellular virulence factor of 
enteropathogenic and enterohemorragic E. coli, binding to human plasminogen and 
fibrinogen and interacting with intestinal epithelial cells [16,17]. Therefore, in the 
present study, we tested if maternal vaccination with rGAPDHE.coli confers protection 
of their offspring against E. coli infections. Surprisingly, GAPDH-based maternal 
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vaccination instead of induced protection to infected pups, increased its mortality. 
This harmful effect of E. coli GAPDH-vaccine should be taken into account in future 
studies with GAPDH-based vaccines.  
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MATERIAL AND METHODS 
Animals 
Balb/cAnNCrl mice, with a specific-pathogen free (SPF) status, were purchased 
from Charles River (Italy). All the animals were kept in the animal facilities of the 
Institute Abel Salazar during the time of the experiments. Mice were housed in 
Techniplast ventilated polycarbonate cages under negative pressure with hardwood 
bedding and provided with Mucedola Diet and fresh tap water, ad libitum, throughout 
the study. The temperature was maintained at 21–23˚C and the relative humidity at 
50% ± 20% with a 12 h light/dark cycle. All animals were housed in environmentally 
controlled cages with 40 air changes per hour.  
Ethics statement 
This study was carried out in strict accordance with the recommendations of the 
European Convention for the Protection of Vertebrate Animals used for 
Experimental and Other Scientific Purposes (ETS 123) and Directive 2010/63/EU 
and Portuguese rules (DL 113/2013). The animal experimental protocol was 
approved by the competent national authority Direção Geral de Alimentação e 
Veterinária (DGAV) (Protocol Permit Number: 0420/000/000/2008). All animal 
experiments were planned in order to minimize mice suffering. 
Western Blot  
0.4 μg of purified rGAPDHE.coli and rGAPDHGBS, contained on 10% polyacrylamide 
gel were transferred to polyvinylidene difluoride (PVDF) membranes (Amersham 
Biosciences) according to the manufacturer’s instructions. The membranes were 
probed with the mouse anti-GAPDHE.coli or mouse anti-GAPDHGBS antibody (1 
μg/mL) in Tris-buffered saline with Tween 20 for 2 h at room temperature, followed 
by incubation with an alkaline phosphatase-conjugated goat anti-mouse IgG 
antibody (SouthernBiotec, 1:5000 in TBST) for 1 h at room temperature. Proteins 
were revealed by incubation with NBT/BCIP (Roche) in AP buffer (0.01 M Tris, 0.01 
M NaCl, 0.5 mM MgCl2 (pH 9.5)). 
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In vitro splenic cell cultures  
Spleen cells from 8 weeks old (adult) and 2 days old (newborn) Balb/c mice were 
obtained by gently disruption in RPMI 1640 (Sigma-Aldrich) supplemented with 
penicillin (100 IU/ml, Sigma-Aldrich), streptomycin (50 μg/ml, Sigma-Aldrich), 2-ME 
(0.05 M, Sigma-Aldrich), and 10% FBS (Biowest). Cells were distributed in 96-well 
plate (Nunc, 1 x 106 cells/well) in 200 μL and cultured at 37°C in a humidified 
atmosphere containing 5% CO2. All cells were treated with 6 μg/mL of Polimixin B 
(Sigma-Aldrich) to inhibit possible endotoxin contamination. Splenic cells were 
incubated with medium alone or stimulated with 100 ng/mL of Pam3CSK4 
(InvivoGen), 25 μg/ml of rGAPDHE.coli or 25 μg/ml of rGAPDHGBS. At specific 
timepoints, 150 μL of cell culture supernatant were collected and stored at -80ᵒC 
and cells were used for flow cytometry analysis.  
Cytokine analysis 
IL-6, TNF-α, IL-1β and IL-10 were quantified by ELISA (eBioscience, with exception 
of IL-10, R&D Systems), according to the manufacturer’s instructions. Detection 
levels of 8 pg/ml, 16 pg/ml, 16 pg/ml and 62.6 pg/ml, respectively.  
Flow cytometry analysis  
Splenic cell activation and death was evaluated by flow cytometry analysis. Briefly, 
6, 12 and 18 h after stimulation, cells were harvest from cell culture plates and 
stained. To analyze the proportion of dead/live cells in a culture, 1 μL of propidium 
iodide (PI) was added to 99 μL of PBS. To analyze B cell activation, cells were first 
incubated with anti-mouse CD16/32 (clone 2.4G2) to block Fc receptors. FITC anti-
mouse CD19 Ab (clone MB19-1; Biolegend) was used as B cell marker, PE anti-
mouse CD5 (clone 53-7.3; Biolegend) was used to distingue B cell subpopulations 
(B1a - CD19+CD5+ or B1b/B2 - CD19+CD5-) and PE/Cy5 streptavidin plus biotin 
conjugated anti-CD69 (clone H1.2F3, Biolegend) were used as activation marker. 
Fluorescence was analyzed using an Epics XL cytometer (Beckman Coulter), and 
data were analyzed with FlowJo software (TreeStar).  
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Purification of recombinant GAPDH 
E. coli BL21 (DE3) strain (Novagen) and the pET28a plasmid (Novagen) were used 
for production of the recombinant GAPDH protein from GBS and E. coli. Standard 
recombinant techniques were used as described in [18]. The GBS gapC gene 
(gbs1811; http://genolist.pasteur.fr/SagaList/) and E. coli gapA gene (GenBank: 
ADE90611.1) were PCR amplified and cloned into pET28a to produce a rGAPDH 
containing a carboxylic histidyl tag. E. coli BL21 cells were transformed with the 
resulting recombinant plasmid (pET28aΩgapC and pET28aΩgapA). Following a 3 
h IPTG-induced expression of the fusion protein, the cells were harvested by 
centrifugation and suspended in phosphate buffer containing 10 mM imidazole 
(Sigma). The sample was incubated on ice for 30 min in the presence of 100 μg/ml 
lysozyme and 10% Triton X-100. After sonication, the insoluble material was 
removed by centrifugation and the supernatant was filtered through a 0.45-μm pore 
size filter (Millipore) and applied to a His-trap column (GE Healthcare). The rGAPDH 
was eluted with 300 mM imidazole under native conditions and the eluant 
concentrated by vacuum dialysis and equilibrated in PBS buffer before endotoxin 
removal on Endotoxin Removal Spin Columns (Pierce).  
Maternal Immunizations  
rGAPDHE.coli was used for maternal immunization assays and both rGAPDHE.coli and 
rGAPDHGBS were used in immunization protocols for antibody production . For both 
immunization protocols mice were injected sub-cutaneously (s.c.) three times, with 
a 3-week intervening period, with 200 μL of a preparation containing 20 μg of 
rGAPDH in a 1:40 PBS/alum suspension (Aluminium hydroxide Gel). The sham-
immunized control animals received 200 μL of a 1:40 PBS/alum suspension. For 
maternal immunization assays, female immunized mice were paired with male 
immediately after the third injection. Elevated titers against rGAPDHE.coli were 
confirmed after the second immunization and after birth. For antibody purification, 
terminal blood was collected ten days after the third immunization and IgG 
antibodies purified using a Protein G HP affinity column (GE Healthcare Life 
Sciences). 
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Neonatal Passive immunization 
Antibody treatments were performed in newborn mice 12 h prior to E. coli challenge, 
with 30 μg (i.p. in 60 μL) of mouse anti-rGAPDHE.coli. Control animals received the 
same amount of mouse control IgGs. Pups from each litter were randomly assigned 
to control or to experimental groups, marked, and kept with their mother. 
Neonatal E. coli infection  
Neonatal (< 24 h old) Balb/c mice were infected orally with 2x106 CFU (in 10μL of 
PBS) of extraintestinal pathogenic E. coli (ExPEC) IHE3034 of serotype O18:K1:H7, 
ST95, a neonatal meningitis-associated strain isolated in Finland in 1976 [19]. The 
bacteria was growth to exponential phase in liquid Todd-Hewitt (TH, Difco 
Laboratories) media for 3 h at 37 °C. After several washes, absorbance of the 
bacteria in PBS was adjusted to 0.450 at 600 nm (Jenway 6300 
Spectrophotometer), corresponding to 2 x 108 CFU/mL. Newborns were kept with 
their mothers during the experiment. All pups were euthanized if they were in 
moribund state (lethargic, darker red colour and with no observable milk spot) due 
to ethical reasons. Survival curves were determined over a 15-d experimental 
period.  
Statistical analysis 
All statistical analyses were performed in GraphPad Prism version 5.0 for Windows 
(GraphPad Software, San Diego, California). For ELISA and flow cytometry data, 
two-way ANOVA with Multiple Comparison Test was used to analyse the differences 
between all groups. In the case of ratios, the values were normalized using the 
formula: Arcsin(√(Value/100)) x 180/π, previous to statistical analysis. In case of 
survival analysis the graphs were obtained using the Kaplan-Meier method and 
differences were calculated using the log-Rank test. A P value <0.05 was 
considered statistically significant. 
  
RESULTS 
121 
 
RESULTS AND DISCUSSION 
Antibodies produced against GAPDH of GBS do not recognize the 
GAPDH of E. coli  
In E. coli, GAPDH is encoded by two genes, gapA and gapC. Many laboratory E. 
coli strains have accumulated mutations in gapC gene, generating stop codons 
which result in a truncated, non-functional protein [20,21]. In enterrohemorragic and 
enteropathogenic E. coli strains, GAPDH was detected at the surface of the bacteria 
and expression of the gapA but not the gapC gene accounted for the production of 
GAPDH [16,17]. To examine the amino acid homology between the different 
GAPDH isoforms the protein sequences of gapA (E. coli IHE3034; GenBank: 
ADE90611.1) and gapC (E. coli IHE3034; GenBank: ADE90514.1), gapC (GBS 
NEM316; GenBank: CAD47470.1), Mus musculus (GenBank: AAH83149.1) and 
Homo sapiens (GenBank: CAA25833.1) GAPDH were compared using the multiple 
sequence alignment programs ClustalOmega and Aline (Figure 1A). E. coli gapA 
GAPDH displays 47.64 % amino acid identity with E. coli gapC GAPDH. The E. coli 
gapA GAPDH used in this study displays a 53.38 % similarity with GBS GAPDH and 
67.79 and 64.88 % similarity with mouse and human GAPDH, respectively (Figure 
1A). In order to evaluate if the rGAPDHGBS could also be used as a target for 
vaccination against E. coli infection the cross-reactivity of the antibodies produced 
against the rGAPDHGBS-vaccine and the gapA-encoded rGAPDHE.coli were tested. 
However, as shown in Figure 1B, neither the antibodies produced against 
rGAPDHGBS recognized the rGAPDHE.coli nor the antibodies produced against 
rGAPDHE.coli recognized the rGAPDHGBS (Figure 1B). Therefore, the rGAPDHGBS 
could not be used as a vaccine against E. coli infections. 
 
E. coli GAPDH is unable to trigger B cell activation or induce 
cytokine production in vitro 
A stimulatory effect on splenic B cells and an early induction of IL-10 have already 
been described for the GAPDH of GBS [22]. Therefore, we tested if E. coli rGAPDH 
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also possess this ability. For that purpose, adult and neonatal mouse splenic cells 
were cultured with rGAPDHGBS or with rGAPDHE.coli. To exclude the possibility of 
contamination with endotoxins, the absence of endotoxins was confirmed with the 
highly sensitive e-toxate test and polimixin B was added to cell cultures. Moreover, 
since we have previously observed that TLR2 activation in GBS infection was 
associated with an early IL-10 production and consequent susceptibility to GBS 
infection [23], we also stimulate the cultures with Pam3CSK4, a TLR1/2 agonist, as 
positive control. B cell activation was assessed by expression of early activation 
surface marker CD69 on B1a (CD19+CD5+) and B2/B1b (CD19+CD5-) splenic cell 
population 18 h after the stimulatory treatment. As shown in Figure 2 and 3, 
rGAPDHGBS induces an up-regulation of CD69 on B2 population of both adult and 
neonatal splenic cells and is able to induce activation of newborns’ B1a cells. In 
contrast, rGAPDHE.coli did not induce an up-regulation of CD69 in any of the studied 
populations. This result showed that contrary to GAPDHGBS, the GAPDHE.coli did not 
induce B lymphocyte activation. 
Regarding cytokine production, rGAPDHGBS was able to induce IL-10 and TNF-α 
production in the supernatants of neonatal splenic cell cultures, as soon as 6 h post-
stimulation (Figure 4A). However, rGAPDHE.coli was unable to induce IL-10 or other 
pro-inflammatory cytokine production, in neonatal or adult cells cultures, at any time 
point evaluated (Figure 4). These results showed that the rGAPDHE.coli does not 
induce IL-10 production or B cell stimulation in contrast to the rGAPDHGBS.  
In order to understand the irresponsiveness of both adult and newborn cultures to 
rGAPDHE.coli we analysed cell viability post-stimulation by PI incorporation. As 
observable in Figure 5, rGAPDHE.coli induced cell dead in adult but not in neonatal 
splenic cell cultures after 12 h of stimulation (57% vs 73% of live cells in control). 
Neonatal spleen has a different frequency of the different cell populations than the 
adult counterparts. In neonatal mice the spleen is a site of hematopoiesis, a 
characteristic that is lost with post-natal development [24]. Therefore hematopoiesis 
progenitor cells only exist in the neonatal spleen. Moreover, B cell, T cell and 
dendritic cell populations are distinct in number and properties in neonatal and adult 
spleen [25]. These differences in cell populations could explain the observed 
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resistance to cell dead induced by rGAPDHE.coli in neonatal splenic cultures, when 
compared to the adult ones.  
In contrast to rGAPDHE.coli, rGAPDHGBS did not induced cell dead in any of splenic 
cultures. Actually, at 18 h post-stimulation, the percentage of live cells in newborn 
splenic culture was higher in cells stimulated with rGAPDHGBS, than that in the RPMI 
control (Figure 5A). Having in mind that capacity of rGAPDHGBS to induce cell death 
has already been described on a murine macrophage cell line [18], the result of 
Figure 5 indicates that this property of rGAPDHGBS may be dependent on the cell 
type. 
Notwithstanding the similarities between the amino acid sequences of the two 
GAPDH, their ability to induce B cell activation, IL-10 production or cell death is 
clearly distinct.  
 
Maternal vaccination with rGAPDHE.coli increases neonatal 
susceptibility to E. coli oral infection  
GAPDH have been proposed as suitable target for a vaccination against numerous 
pathogens [12]. In order to understand if rGAPDHE.coli vaccination induces protection 
against neonatal E. coli infection, female Balb/c mice were immunized with rGAPDH 
in Alum adjuvant. Control mice were sham-immunized with the adjuvant alone. After 
the last immunization, females were mated and progeny was orally infected with E. 
coli K1, an E. coli strain associated with neonatal sepsis and meningitis [26]. 
Unpredicted, all but one mouse born from rGAPDH-immunized mothers succumbed 
to infection (13% survival) whereas 8 out of 15 infected pups survived to the E. coli 
challenge in the control group (53% survival) (Figure 6A). To confirm that the lack 
of protection was an effect of the antibody response to rGAPDHE.coli and not by 
induced maternal alterations by immunization, pups were treated 12 h prior to 
infection with specific anti-rGAPDHE.coli or mouse IgG control antibodies. Again, 
antibody treatment was unable to confer protection to infected pups and, although 
not statistically significant due to the number of used mice, the pups treated with 
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anti-rGAPDHE.coli antibodies started to die sooner than control treated ones (Figure 
6B).  
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CONCLUDING REMARKS 
The GAPDH-based vaccines have been gaining some attention, due to their 
success against human and veterinary diseases in animal models [12]. GAPDH 
have already been identified as an extracellular virulence factor of enteropathogenic 
and enterohemorragic E. coli [17] but whether this enzyme could be used as a target 
for vaccination had never been investigated. The obtained results show that 
maternal immunization with GAPDHE.coli increases the susceptibility of the neonates 
to E. coli infection by increasing their mortality. This is, to our knowledge, the first 
time that an increase in mortality was associated with a GAPDH vaccine. This 
harmful effect of GAPDHE.coli vaccination highlight the need for precaution in the 
generalization of the use of GAPDH-based vaccines.  
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Figure Legends 
 
Figure 1. Multiple sequence alignment and cross-reactivity analysis of the 
antibodies specific for rGAPDHGBS or specific for rGAPDHE.coli. (A) Multiple 
sequence alignment of the GAPDH proteins. (B) Western blot analysis of 
rGAPDHGBS and rGAPDHE.coli revealed with mouse anti-GAPDHE.coli IgG antibodies 
(right membrane) and mouse anti-GAPDHGBS IgG antibodies (left membrane).  
Figure 2. Expression of the early activation marker CD69 on neonatal B 
lymphocytes stimulated with different rGAPDH detected by flow cytometric 
analysis. (A) Expression of CD69 on B1a (CD19+CD5+) and B2 (CD19+CD5-) of 
splenic cells of neonates Balb/c mice stimulated with: medium alone (RPMI), 100 
ng/mL of Pam3CSK4, 25 μg/ml of rGAPDHGBS or 25 μg/ml of rGAPDHE.coli at the 
indicated time points. At top the representative dotplots of 18 h post-stimulus. At 
bottom the bars indicate the mean value of fold expression [(%CD69 positive cells - 
%CD69 positive cells in RPMI) / %CD69 positive cells in RPMI] ± SEM of two wells 
per stimulus and correspond to one representative experiment of two independent 
experiments. Two-way ANOVA with multiple comparison *p<0.05; **p<0.01, 
***p<0.001. 
Figure 3. Expression of the early activation marker CD69 on adult B 
lymphocytes stimulated with different rGAPDH detected by flow cytometric 
analysis. (A) Expression of CD69 on B1a (CD19+CD5+) and B2 (CD19+CD5-) of 
splenic cells of adult Balb/c mice stimulated with: medium alone (RPMI), 100 ng/mL 
of Pam3CSK4, 25 μg/ml of rGAPDHGBS or 25 μg/ml of rGAPDHE.coli at the indicated 
time points. At top the representative dotplots of 18 h post-stimulus. At bottom the 
bars indicate the mean value of fold expression [(%CD69 positive cells - %CD69 
positive cells in RPMI) / %CD69 positive cells in RPMI] ± SEM of two wells per 
stimulus and correspond to one representative experiment of two independent 
experiments. Two-way ANOVA with multiple comparison *p<0.05; **p<0.01, 
***p<0.001. 
Figure 4. Cytokine production of splenic cultures stimulated with rGAPDHGBS 
and rGAPDHE.coli. Production of IL-10, IL-6 and TNF-α by splenic cells of neonates 
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(A) or adult (B) Balb/c mice stimulated with: medium alone (RPMI), 100 ng/mL of 
Pam3CSK4, 25 μg/ml of rGAPDHGBS or 25 μg/ml rGAPDHE.coli at the indicated times 
points. The data indicate the mean value ± SEM of two wells per stimulus and 
correspond to one representative experiment of two independent experiments. Two-
way ANOVA with multiple comparison *p<0.05; **p<0.01, ***p<0.001. 
Figure 5. Splenic cell viability after stimulation with with rGAPDHGBS and 
rGAPDHE.coli. Cell viability of splenic cells of neonates (A) or adult (B) Balb/c mice 
stimulated with: medium alone (RPMI), 100 ng/mL of Pam3CSK4, 25 μg/ml of 
rGAPDHGBS or 25 μg/ml rGAPDHE.coli at the indicated times points. Percentage of 
viable cells was determined by exclusion of percentage of PI incorporation by flow 
cytometry. The bars indicate the mean value ± SEM of two wells per stimulus. Two-
way ANOVA with multiple comparison *p<0.05; **p<0.01, ***p<0.001 was performed 
after normalization of the values using the formula: Arcsin(√(Value/100)) x 180/π. 
Figure 6. E. coli GAPDH-based vaccine increase the susceptibility of neonatal 
mice to oral infection with E. coli K1. (A) Survival of pups from rGAPDH-
vaccinated and Sham-immunized mice. Female Balb/c mice were immunized three 
times, with a three week interval, with 20 µg of rGAPDHE.coli plus Alum or Alum 
alone. At the day of the third immunization the females were mated and the progeny 
orally infected with 2x106 CFU of E. coli IHE3034. (B) Survival of Balb/c pups treated 
i.p. with 30 μg of mouse anti-rGAPDHE.coli or control IgG 12 h prior to oral infection 
with 2x106 CFU of E. coli IHE3034 (<24 h old pups). Newborns were kept with their 
mothers during the experiment and were evaluated twice a day. All pups were 
sacrificed if they were in moribund state due to ethical reasons. Survival curves were 
determined over a 15-d experimental period. Log-rank (Mantel-Cox) test. ns – not 
significant (p > 0.05) **p<0.01 
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ABSTRACT 
Escherichia coli is a common cause of neonatal sepsis and meningitis worldwide, with 
special incidence among preterm and very low birth weight infants. The high mortality 
and morbidity associated with these neonatal infections, as well as the increase of E. 
coli antibiotic-resistance, strengthens the need for a prophylaxis treatment. For the 
development of new therapies it is essential to understand how the bacteria interacts 
and evades the host immune system and establishes an infection. To characterize the 
immune response to E. coli infection, we adapted a model of oral infection in neonatal 
mice. For that purpose, Balb/c mice, with less than 24 h old, were orally infected with 
2x106 CFU of E. coli K1 (a strain associated with neonatal sepsis and meningitis) and 
were sacrificed at specific time points. The bacterial colonization was evaluated in 
blood, spleen, liver, lungs, and brain. In addition, the levels of cytokines and 
chemokines, and the immune cell recruitment were analysed in liver and lungs. The 
results showed that like in humans, an age-dependency for the systemic E. coli 
infection was observed. Moreover, bacteria were detected both systemically (a 
characteristic of sepsis) and in the brain tissue (a characteristic of meningitis). 
Interestingly, despite the non-invasive form of infection, bacteria were detected in 
lungs, blood and liver as soon as 30 minutes post-infection. However, the inflammatory 
response to this bacteraemia, evaluated by the production of pro-inflammatory 
cytokines and chemokines and phagocyte recruitment to infected organs, was only 
observed 6 h post-infection. This delay in the development of the innate immune 
response was not due to the induction of the anti-inflammatory IL-10, since the 
treatment with antibody blocking of IL-10 signalling did not influence the outcome of 
infection. On the other hand, anti-IL-1R treatment increased the susceptibility to E. coli, 
providing evidence that the pro-inflammatory cytokine IL-1β, has a protective role 
during E. coli K1 neonatal infection. 
Taken together, these findings indicate that E. coli K1 is able to rapidly colonize the 
neonatal mice but the infected host does not promptly develop an immune response. 
Understanding the reason for the delay in immune response activation should enable 
the characterization of novel therapeutic targets. 
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INTRODUCTION 
From the estimated three million neonatal deaths that occur around in the world each 
year, more than one-third are caused by infections [1]. Neonatal sepsis and 
pneumonia, account for approximately half million of those fatalities [2]. The chances 
of survival are reduced for newborns with a serious infection, in particular for those 
with very low birth-weight [3,4]. For those who are treated and survive, the 
consequences may be severe long-term neurodevelopmental impairment and 
disability [5]. Escherichia coli is the most common cause of Gram-negative bacterial 
neonatal infections, being responsible for a high number of early-onset sepsis and late-
onset meningitis [6-8]. When very low birth-weight infants are considered alone, E. coli 
becomes the most frequent cause of early-onset sepsis, accounting for 33.4% of 
episodes [8]. Despite the use of antibiotics, the morbidity and mortality rates associated 
with E. coli neonatal infections have not decreased over the last few decades, with 
reports of approximately 30% fatality rates in infected infants [7,9,10]. In fact, due to 
an emergence of E. coli ampicillin-resistant clones (with several reports where this 
clones represent more than 70% of the isolates), it is estimated that E. coli neonatal 
infections will continue to increase [11-13].  
Newborns acquire this bacterium perinatally, from maternal contaminated vaginal fluid 
[14]. E. coli is one of the most common organisms in the genital tract, being detected 
in 13% of pregnant women [15]. Not all E. coli strains have the ability to cause 
infections in neonates, but those that do, usually belong to B2 group and express the 
K1 capsular antigen [16-19]. In fact, infants infected with K1 strains have increased 
morbidity and mortality rates compared to infants infected with other E. coli strains [3]. 
After newborn’s colonization, E. coli transcytose from gastrointestinal tract into the 
bloodstream inducing bacteremia, and from there, can traverse the blood brain barrier 
(BBB) into the central nervous system (CNS), causing meningitis [20,21]. Each one of 
these stages of the infection require a specific set of molecular determinants, several 
of which were already identified [19]. Meanwhile, only a few reports shed some light 
on the first stages of E. coli neonatal infection. Neutrophils and macrophages have 
been implicated on both protective [22-24] and detrimental responses to this bacterium 
[25-27], and the role of specific inflammatory mediators is still unclear. A better 
understanding of the neonatal immune response in the first stages of E. coli infection 
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could provide new insights for the susceptibility of neonates to this infection and offer 
the basis for a new generation of therapeutics and prophylactics. In some animal 
models, infection is initiated by parenteral or intranasal administration of bacteria, 
bypassing or ignoring some of the essential steps of the natural process of colonization 
and dissemination, thus creating an incomplete or artificial infection scenario 
[22,28,29]. Oral infection in rats was already employed by several works [25,30-34]. 
Although the neonatal rat has unequivocal advantages when compared with neonatal 
mice, it limits the use of transgenic animals and the comparison with the majority of 
infection and immunological studies, that use mice models. In 1988, Pluschke et al, 
tested oral neonatal E. coli-infections in several mice strains with 3-5 days old, but 
pups only became bacteremic in endotoxin-irresponsive mice and with a success of 
21 and 52% (in B57BL/10ScCr and C3H/HeJb strains, respectively) [35]. The 
remaining results of the paper were obtained using intraperitoneal or intravenous 
routes of E. coli infections and, until now, the mice model for oral E. coli infection has 
been set aside. In this study, Balb/c pups with less than 24 h old were oral infected 
with E. coli K1. In this model all infected animals presented bacteremia and 43% died. 
As also described in other studies, and as occurs in humans [13,31,32,36,37], we 
observed an age-dependency for the systemic E. coli infection and the ability of the K1 
strain to induce bacteremia and meningitis. We detected bacteria in several organs at 
very early-time points, 30 minutes post-infection, that are disregarded in the majority 
of in vivo models. We observed that, despite this rapid systemic E. coli colonization, 
the induction of a pro-inflammatory innate immune response only occurred after 
several hours after infection. Moreover, and as opposite to what was previously 
observed with GBS neonatal infections, the blocking of IL-10 during infection did not 
improve neonatal survival to E. coli infection, indicating that IL-10 is not responsible for 
the delay on the development of the innate immune response.  
By understanding how bacteria induce or take advantage of the tolerant/suppressive 
status of the newborn, novel and targeted therapies against E. coli neonatal infection 
could be developed. 
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MATERIALS AND METHODS 
Animals 
Balb/cAnNCrl mice, with a specific-pathogen free (SPF) status, were purchased from 
Charles River (Italy). All the animals were kept in the animal facilities of the Institute 
Abel Salazar during the time of the experiments. Mice were housed in Techniplast 
ventilated polycarbonate cages under negative pressure with hardwood bedding and 
provided with Mucedola Diet and fresh tap water, ad libitum, throughout the study. The 
temperature was maintained at 21–23˚C and the relative humidity at 50% ± 20% with 
a 12-hours light/dark cycle. All animals were housed in environmentally controlled 
cages with 40 air changes per hour.  
Ethics statement 
This study was carried out in strict accordance with the recommendations of the 
European Convention for the Protection of Vertebrate Animals used for Experimental 
and Other Scientific Purposes (ETS 123) and Directive 2010/63/EU and Portuguese 
rules (DL 113/2013). The animal experimental protocol was approved by the 
competent national authority Direção Geral de Alimentação e Veterinária (DGAV) 
(Protocol Permit Number: 0420/000/000/2008). All animal experiments were planned 
in order to minimize mice suffering. 
Bacteria 
The bacterium used in all experiments was extraintestinal pathogenic E. coli (ExPEC) 
IHE3034 of serotype O18:K1:H7, ST95, a neonatal meningitis-associated strain 
isolated in Finland in 1976. The bacterium was growth to exponential phase in liquid 
Todd-Hewitt (TH, Difco Laboratories) media for 3 hours at 37°C. After several washes, 
absorbance of the bacteria in PBS was adjusted to 0.450 at 600 nm (Jenway 6300 
Spectrophotometer), corresponding to 2 x 108 CFU/mL. 
Neonatal mouse model of E. coli infection  
Neonatal (< 24 h old) Balb/c mice were infected orally with 2x106 CFU of E. coli 
IHE3034 in 10μL of PBS. Littermate controls received the same amount of PBS. 
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Newborns were kept with their mothers during the experiment. All pups were 
euthanized if they were in moribund state (lethargic, darker red colour and with no 
observable milk spot) due to ethical reasons. Survival curves were determined over a 
9-d experimental period. Blood was collected by facial vein puncture after anesthesia 
with isoflurane (IsoFlo® Esteve). Liver, spleen, lungs, and brain of infected pups were 
aseptically removed at indicated time points and homogenized (VWRTM Pellet Mixer) in 
PBS. Liver and lungs were weight and divided prior to homogenization, a part of the 
organs was used for flow cytometry analysis. To quantify the bacterial load, serial 
dilutions in sterile saline were plated on Todd–Hewitt agar and incubated overnight at 
37˚C. 
Antibody treatments  
Antibody treatments were performed in newborn mice 12 h prior to E. coli challenge, 
with 60 μg (i.p. in 60 μL) rat anti-mouse IL-1R (Reg21 Hybridoma), rat anti-mouse IL-
10R mAbs (1B1.3a, Schering-Plough Corporation). Control animals received the same 
amount of control IgGs. Pups from each litter were randomly assigned to control or to 
experimental groups, marked, and kept with their mother. 
Determination of cytokine production  
Organ homogenates were incubated on ice for 10 min with 1:1 lyses buffer (200 mM 
Tris; 300 mM NaCl; 2% Triton X-100; pH=7.4), centrifuged at 14 000 rpm (UEC Micro 
14/B centrifuge) and the supernatants stored at -80ᵒC. IL-6, TNF-α, IL-1β, IL-10, MIP-
2 and KC were quantified by ELISA (eBioscience, with exception of IL-10, R&D 
Systems), according to the manufacturer’s instructions. Detection levels of 8 pg/ml, 16 
pg/ml, 16 pg/ml, 62.6 pg/ml, 15.6 pg/ml and 31.2 pg/ml, respectively.  
 
Flow cytometry analysis  
Neutrophil recruitment in the lungs of infected pups was evaluated by flow cytometry 
analysis. Briefly, 30 min, 1 h, 3 h, 6 h, 12 h, 18 h, 24 h and 48 h after E. coli infection, 
the liver and lungs were removed, gently homogenized in PBS, and passed through 
glass wool to remove cellular aggregates. Anti-mouse CD16/32 (clone 2.4G2) was 
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added to each sample to block Fc receptors. FITC anti-mouse CD45 Ab (clone X; BD 
Pharmingen) was used for leukocyte detection. Neutrophils were identified by biotin 
anti-mouse Ly6G (clone 1A8; BD Pharmingen) plus streptavidin-PECy5 (BD 
Pharmingen) staining and macrophages were identified by PE anti-mouse F4/80 (clone 
BM8; Biolegend) staining. Cell number was evaluated using micro particle size 
standard based on polystyrene with 10 μm (Sigma Aldrich). Fluorescence was 
analyzed using an Epics XL cytometer (Beckman Coulter), and data were analyzed 
with FlowJo software (TreeStar). 
Statistical analysis 
All statistical analyses were performed in GraphPad Prism version 5.0 for Windows 
(GraphPad Software, San Diego, California). For ELISA and flow cytometry data, One-
way ANOVA with Multiple Comparison Test with 95% of confidence was used to 
analyse the differences between all groups. In the case of ratios, the values were 
normalized using the formula: Arcsin(√(Value/100)) x 180/π, previous to statistical 
analysis. For survival curve analysis, Mantel-Cox test was performed. A P value < 0.05 
was considered statistically significant. 
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RESULTS 
Survival of neonatal mice to oral infection with E. coli K1 is pup age 
dependent 
The study of the neonatal immune response to systemic E. coli infection is important 
for the development of new therapeutics/prophylactics for E. coli-associated neonatal 
sepsis and meningitis. These studies would clearly benefit from animal models of 
infection that mimic all features of the disease in the human neonate. Oral bacterial 
feeding parallels the natural route of E. coli infection after gastrointestinal colonization 
and has been used with neonatal rats [25,30-34]. Nevertheless, this rodent model limits 
the use of several reagents and transgenic animals. In order to overcome these 
obstacles, we developed a model of E. coli oral infection in neonatal mice. BALB/c 
mice were orally infected with 2x106 CFU of E. coli K1. As seen in Figure 1, an age-
dependency for neonatal susceptibility to E. coli infection was observed, similarly to 
what is observe in humans [13]. Mortality (~43%) was only observed in pups that were 
infected before one-day old (<24 h old). After date age, the pups were resistant to oral 
infection with E. coli K1. Therefore, in this study, the pups were infected before one 
day of life.  
 
E. coli K1 rapidly develop systemic infection in neonatal pups  
It is widely accepted that, after E. coli aspiration and ingestion during birth, the bacteria 
invades the epithelia of the lung or of the gastrointestinal tract and disseminates 
through the bloodstream [20]. In our model, it was also observed a high bacterial 
colonization in the lungs of infected pups as soon as 30min post-infection (Figure 2). 
This could be due to part of the inoculum reached the neonatal respiratory tract during 
the bacterial administration. Indeed, after oral administration of the bacterium small 
bubbles were observable in pups’ nostrils. As shown in Figure 2, the colonization levels 
were maintained at high levels in neonatal lungs during the first 18 h of infection. Thirty 
minutes post–infection, all animals presented E. coli in bloodstream. To our 
knowledge, this is the first time that a neonatal E. coli systemic colonization is 
quantified at these early timepoints after a non-invasive type of infection. E. coli K1 
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bacterium was also observed in the blood circulation 30 min post-infection and persists 
at the same levels during the first 18 h post-infection. As shown in Figure 2, liver 
colonization starts as soon as bacteria reaches the bloodstream, with 65% of animals 
presenting colonization in the first half hour of infection. Colonization in this organ 
increased overtime and, 18 h post-infection, only 1 out of 14 infected animals 
presented colonization below detection levels. Although E. coli was detected in the 
brain and spleen of some animals at very early timepoints, only at 3 and 12 h post-
infection, the levels of colonization in these organs, respectively, were statistically 
significant.  
 
A delay in the development of the neonatal innate immune response  
During the host response to infection, the balance between pro and anti-inflammatory 
responses, as well as the timing of production of the different immune mediators, 
establishes the fate of the infection [38]. Therefore, the production of cytokines and 
chemokines was evaluated in liver and lungs of infected neonatal mice at several 
timepoints post-infection. As showed in Figure 3, despite the elevated colonization 
observed in these organs (Figure 2) very early after infection, an increase of the levels 
of pro-inflammatory cytokines was only observable 6 hours post-infection. The 
increase in IL-6, TNF-α and IL-1β higher in the lungs than in the liver (Figure 3A vs 
3B), which could explain the decrease in lung colonization after 18 h of infection and 
the maintenance of liver colonization (Figure 2). A decrease on IL-10 production was 
detected in the liver between the 1 h and 3 h post-infection, although the levels 
remained statistically similar to the controls throughout the infection. In lungs, an 
increased in IL-10 production was only detected 24 h post-infection, probably in 
response to the pro-inflammatory cytokines production. 
Another important feature of the innate immune response is the cell recruitment to 
infected organs. We first analyzed chemokine production in the lungs and liver of 
infected mice. As observed with cytokines, until 3 h after E. coli infection, no statistically 
significant production of any analyzed chemokine was observed (Figure 4). MIP-2 was 
preferentially produced in lungs, whereas in the liver, an early and higher production 
of KC was detected. Although 30 min post-infection high levels of KC were detected in 
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the lungs of some animals, the average of KC production is not statistically different 
from controls. 
Next, we analyzed macrophage and neutrophil recruitment to liver and lungs of 
infected mice. Erythrocytes and epithelial cells were excluded from analysis by gating 
CD45 positive cells [39]. The number of leukocytes in the liver of infected animals 
remained at similar levels of controls at all timepoints, with a tendency to decrease in 
the first hour and increase until the 12 h of infection (Figure 5). The percentage of 
macrophages in the liver increase in proportion after 3 h of infection, but differences in 
number of cells are only detected 12 h post-infection. Surprisingly, the number of 
neutrophils, the first immune cells to be recruited to infected organs, is maintained in 
levels that are not statistically different to the observed in control, although a tendency 
to increase between the first and third hour of infection is clearly observable.  
In lungs, the number of CD45 positive cells increases after 6 h of infection. Both 
macrophages (F4/80+) and neutrophils (Ly6G+) increased in number 12 h post-
infection (Figure 6A). Unexpectedly, a population double-positive for F4/80 and Ly6G 
marker was detected in the lungs of infected mice after six hours of infection (Figure 
6A and B). As observable in Figure 6B, this population increased overtime, with a 
decrease in number of single positive Ly6G cells. Dot plot analysis suggests that 
neutrophil population acquire the expression of F4/80 marker post-infection (Figure 
6B). This population was observable in flow cytometry analysis of neonatal lungs in 
mice in another study, but the authors neglected its presence [40]. Double positive 
F4/80+Ly6G+ cells were also detected in peritoneal lavages of adult mice 
intraperitoneally injected with heat-killed Pseudomonas aeruginosa [41]. In this paper, 
the authors designate this population as double-positive myeloid cells and identified a 
similar ability to produce myeloperoxidase in response to P. aeruginosa as single 
positive Ly6G cells [41]. In our model, this double positive population decreases in the 
lungs after 18 h of E. coli oral infection (Figure 6A).  
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Blocking IL-10 signalling does not reduce mortality in E. coli-infected 
pups 
IL-10 has been associated with neonatal susceptibility to GBS-infection [42,43]. In E. 
coli K1 neonatal infections, IL-10 production was been associated with host protection 
[24,44,45]. To determine the importance of this anti-inflammatory cytokine to E. coli-
induced mortality in our model, IL-10 signalling was blocked before infection. As shown 
in Figure 7, anti–IL-10R mAb treatment did not confer resistance to newborns 
challenged with E. coli. Although the mice treated with anti-IL10R mAb started to die 
sooner than controls, the mortality rate at the end of the experiment was similar (Figure 
7). Moreover, in a sub-cutaneous model of neonatal E. coli K1 lethal infection, both the 
lack of expression of IL-10 (in IL-10 KO mice) and antibody blocking of IL-10R in WT 
mice did not have any influence on the outcome of infection (data not shown). 
The importance of the pro-inflammatory cytokine, IL-1β, in E. coli neonatal infection is 
not yet well characterized. To decipher the role of this pro-inflammatory cytokine in our 
model, newborn mice were treated with anti-IL1R antibody 12 h prior to the E. coli K1 
challenge. In orally E. coli K1-infected pups, anti-IL-1R increased the neonatal mortality 
from 47% (controls) to 93% (Figure 7). Therefore, IL-1β conferred protection against 
E. coli infection. 
Contrary to what was observed in neonatal GBS infection, IL-10 has no role on the 
susceptible of neonates to E. coli K1 infection. Moreover, IL-1β production seems to 
has a protective role during E. coli K1 neonatal infection 
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DISCUSSION 
E. coli is the second most common cause of neonatal infections with mortality rates 
that reach the 40% and morbidity in survivors that surpass the 40% [5,7,9,10]. In E. 
coli infections antibiotic-resistance is particularly serious, a recent report, showed that 
75% of obstetric and 95% of pregnant women vaginal E. coli isolates were resistant to, 
at least, one of the antimicrobial agents tested, with 65% of all isolates being resistant 
to ampicillin [15]. Therefore, there is a clear need for more efficient preventive 
measures against E. coli neonatal infections. The understanding of the pathogenesis 
of E. coli and its interaction with the neonatal immune system is essential for the 
generation of new therapeutics and prophylactics. Here we proposed a mouse model 
of studying the neonatal immune response to the E. coli infection that is similar to the 
human route of infection. Gastric and oral neonatal E. coli infection in rodent models 
has been developed in the last decades but in rat [25,30-34]. The development of an 
oral mice model for the study of neonatal E. coli K1 sepsis and meningitis was already 
tried, but was unsuccessful in confer bacteremia and mortality in conventional 
laboratory mice strains [35]. In our mice model, an age-dependency to susceptibility to 
E. coli infection was observed similarly to observed in human neonatal [13]. A twenty-
four hour difference in the age of the animals was enough to abrogate the 43% 
mortality rate. This result could explain the lack of mortality and bacterial recovery on 
Balb/c mice infected orally with E. coli described in Pluschke et al study, where 3 to 5 
days old animals were used [35]. The strong age dependency in E. coli infections has 
been associated with microbiota gut colonization [29] and with the level of the 
maturation of the intestinal mucus barrier [37]. A study with bioluminescent E. coli K1 
oral infection, showed also an age dependency on bacterial colonization on upper 
organs of intestinal track in neonatal rats, as in non-keratinized esophageal tissues 
and in the oral cavity [32]. Neonates, and particularly preterms, exhibit reduced 
esophageal motility and luminal clearance compared to adults [46], which can 
contribute to the vulnerability to colonization and invasion of E. coli K1 in newborns. 
Moreover, despite the existence of a strong correlation between systemic E. coli K1 
infection and gastrointestinal tract colonization, the aspiration of the contaminated fluid 
into the lungs and other regions of respiratory tract may provide an alternative entrance 
to the bacteria into the systemic circulation [32]. In this regard, the majority of the 
articles with non-invasive E. coli K1 neonatal infection in mice models use intranasal 
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inoculation [24,27,47,48]. In our model, both gastrointestinal and respiratory tract 
colonization was achieved. Indeed, E. coli was detected in the stomach and small 
intestine of all infected animals, 30 and 60 min post-infection (data not showed) and, 
during infection, it was observed the formation of small bubbles in nostrils, which 
indicates that part of the inoculum reached the respiratory tract. That was further 
confirmed by the high colonization of the lungs of infected mice as soon as 30 min 
post-infection. Systemic colonization of all pups was observed after half hour of 
infection. Blood colonization was maintained at similar levels from the first to the last 
timepoint (30 min to 24 h) (although a tendency to decrease after 18 h was observable) 
and, in the liver, E. coli colonization increased over time. The spleen was the last 
analysed organ to be colonized, but reached statistically significant values as soon as 
12 h post-infection. E. coli K1 is strongly associated with sepsis and meningitis and we 
found brain colonization 3 h post-infection, with viable bacteria being detected in the 
brain of some animals as soon as 30 min post-infection. We cannot exclude that the 
bacteria present in the blood could account for some of the bacteria found in other 
tissues. The fragility of the organs of the newborn mice and the small timepoints tested 
make impossible the ex vivo perfusion for blood removal. Nevertheless, we observed 
an increase in colonization in all organs, while blood colonization was maintained 
constant throughout the study.  
Pathogen recognition by immune cells and the generation of an immune response is 
initiated as soon as the bacteria enter the host. However, despite the elevated 
colonization observed in lungs and liver at 30 min post-infection, an increase in the 
production of pro-inflammatory cytokines IL-6, IL-1β and TNF-α and chemokines KC 
and MIP-2 was detected only after 6 h of infection (Figure 3). This delay in the induction 
of inflammatory mediators had, as consequence, a delay on the recruitment of cells to 
infected organs. As soon as an increase of cytokines and chemokines was detected, 
an increase in the number of macrophages and neutrophils was also observed (Figure 
4 and 5). Furthermore, in lungs, at 6 h post-infection a double positive population for 
Ly6G and F4/80 appeared that, at 18 h timepoint, accounted for more than 60% of 
CD45 positive cells it this organ. This population was already described  in a study with 
P. aeruginosa infection and was identified  as having the capability of producing the 
same amount of myeloperoxidase as neutrophils in response to this gram-negative 
bacterium [41]. Extra-intestinal pathogenic E. coli has the ability to survive inside 
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neutrophils and macrophages [26,27,49] and, in a neonatal mice model of intranasal 
E. coli infection, neutrophil depletion was associated with resistance to infection [27]. 
In other studies, however, a decrease in neutrophil and macrophage recruitment was 
associated with an increase in E. coli colonization and susceptibility to infection [23,37]. 
The role of IL-1β in E. coli infections is not consensual. The treatment of 10-day E. coli 
i.p. infected mice with recombinant IL-1 conferred resistance to the bacterial-induced 
mortality [35]. In an adult model of E. coli pneumonia, however, IL-1β production in 
lungs was associated with an increase in susceptibility to infection [50]. In our study, 
at 6 h post-infection a significant IL-1β production in lungs and a small production in 
liver were observed. We showed that the production of this pro-inflammatory cytokine 
had a protective effect, once the blocking of its signaling increased the mortality of 
infected pups up to 90%.  
In neonatal GBS infection, the induction of an early IL-10 production by the bacteria 
leads to an inhibition of the recruitment of protective neutrophils to infected organs 
[42,43]. In E. coli infections, IL-10 has been associated with host protective responses 
[24,44,45]. In our model of E. coli infection, IL-10 levels in the liver were maintained 
similar to controls throughout the experiment. In lungs, IL-10 production was detected 
only at 24 h, probably in response to pro-inflammatory cytokine levels. Moreover, 
blocking of IL-10 signaling by anti-IL-10R antibodies did not alter the neonatal 
susceptibility to E. coli infection. Therefore, E. coli K1, despite the similarities with GBS 
in mode of transmission and neonatal manifestations of neonatal diseases, does not 
rely on an early IL-10 production to evade the neonatal immune system. Additional 
studies will be required to determine which immune mediators and bacterial factors are 
responsible for the delay in the immune response to E. coli K1 in our model and for the 
neonatal susceptibility to this bacterium. 
Overall, this study opens the possibility to the use of our mice model to study the key 
features of E. coli-induced neonatal sepsis and meningitis. We shed some light on the 
kinetics of colonization and on innate immune response to this bacterium. We found 
an unexpectedly quick systemic colonization that it is not followed by a promptly innate 
immune response. We believe that a protective immune response should be mounted 
in the first hour of infection in order to prevent systemic dissemination that led to sepsis 
and to inhibit the brain colonization and consequent meningitis sequelae. 
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Figure Legends 
 
Figure 1. Age dependency of E. coli K1-induced neonatal mortality. Balb/c 
pups with less than 24 or 48 h of life were orally infected with 2x106 CFU of E. 
coli IHE3034 in 10 μL. Littermate controls received the same amount of PBS. 
Newborns were kept with their mothers during the experiment and were 
evaluated twice a day. All pups were sacrificed if they were in moribund state due 
to ethical reasons. Survival curves were determined over a 9-d experimental 
period. Log-rank (Mantel-Cox) test *p<0.05 between <24 h old infected and <48 
h old infected groups. 
Figure 2. E. coli K1 rapidly systemically colonize neonatal orally infected 
mice. (A) Lung, (B) blood, (C) liver, (D) spleen and (E) brain E. coli K1 
colonization at specific timepoint post-infection. In this and in the following figures, 
neonatal (< 24 h old) Balb/c mice were infected orally with 2x106 CFU of E. coli 
IHE3034 in 10μL of PBS, the littermate controls received the same amount of 
PBS (0h) and newborns were kept with their mothers during the experiment. 
Blood was collected by facial vein puncture after anesthesia with isoflurane 
(IsoFlo® Esteve). Liver, spleen, lungs, and brain of infected pups were aseptically 
removed at indicated time points and homogenized in PBS. Blood and organs 
were serial diluted in PBS, plated on Todd–Hewitt agar and incubated overnight 
at 37˚C. 30 min (n=6); 1 h (n=10); 3 h (n=13); 6 h (n=15); 12 h (n=12); 18 h (n=14); 
24 h (n=14); 48 h (n=5). One-way ANOVA with Tukey's multiple comparisons test 
between timepoints and one sample t-test for comparison with control (theoretical 
mean = 0) *p<0.05; **p<0.01; ***p<0.001. 
Figure 3. Kinetics of neonatal cytokine production after E. coli K1 oral 
infection. (A) Lung and (B) liver IL-1β, TNF-α, IL-6 and IL-10 levels at specific 
timepoint post E. coli oral infection. Liver and lung were removed at indicated time 
points, homogenized in PBS and lysis buffer was added to allow protein recovery. 
Cytokine production was evaluated by ELISA. 0 h (n=28); 30 min (n=6); 1 h 
(n=10); 3 h (n=13); 6 h (n=15); 12 h (n=12); 18 h (n=14); 24 h (n=14); 48 h (n=5). 
One-way ANOVA with Tukey's multiple comparisons test *p<0.05; **p<0.01; 
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***p<0.001. Statistic on the top of each timepoint represents a comparison with 
controls (0h). 
Figure 4. Kinetics of neonatal chemokine production after E. coli K1 oral 
infection. (A) Lung and (B) liver MIP-2 and KC levels at specific timepoint post 
E. coli oral infection. Liver and lung were removed at indicated time points, 
homogenized in PBS and lysis buffer was added to allow protein recovery. 
Chemokine production was evaluated by ELISA. 0 h (n=28); 30 min (n=6); 1 h 
(n=10); 3 h (n=13); 6 h (n=15); 12 h (n=12); 18 h (n=14); 24 h (n=14); 48 h (n=5). 
One-way ANOVA with Tukey's multiple comparisons test *p<0.05; **p<0.01; 
***p<0.001. Statistic on the top of each timepoint represents a comparison with 
controls (0h). 
Figure 5. Cell recruitment to the liver of pups infected with E. coli K1. FITC 
anti-mouse CD45 Ab was used for leukocyte detection, neutrophils were 
identified by biotin anti-mouse Ly6G plus streptavidin-PECy5 staining and 
macrophages were identified by PE anti-mouse F4/80 staining. Cell number was 
evaluated using micro particle size standard. Fluorescence was analyzed using 
an Epics XL cytometer, and data were analyzed with FlowJo software. 0 h (n=28); 
30 min (n=6); 1 h (n=10); 3 h (n=13); 6 h (n=15); 12 h (n=12); 18 h (n=14); 24 h 
(n=14); 48 h (n=5). One-way ANOVA with Tukey's multiple comparisons test 
*p<0.05; **p<0.01; ***p<0.001. Statistic on the top of each timepoint represents 
a comparison with controls (0h). 
Figure 6. Cell recruitment to the lungs of pups infected with E. coli K1. FITC 
anti-mouse CD45 Ab was used for leukocyte detection, neutrophils were 
identified by biotin anti-mouse Ly6G plus streptavidin-PECy5 staining and 
macrophages were identified by PE anti-mouse F4/80 staining. Cell number was 
evaluated using micro particle size standard. Fluorescence was analyzed using 
an Epics XL cytometer, and data were analyzed with FlowJo software. (A) 
Graphic representation of number of CD45 cells, and number and percentage of 
macrophages, neutrophils and double positive cells of all animals. (B) 
Representative dot plot of Ly6G F4/80 analyses on CD45 gated leukocytes. 0 h 
(n=28); 30 min (n=6); 1 h (n=10); 3 h (n=13); 6 h (n=15); 12 h (n=12); 18 h (n=14); 
24 h (n=14); 48 h (n=5). One-way ANOVA with Tukey's multiple comparisons test 
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*p<0.05; **p<0.01; ***p<0.001. Statistic on the top of each timepoint represents 
a comparison with controls (0h). 
Figure 7. IL-10 and IL-1R signaling in the susceptibility to E. coli K1-induced 
death. Balb/c pups with less than 12 h of life were injected i.p. with 60 μg of anti–
IL-1R mAb, anti–IL-10R mAb, or control IgG 12 h prior to oral infection with 2x106 
CFU of E. coli IHE3034. Newborns were kept with their mothers during the 
experiment and were evaluated twice a day. All pups were sacrificed if they were 
in moribund state due to ethical reasons. Survival curves were determined over 
a 9-d experimental period. Log-rank (Mantel-Cox) test *p<0.05  
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DISCUSSION 
In the 21st century, despite all the medical advances, infections remain one of 
the top causes of mortality worldwide being children and immunocompromised 
adults the main risk populations. This thesis attempts to shine a small, but 
hopefully significant, light on two of the infectious agents, Group B Streptococcus 
(GBS) and Escherichia coli, that continuously affect the life of newborns and 
immunocompromised adults.  
GBS is a known leading cause of life-threatening bacterial infection in newborns 
since the 60’s. Guidelines for screenings and intrapartum antibiotic prophylaxis 
(IAP) to GBS-colonized mothers have successfully reduced early-onset GBS 
disease (EOD; that occur in the first week of life). In the last years, however, the 
rates of EOD were maintained stable and GBS continues to be the most frequent 
cause of neonatal infections [1-3]. The IAP treatment shows severe limitations in 
inhibiting the rates of GBS late-onset manifestations of the disease (LOD; that 
occur between the first week and the first month of life) and the rates of stillbirths 
and prematurity caused by this bacterium [2,3]. Currently, several health entities 
expressed serious concern regarding the use and misuse of antibiotics on a 
global scale [4,5]. The risk of antibiotic overuse, especially during pregnancy, may 
surpass the benefits associated with the prophylaxis [5]. One of the most relevant 
and well known consequences of antibiotic use is the emergence of antibiotic-
resistant strains [6]. IAP use during pregnancy has been shown to, not only have 
an effect on the emergence of GBS-resistance strains, but also to have been 
associated with the shift to Escherichia coli neonatal infections [7-9]. Another 
important aspect of antibiotic use during pregnancy is the alteration of the 
neonatal gut colonization. It is now known that the colonizing microorganisms co-
evolved with host innate immune system, resulting in an elaborate 
interdependency and feedback mechanisms by which microbiota drive postnatal 
maturation of the gut and development of the immune system [10,11]. IAP 
treatment reduces the diversity and composition of maternal intestinal and 
vaginal microbiota, influencing the appearance of beneficial bacteria in the child 
[12,13]. These alterations are linked to an increased susceptibility to the 
development of several diseases [14,15] and may have an influence on emotional 
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responses (like stress, anxiety and depressive-like behavior) and brain 
neurochemistry (altered expression of neurotransmitters or theirs receptors) [16-
19]. 
Vaccination could not only abolish the contraindications of antibiotic use, but also 
prevent the appearance of more cases of GBS neonatal infections and the 
prevention of preterm labor, stillbirths and late-onset GBS infections [20-22]. This 
therapeutic strategy would also allow the prevention of GBS infections in low and 
middle-income countries where IAP, due to its cost, is inaccessible [23]. 
Several GBS vaccines have been developed in the last decades. A major effort 
and hope is being placed on capsular polysaccharide (CPS) conjugated 
vaccines. A trivalent vaccine, with CPS from serotypes Ia, Ib, and III, developed 
by Novartis, is already in Phase II of clinical studies [24,25]. GBS, however, is 
divided into 10 different serotypes, based on their CPS, and each CPS induces 
antibodies with low cross-reactivity with the remaining CPS [26]. The pattern of 
GBS serotypes responsible for invasive infections varies with time and 
geographical location and serotypes that are not contemplated on trivalent CPS 
vaccine are gaining ground on GBS invasive infections [27-30]. Moreover, this 
glycoconjugated vaccines directed against GBS CPS will not protect against 
infections by non-typeable GBS isolates that are increasingly being reported [31-
33]. 
Our group developed a vaccine based on GBS’ glycolytic enzyme 
glyceraldehyde-3-phosphate dehydrogensase (GAPDH) [34,35]. This protein is 
responsible for catalyzing one of the central reactions of glycolysis and is, thus, 
essential for both anaerobic and aerobic cells. On GBS, this protein was found 
extracellularly on clinical invasive strains from all serotypes [35-37], which 
suggests that antibody binding should not be impaired by surface capsular 
polysaccharides. We showed that maternal vaccination with the recombinant 
form of GAPDH was highly effective in protecting the offspring against a lethal 
infection with GBS [35] (Figure 1). The effectiveness of the GBS’ GAPDH 
vaccine, associated with the essentiality of GAPDH to bacterial growth in blood 
and universality of the protein among GBS serotypes, makes it an attractive target 
for the development of a human vaccine. To move a candidate vaccine from the 
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laboratory to the clinic, it has to pass through several mandatory stages and 
preclinical tests on animals to assure its safety [14, 48]. Therefore, one of the first 
questions addressed on Manuscript 1 was: 
i) Is recombinant (r)GAPDHGBS vaccine safe? 
To answer this question, we evaluated a series of toxicological parameters on 
Balb/c mice after repeated administrations of rGAPDH-Alhydrogel formulations, 
using three different doses that showed similar immunogenicity. This is of great 
importance, since antibodies are key mediators of host immune responses 
against GBS [35,38,39]. During the toxicological studies the animals were 
followed closely but none of the animals, in any of the groups, presented any 
clinical signs or histological abnormalities in organs and tissues. Moreover, the 
panel of biochemical and acute inflammation parameters tested confirmed the 
harmlessness of the vaccine. Although preclinical studies must be performed in 
independent laboratories under Good Laboratory Practices (GLP) certification, 
our results point to a favorable outcome of that tests and increases the interest 
of a financial investment in that direction. Another important aspect of the vaccine 
to support clinical trial approval is its stability [40]. In Manuscript 1 we also 
showed that the rGAPDH vaccine conserves its potency and safety, without 
significant alteration, at 4°C for at least 12 months. This feature is especially 
significant for the use of this vaccine in low-income countries where it is often 
difficult to provide appropriate storage conditions [41]. 
In the last decades, a remarkable increase in GBS invasive infections in non-
pregnant adults has been observed, especially among the elderly and patients 
with underlying medical conditions [42-46]. These infections are associated with 
substantial morbidity and mortality, reaching fatality ratios higher than the ones 
associated with neonatal infections [44,45]. In non-pregnant adults, serotypes V 
and Ia are the most commonly associated with GBS invasive disease [29,46-48]. 
Serotype V, is highly associated with antibiotic-resistance and, in some reports, 
more than 50% of the invasive isolates of this serotype had at least one antibiotic 
resistance mechanism [46,49]. Thus, an alternative treatment to antibiotics is 
required against GBS infections in non-pregnant adults. For this reason we 
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investigated the potential of rGAPDHGBS vaccine this group, by answering the 
second question addressed on Manuscript 1: 
ii) Can rGAPDHGBS vaccination confer protection against GBS 
infections in non-pregnant adult mice? 
 
 
Figure 1. rGAPDH vaccination confers protection against neonatal and adult GBS 
infection. Previous work of Madureira et al, proved that maternal vaccination with 
rGAPDH-vaccine protected the progeny against a lethal infection with GBS from 
serotype III (top). In Manuscript 1 we proved that rGAPDH-vaccination also protected 
adult susceptible mice against GBS serotype Ia and V (middle) and diabetic mice against 
GBS serotype V (bottom). 
 
Vaccination promoted an increase in resistance to GBS by abolishing mortality 
and decreasing bacterial colonization in several organs (Figure 1). The decrease 
of bacterial colonization on heart and brain of vaccinated animals was of 
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particular significance since endocarditis and meningitis are the two clinical 
presentations of GBS invasive infections with the worst prognosis in terms of 
morbidity and mortality in non-pregnant adults [38, 39]. Endocarditis and 
meningitis pathogenesis are complex processes, but the ability of GBS to bind to 
host components, such as fibrinogen, fibronectin and plasminogen has been 
associated with both adhesion and disease progression [50-52]. GBS GAPDH 
interaction with host extracellular matrix components, such as plasminogen, actin 
and fibrinogen was already described [37,53]. Thus, a decrease of GAPDHGBS 
association with host molecules could be, in part, contributing to the protective 
effect of anti-GAPDHGBS antibodies in GBS infection.  
We also observed an inflammatory response mediated by production of pro-
inflammatory cytokines associated with protection. This inflammatory response, 
when induced early post-infection, has also associated with GBS clearance in 
adult mice model [54]. Therefore, the protection observed in adults susceptible 
mice by rGADH-vaccination is, probably, a consequence of an increased 
complement activation and phagocytic-activity dependent on antibodies. We 
intend to abrogate the signaling of each pro-inflammatory cytokine to determine 
their direct or indirect role in the protection that we observed.   
An important aspect of vaccination of non-pregnant adults that should be taken 
into account is the fact that the majority of GBS infections in this group occurs in 
elderly adults [42,55,56]. The existence of underling medical conditions, 
hospitalization and bedridden states added to a decreased of integrity of the 
anatomical barriers and immune senescence, make this group particularly 
susceptible to GBS invasive infections [56]. The profound dysfunction in immune 
responses, especially in cell-mediated immunity and neutrophil activity, could 
render vaccination ineffective in this group [57,58]. Nevertheless, pneumococcal 
polysaccharide vaccine is recommended for adults with more than 65 years of 
age [59] and the administration of serotype V CPS conjugate vaccine in healthy 
adults with ages comprised between 65 and 85 years old was able to elicit 
specific antibodies as strongly as those in the 18–50 years old group [60]. 
Moreover, neutrophils from elderly individuals, in the presence of specific 
antibodies against type V CPS, were able to mediate the opsonophagocitic killing 
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of the serotype V GBS strain in vitro [61]. These data validates the possibility of 
eliciting an effective immune response against GBS by vaccination of the elderly.  
From the adult populations usually considered at at-risk for invasive GBS 
disease, individuals with diabetes mellitus stand-out [42,45,62,63]. In fact, the 
rising of the incidence of GBS infections in non-pregnant adults has been 
associated not only with the aging of the population, but also with the increasing 
prevalence of individuals with diabetes [45]. Diabetes mellitus is present in 20 to 
nearly 50% of non-pregnant adults infected with GBS [45,64-66] and, although 
the reason for the propensity of adult diabetics to develop some infections is not 
yet well defined, it appears to be due to a combination of immune dysfunction, 
angiopathy, neuropathy, gastrointestinal and urinary dysmotility [67]. Glycemia 
influences the host defense mechanisms such as wound healing, cellular 
immunity and complement functions [68]. Enhanced susceptibility to GBS 
infection in diabetic mice has already been described for serotypes II and IV 
[69,70]. Having in mind the importance of diabetes in susceptibility to GBS 
infection, in Manuscript 1 we also determined the efficacy of the rGAPDHGBS 
vaccine in a mouse model of diabetes. In this study we used a GBS strain that 
belongs to serotype V, since this is serotype is the most frequent on diabetic 
patients [45]. The experiments on diabetic mice were only performed with males, 
since females are considerably more resistance to the drug used to induce the 
diabetes, streptozotocin [71], probably due to estradiol’s ability to protect 
pancreatic β cells from apoptosis induced by oxidative stress [72]. rGAPDHGBS-
vaccinated mice presented lower colonization levels in all analyzed organs, when 
compared with Sham-immunized animals. These results proved that vaccination 
with rGAPDHGBS also protects adult diabetic mice against GBS serotype V 
infection.  
Overall, GAPDH proved to be a promising target antigen for vaccination against 
GBS infections in the groups of risk: neonates and susceptible adults.  
Since GAPDH is ubiquitously expressed in all type of cells, and several 
microorganisms use this enzyme to bind to extracellular matrices or modulate the 
host-immune response [73-77], we and others use the GAPDH as a target for 
vaccination [78-84]. Having in mind the central role of GAPDHGBS in modulating 
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the neonatal immune system to allow the establishment of GBS bacteremia [35], 
we hypothesized whether other microorganisms use the same mechanism to 
induce a neonatal infection. Due to the growing importance of E. coli as a 
neonatal pathogen [85], and that GAPDHE.coli has already been described as an 
extracellular virulence factor of this Gram-negative bacterium [86], in Manuscript 
2 we addressed the question: 
iii) Can an rGAPDH-based vaccine confer protection against E. coli 
neonatal infections? 
Bacterial GAPDH share a high degree of similarity, which hints to the possibility 
that a vaccine based on the GAPDH protein from one microorganism could 
protect against the others unrelated pathogens. This was already observed for 
the fish pathogens Aeromonas, Edwarsiella and Vibrio species, where cross 
protection (ranging from 62% to 78%) was achieved against five pathogens [87]. 
Although GAPDHGBS shares a 50% amino acids homology with GAPDHE.coli, 
antibodies specific for each GAPDH are not able to recognize the GAPDH from 
the other bacteria. This was also described with the GAPDH from the two mastitis 
pathogens (Streptococcus uberis and Streptococcus dysgalactiae) that a 
difference in few amino acids also resulted in lack of cross protection [83]. 
GAPDHGBS, in addition to the ability to interact with host extracellular matrix 
proteins [53], shows a B cell stimulatory effect in vitro [34], promotes IL-10 
production [34,35] and induces apoptosis in murine macrophages [88]. In 
Manuscript 2, we investigated if GAPDHE.coli had the same properties of 
GAPDHGBS on host immunity. However, the obtained results showed that 
GAPDHE.coli is unable to stimulate B cell activation or induce cytokine production 
and, unlike GAPDHGBS, induces splenic cell death. These results proved that, 
notwithstanding the similarities between the amino acid sequences of the two 
GAPDH, their effects on host immune system are distinct. Furthermore, the 
capacity of rGAPDHGBS to induce cell death appears to be dependent on the cell 
type used since it was already described that rGAPDHGBS induces apoptosis in 
murine macrophages but we did not detect cell death in splenic cells stimulated 
with this protein.  
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The surprising result, however, came from the GAPDHE.coli immunization assays. 
Maternal vaccination with rGAPDHE.coli-Alhydrogel formulations not only did not 
confer protection but also increased the neonatal susceptibility to oral E. coli K1 
infection. A similar tendency, although not statistically significant, was also 
observed with passive immunization with anti-rGAPDHE.coli IgG antibodies to 
pups. This is, to our knowledge, the first time that a negative effect is associated 
with GAPDH-based vaccines. An increase in neonatal susceptibility to an 
infection, especially to a normal colonizer of the gastrointestinal tract, highlights 
the need for precaution in the generalization of the development of GAPDH-
based vaccines. The reason for this phenomenon is not yet clear. An increased 
bacterial accessibility to bloodstream facilitated by antibodies is not excluded and 
will be further investigated. Nevertheless, in our model of oral E. coli infection 
(characterized in Manuscript 3), the bacteria reached the bloodstream very soon 
upon infection, without the need of facilitating antibodies. Moreover, a tendency 
to an increased susceptibility to E. coli infection was also observed when 
antibodies against rGAPDHE.coli were administered i.p., suggesting that the 
negative effect of the antibody administration probably occurs after the bacteria 
reaches the bloodstream. The mechanism by which these antibodies are 
conferring susceptibility in a neonatal model of E. coli infection will be further 
investigated.  
The negative effect that was observed with GAPDH immunization on E. coli 
neonatal infection could not be exclusive to the use of antibodies against this 
used antigen. Indeed, despite several E. coli K1 virulence factors having been 
already identified, there is not any effective vaccine being developed against E. 
coli neonatal infections. It is possible that IgG opsonization of E. coli K1 facilitates 
the internalization of the bacteria by macrophages and neutrophils in a way that 
favors the bacterial survival. The interaction of the bacterium with FcγRI 
(mediated by E. coli K1 outer membrane protein A (OmpA)) is associated with 
bacterial invasion and survival in macrophages [89]. OmpA interacts with FcγRI 
α-chain and avoids the association of the γ-chain (crucial for inducing the anti-
microbial activity of macrophages [90]), even in the presence of IgG2a 
opsonization [89] (Figure 2 and 3). Therefore, it is possible that the antibodies 
IgG binding to FcγRI could enhance the E. coli K1 internalization and intracellular 
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survival in an environment where phagocytic killing is inhibited by OmpA (Figure 
3). We intend to explore this hypothesis with in vivo studies with F(ab)2 specific 
to rGAPDHE.coli to determine the role of the Fc binding to the FcγRI in the 
susceptibility of rGAPDHE.coli vaccination to E. coli K1 neonatal infection. In 
parallel we plan to perform in vitro opsonophagocytic studies with E. coli K1 WT 
and OmpA- to determine the effect of the antibodies on bacterial invasion and 
survival within phagocytes is dependent of this outer membrane protein A. 
Moreover, if E. coli K1 associates with CR3 instead with FcγRI and TLR2 on 
phagocytes, bacterial clearance is achieved [89,91]. IL-10 administration during 
E. coli K1 neonatal bacteremia shifted the intracellular uptake of bacteria towards 
CR3 [91] (Figure 2). Therefore, we also intend to induce CR3 expression on 
phagocytes, by IL-10 administration, in anti-GAPDH treated and E. coli K1 
infected mice. This experiment will allow us to understand if the type of bacteria 
association with phagocytes interferes with the neonatal susceptibility induce by 
antibody administration in our model.  
 
Figure 2. E. coli K1 elimination or survival inside phagocytes is dependent by 
which receptor the bacteria is internalized. E. coli K1 interaction with FcγRI leads to 
bacterial uptake and intracellular survival of the bacteria [89]. Pterin, prostaglandin E-2 
(PGE-2) and NOS production are associated with a balance towards FcγRI expression 
on phagocytes during E. coli K1 infection [91-93]. On the other side of the balance, is the 
E. coli K1 interaction with CR3. This association leads to bacterial uptake and clearance 
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inside phagocytes [89,91]. The expression of CR3 on phagocytes is amplified by IL-10 
production/administration during infection [91].  
 
 
 
Figure 3. Representation of association with E. coli K1 with phagocytes receptors 
and possible mechanism of susceptibility conferred by anti-GAPDH antibodies. 1) 
In the absence of OmpA, E. coli K1 associates with CR3 leading to bacterial clearance. 
Also in this case, when IgG antibody interacts with FcγR, it leads to recruitment of ζ-chain 
and the consequent intracellular activation of microbicidal mechanisms of phagocytes. 
2) E. coli K1 OmpA interacts with FcγRI, inducing the bacterial internalization without 
activation of ζ-chain-dependent mechanisms. In this scenario, TLR2 recognition of E. coli 
K1 also increases the intracellular survival. 3) We speculate that, in our mice model, 
since the microbicidal intracellular cascade of FcγR is inhibited by OmpA, the anti-
GAPDH antibodies are facilitating de E. coli K1 internalization and accelerating bacterial 
dissemination. 
 
Due to increasing interest on GAPDH as a vaccine target for multiple human and 
veterinary vaccines [84] it is possible that, in the next years, other GAPDH-based 
vaccine could be considered against human pathogens. Having in mind the 
negative effect of GAPDH-vaccination in our E. coli K1 infection model, the cross-
reactivity of the antibodies induced by GAPDH-based vaccines with E. coli’ 
GAPDH should be tested, especially if they are intended to be used in women. It 
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is possible that a GAPDH-vaccine, especially against a Gram-negative bacteria, 
could lead to a recognition of the E. coli’ GAPDH and, therefore, induce 
susceptibility to E. coli K1 in neonates, despite the efficacy against the bacteria 
to which they were designed. 
Additionally, there is the possibility that the antibodies against the GAPDH of a 
pathogen recognize homologous protein of probiotic strains and, therefore, 
interfere with microbiota colonization. This possibility, regarding the GAPDHGBS 
vaccine, is being investigated by our group.  
We showed that GAPDH, despite being a virulence factor for intestinal-
pathogenic E. coli [86], is not relevant for neonatal E. coli K1 infection. However, 
how this Gram-negative bacterium survives and colonizes the neonates? This 
question was addressed in Manuscript 3. 
 
 
Figure 4. E. coli K1 bacterial dissemination in humans and in rodent models of 
neonatal infection. During birth, the newborn aspirates the E. coli K1 contaminated 
vaginal fluids. The bacteria can assess both the respiratory and the digestive system. In 
a rat model of E. coli K1 infection, the bacteria has been shown associated with the oral 
cavity, esophagus tissue and intestine [94]. Mice models with intranasal E. coli K1 
infection, prove that this bacteria as the ability to transverse the respiratory tract [89]. In 
our model of oral E. coli K1 infection, we achieved both respiratory and digestive tract 
infection. Newborn - illustration of Amanda Montanez.      
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E. coli, as GBS, are bacteria that the newborns can acquire perinatally from 
contaminated vaginal fluids [95] (Figure 4). Therefore, first, we selected a model 
that allowed to mimic of that type of infection and, at the same time, enabled the 
characterization of the kinetic of the neonatal immune response. Oral E. coli 
neonatal infections had already been employed in rats, with positive results, and 
shed some insights about the complex and dynamic patterns of E. coli K1 
colonization and dissemination [94,96]. However, an oral neonatal mice model 
has not yet developed and the use of mice is preferable to study the host-E. coli 
K1 interactions since the majority of immunological studies with other neonatal 
pathogens are performed on mice (allowing therefore the comparison of results) 
and rat models limit the use of reagents and transgenic animals. Although in 
1988, an oral E. coli infection was tried in 3-5 days old mice, the results showed 
that it was unable to induce bacteremia or dead in WT mice strains and was, 
therefore, set aside [97]. We change the time of oral inoculation, and 
administrated the bacteria at the day of birth to Balb/c mice. The results showed 
a 43% of mortality rate and a 100% bacteremia at the first hours post-infection, 
but, if the infection was performed after on day of life (>24 h but <48 h), the 
mortality was completed abolished. This age-dependency of E. coli K1 infection 
explains the lack of mortality observed in the 1988 study, where mice with 3-5 
days old were used [97].  
The strong age-dependency in E. coli infections can be associated with external 
or internal factors. During the birth and soon thereafter, bacterial colonization of 
a previously germfree intestinal tract begins, in a dynamic way, as the host 
develops. The hypothesis that the evolution of the microbiota profile with neonatal 
age could contribute to a decrease to the neonatal susceptibility to E. coli K1 
should not be excluded. In this regards, changes in the composition of gut 
microbes in neonates mice by antibiotic exposure during birth, led to a 
deregulation of neutrophil homeostasis and increased the susceptibility to E. coli 
K1 infection [98]. Furthermore, in a study of the human infant intestine, an initial 
colonization with E. coli was detected in an infant that disappeared as soon as 
the colonization of bifidobacteria was detected [99]. Moreover, despite that at the 
anatomical level, the gastrointestinal tract is fully formed at birth it undergoes 
significant morphological and cytological differentiation and maturation in the 
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postnatal period. Some of this physical “immaturity” can contribute to the neonatal 
susceptibility to E. coli K1 infection. A study with bioluminescent E. coli K1 oral 
infection showed that this bacterium adheres to non-keratinized esophageal 
tissues and to the oral cavity of neonatal rats [32]. A reduced esophageal motility 
and luminal clearance, characteristic of neonates (particularly preterms) [46], can 
contribute to the vulnerability to colonization and invasion of E. coli K1 when 
compared to adults. Moreover, the incomplete development of the intestinal 
barrier during early neonatal life, that includes deficits in α-defensins and mucin, 
can provide a permissive environment for translocation of the intestinal 
colonizing-E. coli K1 into the bloodstream [38]. The respiratory tract may also 
provide an alternative entrance to the bacteria into the systemic circulation [32]. 
The majority of studies with non-invasive E. coli K1 infections in neonatal mice 
use an intranasal inoculation and, even in this model, the bacterium showed the 
ability to translocate the epithelial barrier and reach the bloodstream to induce 
meningitis [89,91,100,101].    
In our model, E. coli colonization was observed in both gastrointestinal and 
respiratory tract. The bacterium was detected in the stomach and small intestine 
of all infected animals (data not shown) and in the lung as soon as 30 min post-
infection, consistent with the observation of the entry of inoculum to the 
respiratory tract during infection.  
Interestingly, as shown in Manuscript 3, the bacterium delivered by a non-
invasive way quickly reached the bloodstream and established a systemic 
infection. Indeed, as soon as 30 min post–infection, the bacterium was detected 
in the blood, in levels that are maintained during the first 18 h of infection. Which 
endothelial barrier is first being surpassed by E. coli K1 in our model is yet to be 
known, but it is possible that the bacterium is reaching the bloodstream through 
more than one location and at different timepoints. The use of fluorescent E. coli 
K1 and intravital imaging could help us dissect this question.  
In the liver, spleen and brain the E. coli colonization increased over time. Since 
E. coli K1 is strongly associated with neonatal meningitis in humans, brain 
colonization is essential for a model intended for translational studies of human 
E. coli K1 neonatal diseases. At 12 h post-infection, 76% of the infected pups 
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presented brain E. coli K1 colonization. It is thus likely, that part of the E. coli K1 
survivors of our model will present neurological sequelae. Animal models of E. 
coli K1 meningitis are important to the characterization of pathogenesis of 
disease and to the understanding of the cellular and molecular immune 
mechanisms involved. In humans, long-term sequelae in patients who had 
neonatal E. coli meningitis are frequent, particularly neurosensorial sequelae, like 
deafness and blindness, and neurodevelopmental sequelae, like learning 
impairment  [102]. Ventriculitis with intraventricular haemorrhage frequently 
accompanies neonatal E. coli meningitis (27%) [103]. A characterization of the 
neurodevelopment of the survivors in our model, by analysis of their performance 
on behavioural studies, and histological analysis of the brain could help us 
understand if the E. coli K1 oral infection mice model does, in fact, mimic not only 
the mortality, but also the morbidity associated with E. coli K1 infection in humans.  
Another interestingly result also shown in Manuscript 3, was a delay in triggering 
the immune response after oral infection. It is known that an immune response is 
initiated as soon as the pathogen has contact with an immune cell and its 
pathogen associated molecular patterns (PAMPs) are recognized by pattern 
recognition receptors (PRRs). Several PRRs have been associated with the 
immune response to E. coli K1, including Toll-like receptors (TLR) 4 and 2 
[100,104] and the β2-integrin CD11b/CD18 (complement receptor 3 (CR3)) [91]. 
CR3 expression on neonatal neutrophils is decreased during the first month of 
life and it is further reduced in preterm neonates [105]. On the other hand, basal 
expression and cellular distribution of TLRs is similar in blood monocytes and T 
cells of newborns and adults (with exception of preterms that have diminished 
TLR4 expression) [106-109]. In the case of bacteremia, peripheral blood cells 
from both preterm and term neonates showed the capacity to up-regulate TLR2 
and TLR4 during Gram-positive and Gram-negative bacteremia, respectively 
[110]. Furthermore, the expression of the lipopolysaccharide-binding protein 
(LBP) and CD14 (co-receptor with TLR4 and MD2 for LPS detection) is normally 
up-regulated during neonatal sepsis [111-113]. Nevertheless, in our model, 
despite the elevated colonization of lungs and liver 30 min post-infection, an 
increase in the production of pro-inflammatory cytokines like IL-6, IL-1β and TNF-
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α and the chemokines KC and MIP-2, as well as a recruitment of neutrophils and 
macrophages was only detected after 6 h of infection. 
A similar delay in the neonatal immune response to a pathogen has already been 
described by our group. In the case of GBS neonatal infections, the bacterium 
induces an early IL-10 production that inhibits a protective neutrophil recruitment 
to infected organs [35,114]. In light of these results, we hypothesized that 
neonates are at risk of rapidly developing immunoparalysis after bacterial-
induced sepsis, due to their commitment towards IL-10 production. In E. coli K1 
infection, however, the blocking of IL-10R signaling by antibodies did not alter the 
outcome of infection. Moreover, in a neonatal model of E. coli K1 intranasal 
infection, IL-10 production was associated with host protective responses since 
it prevented the development of hyperinflammatory immune responses and 
induced bacterial clearance [91]. Consequently, the “irresponsiveness” that we 
observed in our model is not dependent on an early and increased IL-10 
production.  
One of the key aspects of early life immunity is tolerance, first, to maternal 
antigens, then to the world antigens, coming from microbiota or food. Therefore, 
the innate immune response is shifted to the production of 
immunossupressive/regulators mediators. As described above, IL-10 is one of 
those mediators, but it is not the only one. Newborns and infants have high levels 
of plasma adenosine, an endogenous purine that accumulates extracellularly as 
a result of its cellular production and transport via membrane nucleoside 
transporters or by extracellular metabolism of ATP by the ecto-nucleotidases 
CD39 and CD73 that are expressed by leukocytes and other host cells [115-117] 
(Figure 5). In newborns, adenosine is associated with the inhibition of TLR-
mediated TNF-α production and consequent polarization of innate immune 
responses towards IL-6 and IL-10 [118,119]. The induction of adenosine 
production has already been associated with E. coli [120,121]. The stimulation 
with E. coli up-regulated the CD39 expression in both murine and human 
macrophages [120] and, in a model of E. coli peritonitis, both CD39 and CD73 
were up-regulated while adenosine-degrading enzymes were down-regulated 
[121]. It is possible that, similarly to what happens with Trypanossoma cruzi and 
Legionella pneumoniae [122,123], E. coli K1 induces CD39 and CD73 expression 
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to generate an adenosine-rich environment which allows it to escape the immune 
surveillance. This hypothesis will be tested using inhibitors of CD39 and CD73 as 
well as antagonists of adenosine receptors in vivo.   
 
 
Figure 5. Possible mechanisms for the neonatal immunosuppression observed 
after E. coli K1 oral infection. 1) Elevated levels of adenosine in neonatal blood act 
through adenosine receptors on neonatal cells and inhibit TLR-mediated pro-
inflammatory cytokines. CD39 expression is upregulated in murine and human 
macrophages stimulated with E. coli [120]. 2) Neonates possess an enriched population 
of immunosuppressive CD71+ cells. These cells compromise the neonatal host defenses 
against E. coli K1 [124]. CD71+ cells as well as infected immune cells produce high levels 
of arginase that degrade L-arginine and, consequently, limit pro-inflammatory cytokine 
production and increase pathogen translocation. (Adapted from [125]).   
 
Recently, a unique population of CD71+ erythroid precursor cells was identified 
as a key element to facilitate the colonization of the neonatal intestine by 
commensal microbiota in a non-inflammatory manner [124]. The depletion of 
these cells in neonatal mice, or natural postnatal age-related decline in their 
numbers, was correlated with an enhanced production of pro-inflammatory 
mediators and increased the neonatal resistance to i.p. infection of Listeria 
monocytogenes and E. coli [124] (Figure 5). It is therefore possible that these 
cells are responsible for the immunosuppressive state that we observed during 
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E. coli K1 oral infection. It is known that the anti-inflammatory property of these 
cells is mediated by arginase-2, since molecular inhibition of this enzyme or 
supplementation with L-arginine outweighs its effects [124]. Small clinical trials 
have shown the benefits of enteral L-arginine supplementation in prevention of 
necrotizing enterocolitis in premature infants [126-128]. We intend to test, at least 
in an initial phase, the effect of L-arginine supplementation in the outcome of E. 
coli K1 neonatal infection.  
After the initial “irresponsiveness” to E. coli K1 infection, we observed a sustained 
production of pro-inflammatory cytokines IL-6, TNF-α and IL-1β and chemokines 
MIP-2 and KC, as well as phagocyte recruitment to infected organs. IL-1β 
production proved to be essential to the host immune response to E. coli K1 oral 
infection, since the blocking of its signaling with antibodies increased neonatal 
mortality. This is another aspect in which the neonatal protective immune 
response to E. coli differs from GBS. Treatment with IL-1R blocking antibodies 
delayed (and slightly decreased) the GBS-induced mortality in neonatal mice 
[114], an effect we did not observe in E. coli K1 infection. The role of other pro-
inflammatory immune mediators was not yet addressed. We also intend to 
quantify the colonization levels in treated animals, to understand if an increase in 
susceptibility is associated with bacterial dissemination.   
The role described for macrophages and neutrophils in some studies of E. coli 
K1 neonatal infection is quite unconventional. In models with intranasal E. coli 
inoculation, these phagocytes have shown to have a more detrimental than 
protective effect [89,101,129]. As previously mentioned, the type of phagocyte 
activation, however, more than its presence, seems to determine the outcome of 
infection [89,91]. In our model, we only observed cell recruitment to the organs 
after the establishment of infection, indicating that the systemic invasion of the 
organs (at least of the liver) is not dependent on the bacterium that is reaching 
the organs inside recruited phagocytes. Nevertheless, we cannot exclude that a 
“Trojan-horse”-like mechanism is not being used by bacteria to evade the immune 
response. We intend to deplete neutrophils and macrophages, prior to infection, 
in order dissect the role and the timing of their importance for the susceptibility 
(or resistance) in our neonatal model of E. coli K1 infection.      
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We detected, in lungs of infected mice, a double positive population for Ly6G and 
F4/80. It is, to our knowledge, the first time that these cells have been described 
in a neonatal infection. Very little is known about this population. In a study with 
Pseudomonas aeruginosa infection these cells were described as having the 
capability of producing the same amount of myeloperoxidase as neutrophils in 
response to infection [130] and were designated as immature myeloid cells. Since 
at 18 h post-infection, these cells accounted for more than half of CD45 positive 
cells in the lung of E. coli K1 infected pups, I believe that it is important to 
characterize this population and understand its role in this neonatal infection. It is 
possible, that the protective role of the depletion of neutrophils and macrophages 
during intranasal E. coli K1 neonatal infection could be, in part, mediated by the 
elimination or modulation of this cell population.  This hypothesis will be tested in 
the future.  
In conclusion, the data presented in this thesis, re-enforces the efficacy of 
rGAPDHGBS immunization, now in a model of adult GBS infection, and provides 
evidence of the safety and stability of this vaccine. The results presented here, 
also highlight the need of precaution in extrapolating the efficacy of GAPDH-
based vaccines to all microorganisms since the maternal vaccination with this 
antigen increases the susceptibility of neonate mice to oral infection with E. coli. 
Moreover, in this thesis, a murine model of E. coli K1 infection that uses a relevant 
route of inoculation was established opening new possibilities to further 
characterize and explore the cellular and molecular immune mechanisms 
involved in the pathogenicity of E. coli K1 neonatal infections.  
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